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ABSTRACT
ESTROGEN REGULATION OF THE PREGNANT BABOON PLACENTAL lip - 
HYDROXYSTEROID DEHYDROGENASE (1 lpHSD>CATALYZED METABOLISM 
OF CORTISOL AND CORTISONE AND ITS EFFECT ON THE DEVELOPMENT OF 
THE FETAL HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
William Adair Davies 
Old Dominion University 
Eastern Virginia Medical School 
Director Dr. Gerald J. Pepe
Pepe and Albrecht previously demonstrated that the estrogen-regulated 
change in transuteroplacental metabolism of cortisol (F) and cortisone (E) from 
preferential reduction (E to F) at midgestation to oxidation (F to E) near term results in a 
decline of bioactive cortisol crossing the placenta and reaching the fetus culminating in 
activation of the hypothalamic-pituitary adrenal axis of the baboon and the ontogenesis of 
rate-limiting steroidogenic enzymes culminating in de novo F secretion. Protein kinase A 
(PK-A) activity in the baboon fetal adrenal gland cytosolic fraction was increased 2-fold 
both at term [day 165 of gestation (term -  184 days)] and following treatment with 
estrogen at midgestation (day 100), compared to levels at mid-gestation. Protein kinase C 
(PK-C) activity in both cytosolic and membrane-bound fractions was similar at mid- and 
late gestation and not altered by treatment with estradiol.
Secondly, we determined whether maturation of the fetal adrenal reflects enhanced 
expression of the mRNA for the ACTH precursor proopiomelanocortin (POMC).
Pituitary POMC mRNA, was greater in baboon fetuses at term than at mid-gestation and 
increased on day 100 in estrogen-treated animals. Immunohistochemical studies 
confirmed that ACTH protein paralleled changes in POMC mRNA. Next, we determined
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
whether the ontogenetic increase in POMC/ACTH in fetal baboon pituitaries reflected an 
increase in hypothalamic corticotropin-releasing hormone (CRH). CRH protein and CRH 
mRNA at mid-gestation were similar to concentrations in fetal baboons of late gestation 
and were not altered in fetuses in which the mother was treated with estradiol. In 
conclusion, the onset of fetal adrenal steroidogenic maturation normally near term and 
prematurely at mid-gestation following estrogen administration reflects increased 
expression of fetal pituitary POMC mRNA / ACTH protein and are not associated with a 
concomitant increase in hypothalamic CRH peptide or CRH mRNA
Thirdly, since the 1 ip-hydroxysteroid dehydrogenase (1 iP-HSD)-catalyzed 
metabolism of maternal cortisol and cortisone by the placenta is an important component 
in the sequence of events regulating the function of the baboon fetal pituitary- 
adrenocortical axis, both baboon llp-HSD-1 and -2  gene promoters were isolated and 
sequenced and shown to exhibit extensive homology to their respective human sequences. 
Both genes were subcloned into luciferase reporter vectors and transiently-transfected into 
human placental JEG-3 cells. In the presence of 17|3-estradiol and estrogen receptor a , basal 
promoter activities of both lip-HSD-1 and -2 increased 8-fold. Finally, RT-PCR analysis 
demonstrated a significant reduction of both 11P-HSD-1 and -2  mRNAs in baboon 
placental syncytiotrophobiast-enriched fractions following reduction of maternal serum 
estrogen in vivo by a highly-specific P450-aromatase enzyme inhibitor, CGS 20267.
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1CHAPTER I 
BACKGROUND AND INTRODUCTION 
A better understanding of the biology of pregnancy maintenance and fetal 
development is essential for formulating strategies for reducing the relatively high 
incidence of neonatal morbidity and mortality associated with prematurity and labor- 
associated fetal stress. In addition, recent studies have proposed the “fetal origins of 
adult disease” (FOAD) hypothesis stating that several of the major diseases o f adulthood, 
including coronary heart disease, hypertension, and type 2 diabetes, originate in impaired 
intrauterine growth and development (Barker and Godfrey, 2000). A major factor 
regulating fetal growth and development is the adrenal gland hormone cortisol. It is 
believed that estrogen, produced by the placenta to levels almost 100-foid higher than 
levels seen in the menstrual cycle, plays a central integrative role in both human and 
baboon pregnancies (Figure 1; Pepe and Albrecht, 1998). For ethical reasons, our 
understanding of the regulation of feto-placental development in humans has been limited 
to hormone concentrations in the circulation, analyses of hormone formation in vitro, 
results from abnormal pregnancies and limited endocrine manipulations during elective 
caesarean section (Pepe and Albrecht, 1998). Although transgenic approaches in rodents 
have resulted in major advances, there are significant differences between rodents and 
primates in placentation, hormone biosynthesis and the endocrine interactions of the 
mother, fetus and placenta. Therefore, a non-human primate model, in which invasive 
experiments can be conducted, is required to study in vivo, the development of the feto­
placental unit and its impact on function in adulthood.
Since the 1970’s, Pepe and Albrecht have utilized the baboon as a non-human 
The journal model for this dissertation is Human Reproduction Update.




30 45 60 75 90 105120135150165180
Days of Gestation
Figure 1. Mean maternal serum estradiol concentrations during baboon pregnancy 
(term =184 days).
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3primate model for the study of the endocrinology of pregnancy and have demonstrated 
that estrogen, the production of which increases during gestation (Figure 1), has three 
major roles in the development and maintenance of pregnancy and fetal growth. First, 
estrogen regulates the production of progesterone within the syncytiotrophoblasts via the 
receptor-mediated uptake of low-density lipoprotein-cholesterol (LDL) and the P4S0 
cholesterol side-chain-cleavagc enzyme (P450scc). Second, estrogen acts directly on the 
fetal adrenal gland to modulate the production of androgen precursors that are 
subsequently aromatized to estrogen by syncytiotrophobiast P4S0 aromatase enzyme 
system. Third, estrogen regulates the syncytiotrophobiast 110- hydroxysteroid 
dehydrogenase (110-HSD-l and -2) enzymes controlling placental cortisol-cortisone 
metabolism and thus indirectly regulates the development of the fetal hypothalamic- 
pituitary-adrenal axis (HPAA). Research endeavors outlined in this proposal have 
focused on this third area of estrogen-regulated processes.
The fetal milieu depends on a functioning placenta, which develops in parallel with 
the fertilized ovum. By 6 to 7 days after conception, the blastocyst consists of an outer 
layer of trophoblast cells and an inner cell mass destined to become the embryo 
(Williams et al., 1998). Implantation commences as the outer trophoblasts invade the 
endometrium and two layers of developing placenta can now be demonstrated. Invading 
trophoblasts form columns to anchor the placenta to the endometrium. Other precursor 
cytotrophobiasts differentiate into syncytiotrophoblasts and are in direct contact with the 
maternal circulation. As the placenta develops, the chorionic villi containing the fetal 
capillaries extend into the maternal lakes of blood within the maternal decidua. The 
syncytiotrophobiast is the major source of hormone production as well as the major site
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4of diffusion between the maternal and fetal blood. Some of the more important hormones 
produced by the placenta include the estrogens (estradiol and estrone), progesterone and 
the protein hormones chorionic gonadotropin and placental lactogen.
PLACENTAL CORTISOL-CORTISONE METABOLISM
Cortisol is a 21-carbon, lipid-soluble, cholesterol-derived, readily membrane- 
diffusible steroid hormone. It is measurable in the fetal circulation throughout pregnancy 
in the human (Murphy, 1982) and non-human primates (Pepe and Albrecht, 1984; Jaffe et 
al., 1978). Cortisol is biologically active and thus binds to the glucocorticoid receptor.
In contrast, cortisone does not bind to this receptor and thus is inactive. In adult serum, 
the amount of cortisol is 5 -  10 times greater than that of cortisone, while in fetal serum, 
cortisone levels exceed those of cortisol (Murphy, 1981). Studies in the human (Beitins 
et al., 1973; Migeon et al., 1957), the rhesus monkey (Kittinger, 1974, Mitchell et al., 
1982), and the baboon (Pepe and Albrecht, 1984) indicate that there is extensive 
movement of cortisol across the placenta, between the fetal and maternal circulation 
throughout gestation. However, it has generally been considered that the major role of 
the primate placenta was to catabolize cortisol to cortisone and thus protect the fetus from 
the relatively high concentrations of cortisol in the maternal circulation (Pepe and 
Albrecht, 1990). Indeed, based exclusively on experiments performed in late gestation in 
humans and non-human primates (Pepe and Albrecht, 1995), the placenta actively 
converts biologically-active cortisol to its inactive metabolite cortisone. The latter 
mechanism is considered an essential component of the FOAD hypothesis.
Thus, in baboons (Pepe and Albrecht, 1984), as well as in humans (Beitins et al., 
1973), the transfer constant (i.e. percent conversion) for the oxidation of cortisol to
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Figure 2. Transuteroplacental interconversion of cortisol (F) and cortisone (E) in 
untreated baboons on days 100 (mid; n = 7) and 16S (near term; n = 4) of gestation and in 
nine baboons treated at midgestation with androstenedione which increased placental 
estrogen production. Values (mean ± SE) represent corticosteroid metabolism by the 
uterus and placenta corrected for fetal contributions. The asterisk indicates that the 
percentage F to E is greater (P<0.05) than the percentage E to F (by r-test for dependent 
observations).
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6cortisone across the placenta near term (36%) was 6-fold greater than that for the 
reduction of cortisone to cortisol, which was minimal (6%). However, when similar in 
vivo isotopic steady-state infusion studies (Figure 2) were performed in baboons at mid­
gestation (Pepe et al., 1990), it was observed that the reduction of cortisone to cortisol 
was quantitatively substantial (35%), and significantly greater than the transfer constant 
for the oxidation of cortisol to cortisone (15%). This same pattern of cortisol metabolism 
(i.e. preferential reduction early in pregnancy to preferential oxidation late in pregnancy) 
may also occur in humans since estimates of cortisol metabolism early in pregnancy 
showed extensive conversion of cortisone to cortisol (Pasqualini et al., 1970). In 
contrast, at both mid- and late gestation, almost all fetal tissues (except the placenta) 
actively convert cortisol to cortisone and thus protect the fetus from abnormally high 
levels of cortisol (Murphy, 1981; Pepe and Albrecht, 1995).
Using the same in vivo experimental paradigms, it was demonstrated that the increase 
in placental oxidation of cortisol to cortisone near term is regulated by estrogen (Pepe and 
Albrecht, 1998). Thus, treatment of intact baboons at mid-gestation with estradiol or 
with androstenedione, which increased placental estrogen production to values normally 
seen late in gestation, significantly increased the placental transfer constant for the 
oxidation of cortisol to cortisone and induced a pattern of placental cortisol-cortisone 
metabolism similar to that seen at late gestation (Figure 2). Further support for the 
regulatory role of estrogen in this process was realized when the elimination of estrogen 
production in the later half of gestation via fetectomy or antagonism of the estrogen 
receptor by ethamoxytriphetol (MER-25) resulted in a pattern of metabolism similar 
to that seen at mid-gestation (Pepe and Albrecht, 1987).
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7Recent studies have now confirmed that the interconversion of cortisol and cortisone 
is catalyzed by two different 11 P-hydroxysteroid dehydrogenase (110-HSD) enzymes 
(Stewart et al., 1994a; Stewart et al., 1994b; Pepe and Albrecht, 1995; Stewart et al., 
1995a; Stewart et al., 1995b): 110-HSD-l, an NADP(H)-dependent dehydrogenase/oxo- 
reductase with low affinity for substrate cortisol (1,000 nM); and 110-HSD-2, a high
affinity (10-100 nM), NAD+-dependent dehydrogenase only oxidizing substrate cortisol 
to cortisone (Albiston et al., 1994; Stewart and Mason, 1995; Whorwood et al., 1995). 
Given the nanomolar Km levels for 11 P-HSD-2, this form is more likely to play an 
important physiological role and appears to be the major form expressed in the primate 
placenta (Burton and Waddell, 1999). In fact, a well-documented role for 11 P-HSD-2 
exists in the distal nephron of the kidney, where the enzyme ensures aldosterone-selective 
access in vivo to otherwise nonspecific mineralocorticoid receptors (MR or type I versus 
glucocorticoid receptor or type II) by rapidly inactivating glucocorticoids (i.e. cortisol), 
serum levels of which are 100- to 1000-fold greater than those of aldosterone. Inhibition 
of this enzyme by competitive inhibitors found in licorice (glycyrrhizic acid, 
glycyrrhetinic acid or its derivative carbenoxolone) allows illicit occupation of MR 
(which in vitro has identical affinity for cortisol and aldosterone) in the distal nephron by 
glucocorticoids, producing sodium retention, hypokalemia and hypertension (Agarwal et 
al., 1995). This syndrome in the congenital form is called apparent mineralocorticoid 
excess (AME). Classic enzyme kinetics (Pepe and Albrecht, 1985a; Baggia et al., 1990a;
Baggia et al., 1990b) demonstrated that baboon placental NAD+-dependent 11 p-HSD-2 
oxidase activity at mid-gestation was increased 4-fold in animals in which placental 
estrogen production was increased by treatment of the mother with aromatizable
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Figure 3. Total NAD-dependent 11 P-hydroxysteroid dehydrogenase activity 
(micromoles of cortisone (E) formed per minute/placenta) in baboons at midgestation 
treated with androstenedione and near term after fetectomy (FTX). Asterisked values 
(mean ± SE) in control baboons are greater at term than at midgestation (P<0.01, by 
unpaired /-test), and the value after FTX is lower than that in untreated animals at term 
(P<0.01, by unpaired /-test).
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androstenedione or estradiol and decreased at term in baboons in which placental 
estrogen production was depleted by fetectomy (Figure 3). In vitro studies (Pepe et al., 
1996b) demonstrated that the baboon placenta expressed the mRNA for 11P-HSD-1 at 
mid-gestation favoring the formation of cortisone to cortisol, presumably catalyzed by the 
11 P-HSD-1 enzyme protein. Although 11 P-HSD-1 mRNA or protein has not been 
consistently detected in human placenta (Lakshmi et al., 1993; Stewart et al., 1994b; 
Whorwood et al., 1995; Sun et al., 1996a), the mRNA and protein for 11 P-HSD-2 have 
always been detected (Stewart et al., 1994b; Krozowski et al., 1995; Stewart et al., 
1995a; Brown et al., 1996a). Recently, both 11 P-HSD-1 and -2 enzyme protein and 
mRNA have been demonstrated in baboon and human placenta (Pepe et al., 1996a; Pepe 
et al., 1999a). Moreover, levels of mRNA and protein increased for both enzymes with 
advancing gestation. Up-regulation of 11 p-HSD-1 seems to contradict previous results 
where transplacental conversion of cortisone to cortisol in utero declined with advancing 
gestation. To address these conflicting results, it has been recently demonstrated that 
changes in transplacental corticosteroid metabolism results from an estrogen-dependent 
change in the compartmentalization of 11 P-HSD-1 and -2 within the syncytiotrophobiast 
(Pepe et al., 2001). Thus, 11 P-HSD-1 was localized extensively to the microvillus 
membranes (MVM) juxta the maternal circulation, whereas 11 p-HSD-2 was located 
throughout the remainder of the syncytiotrophobiast, including the basal membrane 
(BMm) facing the fetal blood compartment. Moreover, there was a developmental 
increase in the ratio of 11P-HSD-2 tol lp-HSD-1 in the syncytiotrophobiast membranes 
juxta the fetal blood compartment, which we propose is consistent with and perhaps the 
subcellular mechanism responsible for the previously demonstrated switch in trans-




















- H E -
IM
(ttphofeliii
— o  |
ACTH
P
Figure 4. Subcellular localization of 11 P-HSD-1 and -2  in the baboon placental 
syncytiotrophobiast at mid- and late gestation; control of cortisol (F) and cortisone (E) 
secretion into the fetus and regulation of the fetal pituitary-adrenal axis.
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placental glucocorticoid metabolism from reduction at mid-gestation to oxidation late in 
gestation (Figure 4; Pepe et al., 2001).
IMPACT OF PLACENTAL CORTISOL METABOLISM ON THE FETUS
Due to the absence of key rate-limiting steroidogenic enzymes (Pepe and Albrecht, 
1990; Mesiano and Jaffe, 1997), specifically 3 (3-hydroxy steroid dehydrogenase (3(3- 
HSD) which converts pregnenolone to progesterone, the fetal adrenal gland in humans 
(Lanman, 1953; Neville and O’Hare, 1982) and non-human primates (Kerr et al., 1969; 
Pepe et al., 1977; McNulty et al., 1981) does not develop the enzymatic capacity to 
synthesize cortisol de novo (i.e., from endogenous cholesterol) until very late in gestation 
(i.e., the last 10%). The anatomical correlates of brain function (Scott and Pepe, 1987) 
and the pituitary’s ability to secrete adrenocorticotrophic hormone (ACTH) in response to 
corticotropin releasing hormone (CRH) in vivo (Berghom et al., 1991) indicate that the 
fetal baboon hypothalamus and pituitary gland develop relatively early in gestation as 
previously shown in the human (Ackland et al., 1986; Blumenfeld and Jaffe, 1986). The 
developmental maturation of the fetal adrenal gland seems to be “out-of-synchrony” with 
that of the hypothalamus and pituitary which are supposed to be integrated as the HPAA. 
It has been demonstrated that at mid-gestation, almost 100% of the fetal baboon serum 
cortisol is of maternal origin whereas at term less than 50% originates from the maternal 
compartment (Figure 5). Based on these observations, it was proposed that the placenta, 
via metabolism of cortisol-cortisone, determines the qualitative and quantitative patterns 
of these corticosteroids reaching the fetal pituitary gland at mid- and term gestation. 
Consequently, this unique process regulates the fetal HPAA and the timely onset of de 
novo cortisol production by the fetal adrenal gland. Thus, preferential conversion of
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Figure 5. Fetal serum cortisol (F) concentrations (left panel) and percentage of fetal F 
derived from production in the fetus (right panel) by the fetal adrenal gland in untreated 
baboons on day 100 (mid) and 165 (late) of gestation and in baboons at midgestation 
following maternal treatment with androstenedione (A4 A). The proportion of fetal F 
produced within the fetus (right panel) and present within fetal serum (darkened area of 
bars of left panel were determined by specific activities of serum F in maternal and 
umbilical veins. Values (mean ± SE) with different superscripts differ from each other at 
P<0.05 (ANOVA with multiple comparison of means by Least Significant Difference 
statistic).
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Figure 6. The role of estrogen (E2) on placental 11 p-hydroxysteroid dehydrogenase (113 
-HSD)-catalyzed metabolism of cortisol (F)-cortisone (E) and regulation of the fetal 
pituitary-adrenocortical axis at mid- and late gestation in the baboon. With advancing 
gestation, the estrogen-induced increase in placental 11 [3-HSD-catalyzed oxidation of 
maternal cortisol to cortisone decreases the concentration of maternal cortisol in the fetus 
and thus disinhibits the fetal pituitary leading to increased adrenocorticotrophic hormone 
(ACTH) production and maturation of and de novo cortisol production by the fetal 
adrenal gland. DHA = dehydroepiandrosterone; P5 = pregnenolone.
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maternal cortisone to biologically active cortisol by the placenta occurs at mid-gestation 
when fetal production of cortisol is low (Figure 6 ). This has a negative feedback effect 
on fetal pituitary ACTH secretion, thereby limiting fetal adrenal definitive zone cell 
growth and the ontogenesis of 30-HSD activity as well as de novo cortisol synthesis 
throughout most of pregnancy. In fact, the activity of 30-HSD, the gene and protein for 
which are apparently restricted to the definitive zone of the fetal adrenal gland, is 
minimal during most of gestation in the fetal adrenal glands of humans, baboons, rhesus 
monkeys and sheep (Pepe and Albrecht, 1995). The production and secretion of C19 
androgens, dehydroepiandrosterone (DHA) and DHA sulfate (DHAS), primarily from the 
fetal adrenal fetal zone cells, is critical for the continued high estrogen levels throughout 
pregnancy. This androgen elaboration would not be compromised because factors of 
placental and/or fetal origin (Brown et al., 1979; Pepe and Albrecht, 1985a; Pepe and 
Albrecht, 1985b; Pepe et al., 1988) have been shown to modulate adrenal androgen 
production. By term-gestation, however, the estrogen-induced increase in oxidation of 
cortisol to biologically-inactive cortisone by the placenta, as well as fetal tissue (Waddell 
et al., 1988b), reduces fetal serum cortisol levels, allowing stimulation of fetal 
pituitary secretion of trophic hormone ACTH and the timely onset of de novo cortisol 
production by the fetal adrenal gland. In support of this hypothesis, it has been 
demonstrated that the ontogenesis of de novo fetal adrenal cortisol production (Figure 5) 
was markedly increased with advancing gestation and enhanced prematurely at mid­
gestation following induction of placental NAD+-dependent 11JJ-HSD-2 oxidase activity 
by estrogen to concentrations observed normally at term-gestation (Pepe et al., 1990).
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FETAL ADRENAL GLAND
The adrenal gland originates embiyonically from mesodermal cells attached to the 
urogenital ridge. The fetal adrenals are recognizable by mid-first trimester when 
neuroectodermal (chromaffin) cells invade to commence formation of the medulla.
Shortly thereafter, the adrenal gland is recognizable as consisting of a thin, outer layer 
“definitive” zone and a large, inner “fetal” zone.
In most mammalian species, products of the fetal adrenal gland play an important 
role in regulating maturation of various organ systems in the fetus (Pepe and Albrecht, 
1990) as well as responding to stress (Matthew and Challis, 1995). Preceding parturition, 
fetal organs undergo accelerated maturation that facilitates the transition from intrauterine 
to extrauterine life. Cortisol, produced from cholesterol in the fetal adrenal glands or 
converted from inactive cortisone in the placenta, is one of the key chemical messengers 
involved in stimulating fetal/neonatal lung maturation (Kotas and Avery, 1971; Farrell 
and Zachman, 1973; Mendelson and Boggaram, 1991; Weaver and Whitsett, 1991; NTH 
Consensus Conference, 1995). Cortisol works in concert with hormones such as thyroid 
hormone, prolactin, and insulin to accelerate lung tissue surfactant dipalmitoyl 
phosphatidylcholine (DPPC) synthesis, lung liquid reabsorption as well as lung structural 
modifications (Pepe and Albrecht, 1995; Williams et al., 1998). DPPC is the major 
component of surfactant, which reduces surface tension at the alveolar air-liquid 
interface. Surfactant is synthesized by type II epithelial cells in the lung alveolus and 
secreted into the air by exocytosis. Glucocorticoids also stimulate at least four key 
phosphatidylcholine (PC) biosynthesis enzymes, including fatty acid synthase, choline 
phosphate cytidylyltransferase, phophatidylphophatase and lysoPC:acyl-CoA
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acyltransferase (Pepe and Albrecht, 199S). Approximately 10% of the mass of 
pulmonary surfactant is made up of specialized proteins, known as surfactant proteins 
(SP). The largest and most abundant is SP-A, a 35,000 dalton glycoprotein. Two other 
surfactant-associated hydrophobic proteins are SP-B and SP-C, with molecular weights 
o f8,000 and 5,000 daltons, respectively. Glucocorticoids, at physiological doses (i.e., 1 
mM), also have stimulatory effects on the production of these three proteins.
Cortisol also stimulates gluconeogenesis from amino acids and liver glycogen 
synthesis/accumulation while decreasing peripheral utilization of glucose (Greengard and 
Dewey, 1970; Greengard, 1973; Eisen et al., 1973; Seron-Ferre and Jaffe, 1981). 
Moreover, glucocorticoids promote the differentiation of preadipocytes into mature fat 
cells and stimulate adipocyte lipoprotein lipase to increase lipid mobilization and 
triglyceride sequestration (Whorwood et al., 2001). Additionally, cortisol increases 
methyiation of norepinephrine to epinephrine, the hepatic conversion of T4 to T3 and the 
induction of several enzymes in the brain, retina, pancreas and gastrointestinal tract of the 
fetus (Moscona and Piddington, 1966; Piddington and Moscona, 1967; Moog, 1971; 
Giannopoulos, 1975). In addition to cortisol’s major effects on intermediary metabolism, 
cortisol suppresses the immune response (promotes lymphocyte lysis) and the 
inflammatory response (decreases the number and migration of leukocytes and inhibits 
the production of prostaglandins and leukotrienes). While glucocorticoids play a crucial 
role in the final maturation of fetal organ systems, excess glucocorticoid exposure retards 
fetal growth, including pancreas and adrenal glands, and may impair fetal brain 
development and immune system function (Kay et al., 2000). Because glucocorticoids 
provide key signals in cellular differentiation, many of their effects are long-lasting, and
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excess glucocorticoid exposure in utero has been directly linked to the subsequent 
development of hypertension and hyperglycemia in adult life (Burton and Waddell, 1999) 
and perhaps delayed puberty (Smith and Waddell, 2000).
In most species investigated to date, late pregnancy is characterized by rising 
concentrations of cortisol in the fetal circulation (Liggins, 1994) and the maternal 
circulation (Burton and Waddell, 1999). In sheep, cortisol concentrations rise sharply 
prepartum and induce parturition, presumably by increasing the placental enzyme, 
P4S0cl7ahydroxylase (Liggins et al., 1973; Seron-Ferre and Jaffe, 1981) which results 
in decreased placental progesterone secretion, increased placental estrogen secretion and 
consequently increased uterine prostaglandin production. In human and non-human 
primates, fetal cortisol levels increase more slowly and the role of the cortisol surge in the 
initiation of labor is less convincing (Muller-Huebach et al., 1972; Liggins, 1976; Liggins 
et al., 1977; Casey and MacDonald, 1988). Nevertheless, fetal adrenal gland de novo 
cortisol production appears to be a factor in determining the timing of parturition 
(Sucheston and Cannon, 1969; Turnbull and Anderson, 1984).
In addition to these roles for fetal adrenal cortisol, it is well established that the fetal 
adrenal gland in primates, as well as humans, is important to the synthesis and secretion 
of androgen precursors essential to the production of estrogen by the P-4S0-placental 
aromatase enzyme complex (Diczfalusy, 1964; Siiteri and MacDonald, 1966; Oakey,
1970; Diczfalusy, 1974). The principal secretory androgen of the human fetal adrenal 
gland throughout gestation is DHAS and to a lesser extent its nonconjugated form DHA 
(Seron-Ferre and Jaffe, 1981). The production of adrenal androgens from pregnenolone 
requires 17a-hydroxylation, thus the major source of DHAS in the fetus is the adrenal
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fetal zone. In the fetal rhesus monkey, the serum levels and daily production rates of 
DHAS increase steadily during gestation and parallel fetal cortical growth (Seron-Ferre et 
al., 1983). DHAS is extensively metabolized to 16a-OH DHA by the fetal liver in the 
human but not in the baboon. Both DHAS and 16a-OH DHAS can be hydrolyzed by the 
human placental steroid sulfatase to the non-conjugated form (Bolte et al., 1964), and 
then converted by placental 3f3-HSD to androstenedione (A«). A* can then be converted 
to either estrone (Hi) directly by P4S0 aromatase or to testosterone by 170-HSDII and 
then subsequently aromatized by P4S0 aromatase to estradiol (E2). 16a-OH DHAS is 
aromatized by the placenta to estriol (E3), quantitatively the major estrogen present in 
pregnant woman, whereas DHA is aromatized to estrone (Ei), and estradiol (Seron-Ferre 
and Jaffe, 1981). Estriol and estrone are weaker estrogens than estradiol and exhibit 
activities l/80th and l/12,h, respectively, of that of estradiol. Thus, fetal adrenal 
androgens are precursors for placental aromatase production of estrogens in humans 
(Simmer et al., 1964; Easterling et al., 1966; Chang et al., 1976) and non-human primates 
(Kling et al., 1972; Townsley, 1976; Walsh etal., 1979; Jaffe etal., 1981; Seron-Ferre et 
al., 1983; Pepe and Albrecht et al., 1980). The interdependence o f fetus, placenta and 
mother in the formation of estrogens has led to the concept of the "fetoplacentomatemal 
unit" (Seron-Ferre and Jaffe, 1981; Pepe and Albrecht, 1990). Human and non-human 
primate placentas lack P4S0cl7a-hydroxylase enzyme and are therefore solely dependent 
on both the maternal adrenal and especially the fetal adrenal glands to provide necessary 
androgen precursors in the form of DHA and DHAS for the continually increasing 
placenta production of estrogen via placental P4S0-aromatase.
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The adult adrenal gland is comprised of an outer cortex and an inner medulla. The 
outer cortex is richly vascularized and is composed of three zones: an outer zona 
glomerulosa that lacks P4S0cl7a-hydroxylase and can only produce aldosterone, a zona 
fasciculata (75% of the cortex) and an inner zona reticularis. Both zonae fasciculata and 
reticularis are responsive to ACTH and generate cortisol and androgens. The fetal 
adrenal gland, on the other hand, lacks the typical zonation of the adult adrenal gland. 
Thus, throughout the majority of gestation, the fetal adrenal gland in human and non­
human primates is comprised of two morphologically distinct zones: an inner fetal 
cortical zone, which comprises about 85% - 95% of the gland, and an outer definitive, 
that occupies the remaining 5% - 15% of the gland late (Pepe and Albrecht, 1990; Seron- 
Ferre and Jaffe, 1981). This type of zonation and adrenal development is not present in 
fetal adrenal glands o f non-primates. The fetal zone contains large eosinophilic cells with 
large pale nuclei and distinct cell outlines that have the ultrastructural characteristics of 
steroid-secreting cells. The definitive zone consists of small basophilic cells with dark 
staining nuclei (Seron-Ferre and Jaffe, 1981). Structural and functional evidence have 
described a third zone, the transitional zone (Sucheston and Cannon, 1968; Mesiano and 
Jaffe, 1997). This zone, which appears in human and non-human primates late in 
gestation lies between the definitive and fetal zones and is comprised of large acidophilic 
cells with indistinct cell boundaries and is believed to be the site of cortisol synthesis. 
These three zones are thought to form the zona glomerulosa (definitive), fasciculata 
(transitional) and reticularis (fetal zone) of the adult adrenal.
During the course of gestation in human (Lanman, 1953; Neville and O'Hare, 1982) 
and non-human primates (Kerr et al., 1969; Pepe et al., 1977; McNulty et al., 1981;
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Seron-Ferre et al., 1983; Albrecht and Pepe, 1988), the fetal adrenal gland grows rapidly, 
with marked growth occurring primarily during the last one-third of intrauterine 
development. In humans, the weight of both fetal adrenal glands is less than 100 mg at 
10 weeks gestation and increases to approximately 2000 mg by week 20 (Swinyard,
1941; Bocian-Sobkowska et al., 1997a; Bocian-Sobkowska et al., 1997b). Between 20 
and 30 weeks of gestation, the gland doubles in size, with the ontogenesis of adult-type 
zonation (Sucheston and Cannon, 1968). By term, the human fetal adrenal weighs 
approximately 4000-8000 mg (Swinyard, 1941), about twice the weight of adult adrenals, 
and represents 0.5 percent of total body weight, compared with 0.005 percent in the adult 
(Miller and Tyrrell, 1995). Similar increases in fetal adrenal weight occur in the baboon 
(Pepe et al., 1985b) and the rhesus monkey (McClellan and Brenner, 1981). The increase 
in weight is achieved mainly by an increase in the size of the fetal zone with some growth 
in the outer zones, but not until late in gestation. Thus, by day 150 of gestation in the 
rhesus monkey (term = 165 days), a presumptive zona glomerulosa and a zona fasciculata 
are present but these adult-type zones still only occupy less than 20% of the cortex 
(McClellan et al., 1981). In the human fetal adrenal gland, the fetal zone apparently 
undergoes rapid involution during early postnatal life. By the second week after birth, 
adrenal weight has decreased by one-third. The fetal zone is no longer detectable by age 
1 year (Miller and Tyrrell, 1995). A similar process occurs in the baboon and rhesus 
monkey (McNulty et al., 1981), since distinct adult-type zones are observed in neonates 
by 6-12 months of age (Pepe and Albrecht, 1985a; Pepe and Albrecht, 1985b; Pepe and 
Albrecht, 1985c).
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The factors regulating the remodeling of the fetal gland into the permanent mature 
cortex remain to be elucidated. After birth in the non-human primate, proliferation of the 
definitive zone with absence of necrosis within the fetal zone was observed. This 
postnatal morphology in rhesus monkey was interpreted to represent the development of 
the zona fasciculata by transformation of the fetal zone (Holmes, 1968). In baboons 
(Papio anubis), it was suggested that the zona fasciculata develops by proliferation of 
new cells within its upper margins and not by transformation of preexisting cells in the 
fetal zone (Ducksay et al., 1991). In contrast, it was originally suggested (Sucheston and 
Cannon, 1968) that the fetal zone in humans disappears and that it is the fetal definitive 
cortex which gives rise to the three zones of the adult adrenal gland (i.e. glomerulosa, 
fasciculata and reticularis) during the first year of life. However, more recent studies 
have questioned this theory and it has been proposed that each zone develops 
independently with the definitive zone being analogous to the adult zona glomerulosa, the 
transitional zone to the adult zona fasciculata and the fetal zone to the adult zona 
reticularis (Mesiano and Jaffe, 1997).
The principal secretory products of the human fetal adrenal gland are the C 19- 
androgens, DHA and DHAS, and the C2 i-steroids, aldosterone and cortisol. Based 
primarily on in vitro studies utilizing human fetal adrenal tissues obtained early in 
gestation, it is apparent that cholesterol, derived from circulating low density lipoprotein 
(LDL)-cholesterol produced in the fetal liver, is a major substrate for fetal adrenal 
steroidogenesis (Williams et al., 1998). Thus, the quantity of DHAS and cortisol 
synthesized by human fetal adrenal cells in culture increased as a function of the 
concentration of LDL-cholesterol present in the culture media (Mason and Rainey, 1987).
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Additionally, using in situ perfusion, it was demonstrated that neither circulating acetate 
nor free cholesterol were efficient precursors for human fetal steroidogenesis (Solomon et 
al, 1967). Similar conclusions have been deduced from in vivo studies in baboon (Pepe 
and Albrecht, 1984) and rhesus monkeys (Ducsay et al., 1985) in which less than 5% of 
placental progesterone and pregnenolone secreted into the fetus were utilized for cortisol 
production between mid and late gestation. Pregnenolone does not appear to be a 
quantitatively significant precursor in the human as well, because the total amount of this 
precursor estimated to be used for steroidogenesis is less than 1% of the fetal production 
rate of DHAS (Simpson et al., 1985).
Fetal adrenal uptake of LDL-cholesteroI occurs by LDL receptor-mediated 
endocytosis. Treatment of human fetal tissue fragments with radiolabeled LDL- 
cholesterol, in the presence or absence of ACTH, indicated that fetal adrenal LDL- 
cholesterol uptake was saturable, and presumably mediated by a population of high- 
affinity, low-capacity binding sites (Carr et al., 1980a; Carr et al., 1980b; Carr et al., 
1980c). As in the adult adrenal, where less than 10 percent of LDL enters the cell by a 
receptor-independent mechanism (Brown et al., 1979; Gwynne and Strauss, 1982), LDL- 
cholesteroI binds to fetal adrenal gland LDL receptors that are internalized in coated 
vesicles. Following this, the LDL-cholesterol is then separated from its receptor, which 
is recycled back to the plasma membrane and acid proteinases degrade LDL-cholesterol 
apolipoproteins to amino acids, and acid lipases free cholesterol from esters (Miller and 
Tyrrell, 1995). ACTH stimulates LDL receptor synthesis, the uptake of LDL-cholesterol 
(Golos and Strauss, 1988) and degradation of LDL-cholesterol by fetal adrenal tissue 
fragments (Carr et al., 1980c; Carr and Simpson, 1981). To investigate the nature and
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regulation of the receptors involved in the endocytosis of LDL-cholesterol, the binding of 
LDL-cholesterol to membrane fractions prepared from adrenals of normal and 
anencephalic human fetuses was assayed (Carr and Simpson, 1981; Ohashi et al., 1981a; 
Ohashi et al., 1981b). In tissues from both sources, binding was of high affinity.
However, compared to values in tissues from anencephalics, LDL-cholesterol binding 
and degradation were greater in normal fetuses. Only in normal tissue, however, were 
the latter processes stimulated by ACTH. Although there was substantial binding of 
high-density lipoproteins (HDL) by human fetal adrenals (Ohashi et al., 1981a; Ohashi et 
al., 1981b), HDL was not degraded nor regulated by ACTH. Moreover, HDL does not 
stimulate or sustain human adrenal steroidogenesis (Gwynne and Strauss, 1982; Ohashi et 
al., 1981a; Strauss and Miller, 1991).
Because no more than 20% of cholesterol in the fetus is derived from the maternal 
compartment (Lins et al., 1977; Simpson et al., 198S), it has been suggested that the 
majority of circulating LDL-cholesterol arises from de novo synthesis within the fetus. In 
support of this, extensive cholesterol production by human fetal liver, testes and adrenal 
glands has been demonstrated (Carr and Simpson, 1982). Despite the importance of 
LDL-cholesterol, it has also been demonstrated (Carr et al., 1981; Carr and Simpson,
1981; Mason and Rainey, 1987) that the adrenal readily synthesizes cholesterol from 
acetyl-Co A in response to trophic stimulation by ACTH. Moreover, de novo cholesterol 
production catalyzed by the rate limiting enzyme 3 -hydroxy-3 -methyl-glutaryI coenzyme 
A (HMG-CoA) reductase, could account for as much as 30% of the daily secretion rate of 
DHAS and cortisol by the human fetal adrenal. As in the adult, fetal de novo cholesterol 
synthesis was only an important source of substrate in certain situations. Thus, in the
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absence of LDL-cholesterol, steroidogenesis by human fetal adrenal cells in culture could 
be maintained almost entirely by the de novo pathway (Mason and Rainey, 1987). 
Additionally, the principal molecular species o f fetal adrenal HMG-CoA reductase in 
both cultured and fresh adrenal tissue was a 97,000-dalton protein, the appearance of 
which correlates with in vitro measures of enzyme activity. Moreover, because loss of 
HMG-CoA reductase enzyme protein associated with culture of fetal adrenal cells in the 
absence of ACTH was prevented by concomitant treatment with ACTH, it appeared that 
HMG-CoA reductase activity in fresh adrenal tissue was regulated by ACTH. Indeed, de 
novo cholesterol synthesis in adrenals of anencephalics was significantly lower than that 
in tissue of normal fetuses (Carr et al., 1981). In the adult adrenal, HMG-CoA reductase 
is inactivated by phosphorylation and is activated by dephosphorylation in response to 
intracellular increases in cAMP following the binding of ACTH to its ACTH-receptor 
(Gwynne and Strauss, 1982). In the fetal adrenal however, ACTH may not activate 
HMG-CoA reductase by stimulating dephosphorylation but rather, as demonstrated in 
adult bovine adrenals cells, ACTH may promote increased rates of accumulation of 
HMG-CoA reductase protein (Rainey et al., 1986).
CHEMISTRY OF STEROID HORMONES
Cholesterol (C27), the original precursor molecule for steroid synthesis, is stored 
mainly within lipid droplets esterified (acyl-CoA:cholesterol acyltransferase {ACAT}) to 
polyunsaturated fatty acids following de novo synthesis from acetate via HMG-CoA 
reductase and/or acquisition from LDL-cholesterol extracellularly via LDL-receptor 
uptake. About 80% of the cholesterol used for steroid hormone synthesis comes from 
dietary sources and is transported to the adrenal in plasma as LDL-cholesterol.
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Stimulation of adrenal cells (i.e. ACTH) stimulates cholesteryl ester hydrolase (CEH), 
inhibits ACAT, and results in the release of free cholesterol. Cholesterol is then 
transported to the mitochondria via sterol carrier protein 2 (SCP-2) assisted by 
steroidogenic acute regulator (StAR) protein. StAR is rapidly induced by cAMP. The 
conversion of cholesterol to pregnenolone in mitochondria by P450 cholesterol side- 
chain-cleavage (P450scc) is the first and rate-limiting step in the synthesis o f steroid 
hormones from cholesterol. This step involves three distinct chemical reactions: 20- 
hydroxylation, 2 2 -hydroxylation, and scission of the C20-C22 cholesterol side chain to 
yield pregnenolone (C21) and isocaproic acid (Miller, 1988). Pregnenolone is then 
returned outside the mitochondria to the cytosol before further steroidogenesis occurs. 
Pregnenolone may be converted to 17a-hydroxypregnenolone by P450cl7a-hydroxylase 
or to progesterone by A53 (3-hydroxysteroid dehydrogenase-isomerase (3P-HSD). 3p- 
HSD, a single 42,000-dalton microsomal enzyme (Thomas et al., 1989), catalyzes both 3 
P-hydroxysteroid dehydrogenation and the isomerization of the double bond from the A3 
steroid to the A4 steroid (A represents double bond). There are at least two isoforms of 
human 3P-HSD, encoded by two different genes. The 3P-HSD type I gene is expressed 
in the placenta, skin, mammary gland, and possibly other peripheral tissues (Lorence et 
al., 1990; Lachance et al., 1991). A distinct 3P-HSD type II gene is expressed in the 
adrenals and gonads (Lachance et al., 1991; Rheaum et al., 1991). Both pregnenolone 
and progesterone may undergo 17a-hydroxylation to yield 17a-hydroxypregnenolone 
and 17a-hydroxyprogesterone, respectively. These two reactions are mediated by a 
single enzyme, cytochrome P450cl7a-hydroxylase, 17/20-lyase (P450cl7). As P450cl7 
has both 17a-hydroxylase activity and C 17,20-lyase activity, it is a key branch point in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
26
steroid hormone synthesis, catalyzing production of either glucocorticoids (17a- 
hydroxylation but not Ci7,2o cleavage) or androgens (both 17a-hydroxyiation and Cp, 20 
cleavage). These l7a-hydroxylated steroids may then undergo scission of the C n / C20 
carbon to yield the 19-carbon steroids, DHA and androstenedione (A4A). Subsequent 
conversions of progesterone and 17a-hydroxyprogesterone to 11-deoxycorticosterone 
and 11-deoxycortisol respectively occur in the smooth endoplasmic reticulum by 
P450c21 -hydroxylase. The nature of the 21-hydroxyiating step has been of great clinical 
interest because congenital adrenal hyperplasia most frequently results from 21- 
hydroxylase deficiency. In human fetuses affected with this genetic disorder, the 
dysfunctional adrenal can produce enough androgen to virilize a female fetus to a male 
phenotype (New et al., 1981; Saenger, 1984). 11-deoxycortisol is then further 
hydroxylated within the mitochondria by the P450cl 1P1 -hydroxylase enzyme to form 
cortisol. This enzyme is inhibited by metyrapone and therefore interrupts the negative 
feedback on the HPAA. 11-deoxycorticosterone undergoes three conversions all 
catalyzed by a single mitochondrial enzyme, P450cl 1 (32-hydroxylase enzyme 
(aldosterone synthase) to yield the mineralocorticoid aldosterone. A summary of steroid 
biosynthesis in the adrenal gland with the major secretory products and enzymes is 
presented (Figure 7).
REGULATION OF FETAL ADRENAL STEROIDOGENESIS
Steroidogenesis by the fetal adrenal is regulated at least partly by ACTH. The 
orphan nuclear receptor steroidogenic factor 1 (SF-1) is critical for development and 
function o f the fetal adrenal gland. Many cell transfection studies have highlighted 
important roles for SF-l in the transcriptional activation of the genes that encode
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Figure 7. Outline of major pathways in adrenocortical hormone biosynthesis. The major 
secretory products are underlined. Pregnenolone is the major precursor of corticosterone 
and aldosterone, and 17-hydroxypregnenolone is the major precursor of cortisol. The 
enzymes and cofactors for the reactions progressing down each column are shown on the 
left and from the first to the second column at the top of the figure. When a particular 
enzyme is deficient, hormone production is blocked at the points indicated by the shaded 
bars.
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steroidogenic enzymes, while targeted disruption of the mouse gene encoding SF-1 
clearly defined the essential role for SF-1 in adrenal, as well as gonadal, development 
(Hanley et al., 2001). It is well established that the expression and activity of the 
enzyme 30-HSD, responsible for the synthesis of A43-ketosteroids (i.e. cortisol) from 
pregnenolone (Ps) is minimal during the majority of intrauterine development in the fetal 
adrenal o f human (Lanman, 19S3; Neville and OUare, 1982) and non-human primates 
(Pepe et al., 1977; Kerr et al., 1969; McNulty et al., 1981; Simonian and Gill, 1981; 
Seron-Ferre et al., 1983; Albrecht and Pepe, 1988; Mesiano and Jaffe, 1997; Coulter et 
al., 1996). When, however, human fetal definitive zone explants from the first and 
second trimester are cultured in the presence or absence of ACTH and other agonists of 
the protein kinase A pathway, the capacity for cortisol secretion is significantly induced 
as is the activity of 3J3-HSD (Bolte et al., 1964; Beitins et al., 1972; Beitins et al., 1973; 
Branchaud et al., 1978; Doody et al., 1990). Consequently, adrenals of fetuses early in 
gestation are competent to respond to ACTH but may not have been exposed to sufficient 
ACTH in vivo during this developmental period.
Recent immunohistochemical evaluation of the cellular localization and ontogeny of 
steroidogenic enzymes has provided additional insight into the regulation of 
steroidogenesis in utero. P450scc is expressed in all cells o f the adrenal cortex in both 
the mid-gestation and the term-gestation rhesus monkey fetus (Coulter et al., 1996). In 
contrast, 3p-HSD was localized primarily in the definitive zone cells from mid-gestation 
fetuses, whereas at term-gestation it was localized in both the definitive and transitional 
zone cells. P450cl7 expression was detected in the transitional and fetal zones. ACTH 
only increased secretion of cortisol by fetal transitional zone cells, indicating that 3|3-
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HSD is not present in fetal zone cells (Doody et al., 1990). Western blot confirmed the 
absence of 30-HSD protein in the fetal zone and its exclusive presence in the 
definitive/transitional zone (Doody et al., 1990). The absence of 3{3-HSD in the fetal 
zone explained the low ACTH-stimulable cortisol secretion from these cells in vitro 
relative to a 5-fold increase in ACTH-stimulable cortisol secretion from similarly 
cultured definitive/transitional zone cells. Coexpression of 3(3-HSD and P450cl7 
enzymes in the transitional zone by term-gestation in the primate fetal adrenal gland 
indicates the capacity of these cells to synthesize de novo cortisol. These findings are 
also supported by in vivo observations where a rise in the serum concentrations of cortisol 
in the baboon fetus (Pepe and Albrecht, 1984) and in the umbilical artery in humans 
(Murphy and Diez d'Aux, 1972; Smith and Shearman, 1974; Murphy, 1982) and rhesus 
monkeys (Mitchell et al., 1982) occurs late in gestation. Studies in the baboon (Pepe et 
al., 1977; Pepe and Albrecht, 1984; Waddell et al., 1988a; Waddell et al., 1988b) have 
confirmed that the increase in cortisol levels reflects production by the fetal adrenal gland 
and is not the result of an increase in placental transfer of maternal cortisol nor an 
alteration in fetal cortisol metabolic clearance (Figure 5).
In contrast to expression late in gestation of 30-HSD, the activities, mRNA and 
proteins for the enzymes catalyzing conversion of cholesterol to pregnenolone (P450scc) 
and hydroxylations (P450cl7, 21,11) at steroid carbons 17, 21, and 11 respectively 
appear to be present earlier in gestation (Smith and Shearman, 1974; Pepe et al., 1977; 
ShoU, 1981; ShoU, 1982; ShoU, 1983; Voutilainen and Miller, 1986; Di Blasio etal.,
1987; Jaffe et al., 1988). However, despite the apparent abundant levels of C-17, -21, 
and -11 hydroxylases throughout gestation, the primate fetal adrenal gland (Pepe et al.,
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1988; Pepe and Albrecht, 1990) appears to have a very limited capacity to utilize 
exogenous progesterone (Pepe et al., 1979; Winkel et al., 1980; Ducsay et al., 198S) or 
pregnenolone (Pepe, 1977; Pepe and Albrecht, 1980) as substrate for cortisol. Thus, 
although it was originally suggested that the fetal adrenal utilizes placental progesterone 
for corticosteroid synthesis (Solomon et al., 1967; Voutilainen et al., 1979; Branchaud et 
al., 198S), it has been shown in rhesus monkeys (Ducsay et al., 1985) and baboons (Pepe 
and Albrecht, 1980) that less than 6% of placental progesterone and pregnenolone 
secreted into the fetus prior to term is used to synthesize cortisol. Although the 
steroidogenic pattern as well as the growth and differentiation of the definitive and fetal 
cortical zones of the human and non-human primate fetal adrenal gland are clear features 
of intrauterine development, our understanding of the factors regulating these processes is 
incomplete.
FETAL PITUITARY GLAND
The pituitary gland is an oval, bean-shaped, symmetrical, brownish red organ. It 
weighs about 100 mg in a term human fetus, 25 mg in a term baboon fetus and 600 mg in 
the adult human. The pituitary is located under the brain in a bony cavity called the sella 
turcica and is attached to the median eminence of the hypothalamus by a stalk through 
which axons (about 100,000) and neurosecretion-containing blood pass. The pituitary 
gland develops embryologically as a fusion between an up-growth of ectodermal cells 
from the pharynx (Rathke’s pouch) to form the anterior lobe (adenohypophysis), and a 
down-growth of neural tissue from the hypothalamus to form the posterior lobe 
(neurohypophysis). Between both lobes is found a small partition or intermediate lobe. 
The adenohypophysis constitutes 80% of the gland. The pituitary is evident early in the
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first trimester and near the end of the first trimester is recognizable as an adult pituitary, 
only smaller. Both growth hormone and ACTH are evident in the adenohypophysis by 
this time (Williams et al., 1998). Luteinizing, follicle-stimulating and thyroid-stimulating 
hormones as well as prolactin are evident in the adenohypophysis shortly thereafter. The 
neurohypophysis contains unmyelinated, hypothalamus-originating nerve fibers that 
contain and release oxytocin and arginine vasopressin (AVP).
The adenohypophysis is the most richly vascularized of all mammalian tissues, 
receiving 0.8ml blood / g /  min from a unique capillary-vein-capillary network called the 
hypothalamo-hypophysial portal system. This portal circulation connects the median 
eminence of the basal hypothalamus and the adenohypophysis and plays an important 
role in the regulation of adenohypophysial hormone production and secretion.
During the past decades, it has generally been accepted that ACTH is the principal 
trophic hormone regulating the fetal adrenal gland (Gulyas et al., 1977; Carr and 
Simpson, 1981; Jacobs et al., 1994). ACTH, whose biological half-life is approximately 
8 minutes, is a 39-amino-acid (4,S00-dalton) peptide synthesized as part of a large, 241- 
amino-acid (28,500-dalton) precursor molecule, pro-opiomelanocortin (POMC). POMC 
is translated from a single mRNA molecule (chromosome 2) and undergoes extensive 
post-translational processing, including glycosylation, enzymatic cleavage and 
phosphorylation, NHr-terminal acetylation, and COOH-terminal amidation of certain 
cleaved peptides. Enzymatic cleavage of POMC protein occurs by prohormone 
convertases (PC), a family of seven subtilisin-like endoproteases. PCs are responsible for 
the processing of neuropeptides, adhesion molecules, receptors, growth factors, cell 
surface glycoproteins and enzymes. PCI and PC2 are the best-known and most studied
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PCs that accomplish neuroendocrine-specific processing of protein precursors directed to 
the regulated secretory pathway (Muller and Lindberg, 1999). PCI and PC2 share more 
than 50% homology in their catalytic domains, but exhibit differences in substrate 
specificity and susceptibility to inhibitors (Apletalina etal., 2000).
POMC protein is cleaved at dibasic amino acids by PCI and/or PC2 into (a) ACTH, 
which can give rise to melanocyte-stimulating hormone (a-MSH) and corticotropin-like 
intermediate lobe peptide (CLIP): (b) (3-lipotropin ((J-LPH), which can yield y-LPH, 0- 
MSH, and (3-endorphin (and thus a - and y-endorphins); and (c) a large NHr-terminal 
peptide, which generates y-MSH. In the human adenohypophysis however, ACTH1.39 is 
not cleaved any further. Both immunocytochemical and biochemical studies have shown 
that ACTH is present in the human pituitary gland after ten weeks of gestation (Baker 
and Jaffe, 1975; Silman etal., 1976; Begeot et al., 1977). Corticotrophs (ACTH- 
containing cells) appear basophilic (vice acidophilic) upon hematoxylin and eosin 
staining and represent about 15 -  20% of all adenohypophysial cells. Mean plasma 
ACTH concentrations o f240 pg/ml have been found in cord blood samples obtained at 
14-34 weeks in human fetuses delivered by hysterectomy. A decrease in plasma ACTH 
concentrations to 160 pg/ml occurs after 34 weeks. However, these single point 
determinations of fetal ACTH may not accurately reflect hypothalamic-pituitary function 
in vivo because of the multiple sites of secretion, stress and potential pulsatile nature of 
pituitary ACTH release (Pepe et al., 1994). In sheep, immunoreactive ACTH becomes 
detectable in fetal blood on about day 1 0 0  of gestation and steadily increases at a rate of 
approximately 5 pg/ml between days 100 to 140 of gestation (Jones et al., 1977; Jones 
and Roebuck, 1980; Saez et al., 1984; Challis and Brooks, 1989). Progressive gestational
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increases in fetal pituitary POMC mRNA and ACTH output by the human (Siler-Khodr, 
1974) have also been described. In anencephalic human (Johannsson, 1979; Bocian- 
Sobkowska et al., 1997a; Bocian-Sobkowska et al., 1997b) and rhesus monkey (Novy et 
al., 1977) fetuses, fetal adrenal gland size and weight are considerably reduced compared 
with normal. In human anencephalic fetuses, plasma levels of ACTH are low (Seron- 
Ferre and Jaffe, 1981), and the fetal adrenal gland develops normally up to IS weeks of 
gestation (Williams et al., 1998). Fetal adrenal adenylate cyclase activity was not 
detectable in cultured human fetal adrenal cells from anencephalics, although enzyme 
activity was very high in both the definitive and cortical zones of glands obtained from 
normal fetuses. When the HPAA is suppressed in normal fetuses treated with 
glucocorticoids, the fetal adrenal gland in humans (Easterling et al., 1966; Simmer et al., 
1974; Gray and Abramovich, 1980; Ballard et al., 1980), rhesus monkeys (Challis et al., 
1974) and baboons (Townsley, 1976; Leavitt et al., 1997; Aberdeen et al., 1998; Leavitt 
et al., 1999) atrophies and exhibits reduced steroidogenesis. Similar observations have 
been made in the lamb in which the maturation of immature fetal cells was prevented by 
removal of the fetal pituitary (Liggins et al., 1973; Robinson et al., 1983).
Recent studies using in vitro and in vivo experimental paradigms to study the relative 
importance of fetal pituitary ACTH upon fetal adrenal growth, differentiation, and 
steroidogenesis have yielded equivocal results. For example, it has been shown in 
cultures of human fetal adrenal cells that ACTH inhibits (Simonian and Gill, 1981), 
activates (Diblasio et al., 1990), partially activates (Jaffe et al., 1977) or has no effect 
(Simonian and Gill, 1981) on cell proliferation and/or steroidogenesis. A stimulatory 
effect of ACTH on proliferation of the adult-type definitive zone cells was reported after
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culture of collagenase-dispersed human fetal adrenal cells obtained early in gestation. 
However, ACTH caused involution and subsequent disappearance of the large fetal 
cortical zone cells under the same experimental conditions (Kahri et al., 1976; Fujieda et 
al., 1982). Jaffe et al (1977) demonstrated ACTH binding and cortisol secretion in the 
definitive/transitional zone cells of human fetal adrenals in early gestation but ACTH 
induced inconsistent secretion of DHAS from the fetal zone cells. In different culture 
conditions, addition of ACTH increased the rate of growth and the cytoplasmic size (i.e. 
hypertrophy) of the definitive cells over an 8-day period but had no apparent effect on 
fetal zone cells (Kahri and Halinen, 1974; Kahri et al., 1976). These results contrast with 
studies demonstrating that ACTH induced proliferation and enhanced steroidogenesis of 
cultures of fetal zone cells obtained from fetuses at 18-20 of weeks of gestation (Diblasio 
etal., 1990).
Moreover, 30-HSD expression, used as a marker to assess adrenal corticosteroid- 
producing cell proliferation, was increased in response to ACTH in human definitive and 
fetal zone cells in vitro (Mesiano and Jaffe, 1997; Mason et al., 1993). Additionally, 
stimulation of rhesus monkey fetal pituitary ACTH release resulted in increased 30-HSD 
protein and mRNA expression in both the definitive and transitional zones (Coulter et al., 
1996). The ACTH-induced increase in P4S0cl7a-hydroxylase mRNA in the transitional 
zone exceeded that in the fetal zone. In contrast, the relative abundance of P450scc 
detected in all three zones was not altered by increased ACTH secretion. It has also been 
shown that ACTH inhibits mitosis of adult human and bovine adrenocortical cells in 
culture (Hornsby and Gill, 1977; Hornsby and Gill, 1978) as well as human fetal 
definitive and cortical cells cultured for more than 6 days (Simonian and Gill, 1981).
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Additionally, ACTH appears to be important to the increase in P450cl7a-hydroxylase 
measured late in gestation, but ACTH may not be required for the initial expression of the 
P-450 hydroxylases (cl ip i-, cl 132- and 21-) in sheep fetal adrenal glands (John et al., 
1987). Similar conclusions have been obtained using bovine fetal adrenal cells (Lund et 
al., 1988). An important limitation of primary cultures of fetal adrenal cortical cells is 
that they undergo “maturation” and other phenotypic changes in vitro including the 
capacity to synthesize cortisol in the presence of added ACTH (Kahri and Halinen,
1974). Simonian and Gill (1981) demonstrated that initially, fetal and definitive zone 
cells in culture increased their secretion of their characteristic steroids, DHAS and 
cortisol, respectively, however, after 3-4 days of exposure to ACTH the pattern of steroid 
secretion by the fetal zone cells shifted to cortisol production, indicating induction of 33- 
HSD activity in these cells. Therefore, primary cell culture of fetal adrenal gland may 
not be the best model to evaluate the role of ACTH on fetal and definitive zone function 
and development in vivo.
Collectively, these findings suggest that factors of fetal pituitary origin (i.e. ACTH) 
are essential to fetal adrenal growth and maturation, at least during the last two-thirds of 
intrauterine development. Since adrenal glands develop normally up to 15 weeks of 
gestation in anencephalic fetuses, extrapituitary factors, perhaps o f placental and/or 
maternal origin, may also be important to adrenal maturation, at least early in gestation. 
Some of these factors may be placental ACTH, placental CRH, fetal adrenal/hepatic IGF- 
II (Aberdeen et al., 1999), placental estradiol and placental chorionic gonadotropin 
(HCG). Both activin and inhibin appear to inhibit fetal zone proliferation and ACTH- 
stimulable shift of steroid production from DHAS to cortisol (Williams et al., 1998).
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Therefore, the role of ACTH per se on growth (hyperplasia and/or hypertrophy), 
maturation and steroidogenic capacity of the fetal adrenal gland is only partially 
understood.
In the adult adrenal, ACTH stimulates the synthesis and release of steroids by binding 
with high-affinity to its cell-surface ACTH receptor (ACTH-R), stimulating adenylate 
cyclase via G-protein coupled activation and the production of cAMP (Nicholson et al., 
1978; Kojima et al., 1985; Jefcoate et al., 1986). Classically, cAMP then binds to the 
regulatory subunits of cAMP-dependent protein kinase A (PKA) which releases the 
catalytic subunits. PKA catalytic subunits are now capable of phosphorylating other 
cytosolic and/or nuclear proteins at their serine and/or threonine amino acids. One of the 
proteins phosphorylated is cholesteryl ester hydrolase (CEH), increasing its activity. 
Consequently, more free cholesterol is released from cholesterol esters and converted to 
pregnenolone in the mitochondria (Greenspan and Strewler, 1997). Two other roles for 
cAMP include activation of cAMP-gated channels and binding to and activating cAMP- 
Guanine Nucleotide Exchange Factors (cAMP-GEFs). cAMP is inactivated by 
hydrolysis by any one of twenty-one mammalian phosphodiesterases (Conti, 2000).
The cAMP response element binding (CREB) and cAMP response element 
modulator (CREM) proteins bind to cAMP response elements (CRE) in genes regulated 
by cAMP. Both CREB and CREM are members of a family of DNA-binding 
phosphoproteins which contain glutamine-rich transactivation domains and basic amino 
acid (le u c in e  zipper) rich regions (bZIP). CREB protein is a cAMP-inducible activator of 
transcription following PKA phosphorylation and binds as a homodimer to CREs, a 
palindromic octamer (TGACGTCA) that usually lie upstream of the basal promoter of a
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significant number of genes. CREB is therefore responsible for regulation of gene 
transcription in response to hormonal stimulation of the cAMP pathway (Meyer and 
Habener, 1993). CREM protein, on the other hand, acts as a transcriptional repressor in 
most tissues (Daniel et al., 2000). cAMP also autoregulates its own expression by 
modulating three cAMP response elements responsible for cAMP induction of 
transcription (Meyer et al., 1993; Walker et al., 1996). Extracellular calcium, which 
enters through T-type calcium channels, independent of adenylate cyclase activation, is 
required for optimal ACTH binding and ACTH-induced steroidogenesis (Williams et al., 
1998). All of the specific proteins phosphorylated in response to ACTH to activate 
steroidogenesis are not known. Increases in expression of immediate early genes fos-B, 
jun-B, c-fas and c-jun have been implicated (Williams et al., 1998). However, 
accumulation of cAMP does precede steroidogenesis, and binding of cAMP to the 
regulatory subunit of protein kinase correlates well with stimulation of steroidogenesis 
(Hayashi et al., 1979). It has been proposed that cAMP also acts directly on exocytotic 
machinery independent of PKA to stimulate hormonal release (Ozaki et al., 2000).
The effects of ACTH on steroidogenesis are two-fold. Acute effects occur within a 
few minutes and involve an increase in adrenal blood flow and stimulation of cholesterol 
uptake (via LDL-cholesterol receptors), availability and transport to the inner 
mitochondrial membrane and conversion to pregnenolone by mitochondrial P450scc 
(Williams et al., 1998). Steroidogenic acute regulatory protein (StAR) is an ACTH- and 
SF-l-inducible protein and is a key modulator of cholesterol transport into mitochondria. 
A second protein involved in this process is the peripheral-type benzodiazepine receptor 
(PBR), which completes the final step of cholesterol delivery to P4S0scc for
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transformation into pregnenolone (Lacroix et al., 2001). ACTH also up-regulates the 
immediate early genes c-fos and c-jun via the PKA pathway as well as its own receptor, 
the ACTH-R. Only small amounts of cortisol are stored in the adrenal. The long-term or 
chronic specific responses to ACTH require hours or days and are manifested as 
increased synthesis in DNA and mRNA for most of the steroidogenic enzymes (30-HSD 
II, P450cl7, P4S0 c21 and P450cl 1) and also cellular growth (hyper-vascularization, 
cellular hypertrophy, and cellular hyperplasia). This long-term regulation is complex, as 
no clear correlation exists between mRNA and protein levels of steroidogenic enzymes in 
vivo (Lacroix etaI., 2001).
The ACTH-R is the smallest member (297 amino acids) of the super family of G 
protein-coupled receptors with seven hydrophobic transmembrane domains (Mountjoy et 
al., 1992). The ACTH-R belongs to the melanocortin receptor subfamily which is 
characterized by short NHr-terminal extracellular domains (which contain two putative 
N-glycosylation sites), short COOH-terminal intracellular domains and unusually short 
fourth and fifth transmembrane-spanning domains (Allolio and Reincke, 1997). As in the 
adult adrenal, in vitro studies of human adrenal cortical cells from mid-gestation fetuses 
has shown that these cells do contain ACTH receptor mRNA and that ACTH receptor 
expression is upregulated by its own ligand and also by angiotensin II. ACTH 
specifically increases the transcription rate of the ACTH-R and the ACTH-R mRNA half- 
life. This upregulation is apparently mediated in the human (Lebrethon et al., 1994a; 
Lebrethon et al., 1994b; Mesiano et al., 1996) and baboon (Davies et al., 1993) fetal 
adrenal by a PKA (i.e. cAMP mediated), not a PKC (i.e. calcium and/or diacylglycerol), 
mechanism. Recently, our laboratory (Albrecht et al, 1996) demonstrated that adrenal
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ACTH-R mRNA levels in the baboon fetus increase 13-fold from early to mid gestation 
and then unexpectedly decline by 70% in term adrenal. This biphasic, monomodal 
developmental expression contrasts with previous data demonstrating a progressive 
increase in adrenal weight (Albrecht et al., 1996), an ontogenic increase in activity of 
steroidogenic enzymes (Pepe and Albrecht, 1991) and an increase in de novo cortisol 
production near term (Pepe et al., 1990). These three increases are consistent with action 
of ACTH in both fetal and definitive zone cells.
Additionally, it has recently been demonstrated that in contrast to the developmental 
increases in growth and function of the definitive zone, there is a decline in the output per 
cell of fetal zone-specific DHA, between mid- and late gestation (Berghom et al., 199S). 
Although the secretion of DHAS increased with advancing gestation, the absolute levels 
of DHA and DHAS were lower compared to cortisol levels near-term. The increase in 
size of the fetal adrenals, apparently accounts for the progressive increase in total adrenal 
Ci9-steroid output. These findings suggest that there is an uncoupling of development 
between the fetal zone and the definitive zone in the second half of pregnancy, again 
indicating a multifactorial regulation of fetal adrenal maturation.
FETAL HYPOTHALAMUS
The hypothalamus and pituitary form a unit which is recognizable and mature by mid­
gestation and able to exert control over adrenal function (Ackland et al., 1986;
Blumenfeld and Jaffe, 1986; Scott and Pepe, 1987; Berghom et al., 1991). The median 
eminence at the base of the third ventricle of the hypothalamus is the site at which 
adenohypophysis-regulating neurons release their secretions into the capillaries of the 
hypothalamo-hypophyseal portal system. The median eminence, which is evident by the
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9* gestational week, contains special features including densely packed nerve endings, 
fenestrated (windowed) capillaries and supporting glial and ependymal (tanycytes) cells 
which allow feedback effects of pituitary and adrenal gland hormones (Williams et al., 
1998). Some of the nerve endings in the median eminence are the terminals of 
corticotropin releasing hormone (CRH) neurons, which originate in the paraventricular 
nucleus of the mediobasal hypothalamus. CRH, a 41 amino acid peptide, is synthesized 
as a 196 amino acid pro-hormone and undergoes enzymatic cleavage at basic amino acid 
pairs prior to release. CRH belongs to a family of peptides that includes sauvagine from 
frog skin and urotensin I from teleost fish, both of which have ACTH-releasing and 
hypotensive activities like those of CRH (Williams et al., 1998). CRH acts by binding to 
its specific CRH receptor type I (CRH-R1) on adenohypophysial corticotrophs and 
activating adenylate cyclase, thereby increasing intracellular cAMP levels which 
summarily activate PKA, increasing the influx of extracellular calcium through L-type 
calcium channels and increasing the production of lipoxygenase metabolites of 
arachidonic acid. A prompt release of ACTH ensues as well as an increase in the POMC 
mRNA transcription rate (Williams et al., 1998). About S0% of CRH-containing 
parvocellular neurons contain arginine vasopressin (AVP) which can be concomitantly 
released with CRH to synergistically stimulate ACTH release from the adenohypophysis. 
AVP exerts its effect by binding to vasopressin (V3) receptor, thereby activating 
phospholipase C-mediated hydrolysis of phosphatidylinoshol 4,5-bisphosphate (PIP2) to 
produce inositol 1,4,5-trisphosphate (IP3), which mobilizes intracellular calcium, and 
diacylglycerol, which activates phospholipid- and calcium-dependent protein kinase C 
(PKC). CRH and AVP are secreted into the hypophyseal-portal circulation in a pulsatile
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fashion. These rhythms are responsible for pulsatile release (about 15-18  pulses per 24 
hour day) of ACTH and contribute to peak levels of ACTH and cortisol in the early 
morning. Important hypothalamic excitatory inputs which increase CRH and AVP 
release come from the suprachiasmatic nucleus (the regulator of circadian rhythms), the 
amygdala (a way station of the limbic system, i.e. “emotional” brain), the raphe nuclei of 
the brain stem (site of origin of the serotonergic system), and the locus ceruleus of the 
brain stem (site o f origin of ascending noradrenergic fibers). Vasoactive intestinal 
peptide (VIP), pituitary adenylate cyclase activating peptide (P ACAP), angiotensin II 
(Ang-II), neuropeptide Y (NPY), cholecystokinin (CCK), gastrin-releasing peptide 
(GRP), interleukin-I (IL-1), tumor necrosis factor a  (TNF-a), interleukin-6 (IL-6), 
serotonin, histamine and acetylcholine mildly enhance CRH and AVP secretion (Lacroix 
et al., 2001). Inhibitory inputs on CRH secretion arise in the hippocampus and in the 
locus ceruleus of the midbrain (Williams et al., 1998). Atrial natriuretic peptide (ANP), 
substance P, somatostatin and nitric oxide (NO) suppress CRH release. Psychological 
and physical stress can activate the HPAA with an increase in both ACTH and cortisol 
secretion. In addition to adrenal cortisol release, the ACTH released by CRH stimulates 
the secretion of other adrenal steroids, including aldosterone and DHA. Cortisol inhibits 
secretion of CRH, AVP and ACTH and the synthesis of their respective mRNAs. The set 
point o f plasma cortisol feedback inhibition is determined by the central nervous system.
In humans, as well as non-human primates, CRH is produced by the placenta (Pepe 
and Albrecht, 1999). Placental CRH is identical in immunoreactivity and bioactivity to 
hypothalamic CRH. During human pregnancy, maternal plasma CRH concentrations rise 
exponentially in the second and third trimesters and fall precipitously after delivery. The
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absolute CRH levels, and perhaps the rate of increase, correlate with the timing of 
parturition (Reis et al., 1999). Apparently, part of this parturition mechanism involves 
CRH binding to its type-II receptor in the myometrium and modulating labor (Stevens et 
al., 1998). In baboons, plasma CRH concentrations peak in the first half of pregnancy, 
then decline to lower levels for the remainder of gestation. In both species, placental 
CRH is secreted into the fetus but at concentrations 100-fold lower than those in the 
mother. CRH stimulates placental ACTH production in vitro suggesting a possible 
paracrine role for placental CRH (Williams et al., 1998). However, cortisol has no 
inhibitory effect on CRH or POMC release as in the hypothalamo-pituitary unit. CRH 
type-I receptors have also been localized to human fetal adrenal gland fetal zone cells. 
Moreover, CRH, via the phospholipase C-inositol phosphate PKC second messenger 
system vice the classical adenylate cyclase-cAMP-PKA pathway seen in pituitary 
corticotrophs, increased the mRNA for P450scc and P450cl7a-hydroxylase, but not 3(3- 
HSD (Chakravorty et al., 1999). Additionally, CRH was as effective as ACTH in 
stimulating DHAS production and release in cultured human fetal adrenal fetal zone 
cells, but not cortisol release (Smith et al., 1998). Finally, among the hypophyseotropic 
hormones, CRH is the only one for which a specific binding protein (in addition to the 
receptor) exists in tissue or blood. (Williams et al., 1998). The placenta and livers are the 
principal sources of pregnancy-related CRH-binding protein, which complexes, and 
renders inactive, up to 80% of plasma CRH (Pepe and Albrecht, 1999). The functional 
significance of the CRH-binding protein is not fully understood although its presence in 
corticotrophs may act to sequester and/or terminate the action of membrane-bound CRH.
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A second role for the CRH system is in energy homeostasis via direct central 
actions independent of HPAA control. A CRH-related peptide, urocortin, has a much 
higher affinity for another CRH receptor, (CRH-R2), which is expressed in the heart, 
muscle, GI tract and brain. Both CRH and urocortin, when administered centrally, inhibit 
feeding, decrease appetite and stimulate metabolism, in opposition to the role of 
hypothalamic CRH in stimulating cortisol release and enhancing energy storage (Cullen 
etal., 2001).
STEROID HORMONE ACTION
Estrogens exert a wide variety of effects on growth, development and differentiation, 
including important regulatory functions within the reproductive, central nervous and 
hypothalamo-pituitary axis systems. Estrogens mediate these activities through binding 
to specific, high-affinity, intranuclear receptor proteins, the estrogen receptor alpha 
(ERa), and the estrogen receptor beta (ER(3), encoded by two separate genes located on 
human chromosomes 6 and 14, respectively. Both receptors function as signal 
transducers and transcription factors to modulate expression of target genes (Klinge, 
2000). Both receptors are sequestered in an “inactivated” form in the nucleus and, upon 
binding of ligand, undergo conformational changes, presumably by dissociation of heat 
shock proteins (hsp90 and hsp70) to form an “activated” receptor. The estrogen receptors 
can then dimerize (oux, (3(3 or a(3) and bind to specific DNA sequences, estrogen response 
elements (EREs), and stimulate estrogen-target gene transcription. The minimal 
consensus ERE is a palindromic inverted repeat (IR): 5’-GGTCAnnnTGACC-3\ where 
n -  any nucleotide. Most estrogen-regulated genes contain imperfect, non-palindromic 
EREs (Klinge, 2000). Secondly, ER can enhance gene expression without direct DNA
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binding. One mechanism accounting for this effect is interaction between ER and other 
transcription factors that may stabilize the DNA binding of that transcription factor 
(Webb et al., 1999). Examples of this DNA-binding-independent mechanism include ER 
a  interaction with SP1 and ERa/ ER0 interaction with AP-1 (Klinge, 2000). Thirdly, in 
addition to the classic ligand-mediated activation pathways, it has been shown that ER, in 
the absence of ligand, can be activated following phosphorylation by growth factors 
(EGF) or kinases (PKA, MAPK or CDK2; Hall and McDonnell, 1999). Finally, the 
fourth possible mechanism for estrogen action is the putative existence of a cytoplasmic 
membrane, G-protein coupled ER (Razandi et al., 1999), with downstream effects on 
calcium flux and cAMP generation.
ERa and ER3 are members of the steroid hormone/nuclear receptor (NR) 
superfamily (about ISO members) of transcription/enhancer proteins. The superfamily 
includes the class I NR the steroid receptors, e.g. glucocorticoid, mineralocorticoid, 
progesterone, and androgen receptors and the class n  NR e.g. retinoic acid receptor, 
retinoid X receptor, vitamin D receptor, thyroid receptor and peroxisome proliferator 
activated receptor. Additionally, the NR superfamily includes about SO “orphan 
receptors” which are putative NRs that have no identifiable ligand. Molecular cloning of 
the cDNA of the NRs has led to rapid advances in our knowledge of these proteins 
including the fact that they all share common functional domains (A, B, C, D, E and F) 
for DNA binding (DBD), ligand binding (LBD) and activation function (AF). The N- 
terminal domain, termed the A/B domain, is of variable length and has the lowest degree 
of sequence similarity. This domain usually harbors an activation function (AF-1) that 
contributes to transcriptional activity. Adjacent to the A/B domain is the C domain or
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DNA-binding domain (DBD). This is the most highly conserved region and consists of
2+two cysteine-rich (8 total cysteine amino acids) Zn finger motifs that confer specific
DNA-binding capacity. Within the DBD is the P-box which encompasses six amino
2+acids (four cyteines) and the first Zn finger and confers DNA-binding specificity (i.e.,
recognition of target genes). Additionally within the DBD is the D-box, which utilizes 
2+the second Zn finger to confer dimerization activity and is important for efficient DNA
binding at palindromic, direct repeat or inverted repeat hormone response element DNA 
sequences. Adjacent to the DBD or C domain is the D domain which is poorly conserved 
and contains the hinge region (40 -  SO amino acids) involved in association with the 
molecular chaperone heat shock protein 90 (hsp90), nuclear localization, dimerization 
and cofactor binding. At the C-terminus is the ligand binding region or E/F domain 
which displays a high degree of homology among the NR superfamily members. This 
multifunctional region is involved in dimerization, ligand binding (agonists and 
antagonists), cofactor binding, activation functions (AF-2), nuclear localization and 
hsp90 interactions.
The human ERa gene is extremely complex. To date, six different mRNAs (± 1,785 
bases) transcribed utilizing three different promoters from the same gene have been 
described (Flouriot et al. 1998). These transcripts encode a common protein (595 amino 
acid, 66,182-daltons) but differ in their 5’-untranslated region. ERa has a rapid turnover 
rate in cells (3 -4  hours). The human ER0 gene also appears to be complex (Hall and 
McDonnell, 1999). Three isoforms of ER0 have been described: ER0-short (485 amino 
acids) and ER0-long (548 and 530 amino acids). The expression patterns of ERa and
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ER0 mRNAs are different. ER|3 mRNA (7 kb and 9.S kb) is more widely expressed than 
ERa and is highest in endometrium, placenta, prostate, ovary, lung, adrenal, testis, 
kidney and spleen (Albrecht et al., 1999; Brandenburger et al., 1997). The highest 
expression of ERa mRNA in the human has been found in ovary, testis, pituitary, colon 
and uterus (Enmark et al., 1997; Mosselman et al., 1996).
The DBDs of the two ERs share approximately 97% sequence similarity. In the 
LBD, the overall amino add identity is 5S% (Pettersson and Gustafsson, 2001). The 
major differences in ligand binding between ERa and ERP lie in the affinities for various 
compounds, and the transcriptional response a given compound is able to elicit. Binding 
of an agonist to the LBD induces a conformational change that is assodated with the 
transition to a transcriptionally active complex. With regard to the ability to activate 
transcription with ERE-containing constructs, ERp is weaker (20-60%) than ERa in 
most cell systems tested. This is at least partly attributable to the fact that ERP does not 
contain a strong AF-1 within its amino-terminus A domain, but rather contains a 
repressor domain that when removed, increases the overall transcriptional activity of the 
ERP (Hall and McDonnell, 1999). Finally, phosphorylation plays a major role in the 
multistep process of ER activation. ER phosphorylation occurs as part of both ligand- 
induced activity and ligand-independent transcriptional activation (Pettersson and 
Gustafsson, 2001). Phosphorylation of both ER’s tyrosine in the LBD, serines 118 and 
236 in ERa and serines 106 and 124 in ERP enhances dimerization and/or transcriptional 
activity in vitro.
However, significant gaps still exist in our understanding of the mechanism by which 
receptors stimulate or repress gene transcription. A more recent advance in the
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understanding of NR gene regulation considers a new class of proteins called 
coregulators. These proteins have the faculty to repress (corepressors) or to enhance 
(coactivators) the activity o f genes regulated by nuclear hormone receptors in a ligand- 
dependent fashion (Robyr et al., 2000). Approximately 19 different ERa coactivator 
proteins have been identified. Three of the most studied include SRC-1, SRC-2 and 
CBP/p300 which form complexes with ER to increase the rate of hormone-responsive 
gene transcription. These coactivators contain unique, conserved leucine-rich amino acid 
repeats (LXXLL), also called NR boxes, which form hydrophobic surfaces and are 
responsible for binding to/interacting with ERs. Some of these coactivators, including 
SRC-1 and -3 (steroid receptor coactivator) have histone acetyltransferase (HAT) 
activity. HATs acetylate lysine residues on the N-terminal tails of histones H3 and H4 in 
chromatin, resulting in weaker association of the histones with DNA. This disruption of 
higher-order chromatin structure facilitates access of transcription factors (i.e., RNA 
polymerase II) to promoter elements and is associated with increased transcriptional 
activity (Pettersson and Gustafsson, 2001). Corepressors, on the other hand, recruit 
proteins that have histone deacetylase (HDAC) activity that is believed to repress gene 
expression by maintaining chromatin in a more condensed state (Klinge, 2000). 
Corepressors may also interact with ERs and obstruct recruitment of coactivators. Two 
such corepressors are NcoR (nuclear receptor corepressor) and SMRT (silencing 
mediator for retinoid and thyroid hormone receptors). Recent studies suggest that it is the 
repertoire of transcription factors (including coactivators and corepressors) present within 
a cell in addition to the selective use of a specific promoter that determines transcriptional 
activity of ERa and ERP (Donaghue et al., 1999).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
48
Cortisol can bind to two intracellular receptors, type I (the mineralocorticoid 
receptor, so named because it binds aldosterone and glucocorticoids with high affinity) 
and type n  (glucocorticoid receptor, which has low affinity for mineralocorticoids). 
Glucocorticoid action involves binding of the steroid-receptor complex to regulator 
sequences in the genome and/or binding to coregulator proteins. Type I receptors are 
saturated by basal levels of glucocorticoids, whereas type II receptors are not saturated 
under basal conditions but approach saturation during peak phases of the circadian 
rhythm (i.e. early AM) and during stress (Williams et al., 1998). The majority of cortisol 
effects occur via the type IIGR, which exists in two isoforms, GRa and GRp. The GRa 
and GRP transcripts are a result of alternative gene splicing (chromosome S) with 
identical NH2-terminal amino acid sequences through amino acid 727. Thereafter GRa 
has an additional SO amino acids whereas GRP has an additional, non-homologous IS 
amino acids. In contrast to GRa, GRP does not bind glucocorticoid agonists or 
antagonists but apparently exerts inhibitory actions by heterodimerizing with ligand- 
bound GRa and/or repressing GRa actions on glucocorticoid responsive promoters 
(Dahia et al., 1997; Bamberger et al., 199S; Oakley et al., 1996). In addition to the 
hypothalamo-pituitary unit mentioned above, the placenta is also a glucocorticoid target 
organ with placental growth and endocrine function known to be affected by 
glucocorticoids (Burton and Waddell, 1999). Glucocorticoid binding activity has been 
demonstrated in placental tissue of rodents, rabbits and humans (Burton and Waddell, 
1999). Rat placental GR mRNA has been detected and placental 11P-HSD enzymes may 
locally regulate access o f glucocorticoids to their receptors within the placenta (Burton
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and Waddell, 1999). This phenomenon has been demonstrated in rat testes Leydig cells 
(Monder et al, 1994a; Monder et al, 1994b).
Circulating steroid hormones (i.e. cortisol and estradiol) are largely bound to plasma 
proteins. The major binding proteins are corticosteroid-binding globulin (CBG or 
transcortin), sex hormone-binding globulin (SHBG) and albumin. The binding globulins 
have high affinity (CBG for cortisol and SHBG for estradiol) and low capacity for steroid 
binding, whereas albumin has low affinity and high capacity. Under physiological 
conditions, cortisol (90-97%) is protein bound, most to CBG (383 amino acids; 59,000- 
dalton glycosylated protein) and the rest to albumin. About 90% of DHA and DHAS are 
bound to albumin, as are estrogens. Cortisol and other steroids can also associate with 
erythrocytes. The physiological role of plasma protein binding of steroid hormones is not 
fully understood.
PLACENTAL P450-AROMATASE ENZYME AND ITS INHIBITION
The rate-limiting step in the biosynthesis of estrogens is the aromatization of 
androgens androstenedione (A«) and testosterone (T4) to estrone (Ei) and estradiol (E2), 
respectively, by aromatase enzyme (estrogen synthetase). As mentioned previously, A« 
can be converted to T4, and Ei can be converted to E2 via 17J3-HSD. Aromatase exists in 
a membrane-bound enzyme complex consisting of a cytochrome P-450 hemoprotein 
(aromatase, P^O^om, a 55-kDa protein o f503 amino adds), and a flavoprotein (reduced 
NADPH-cytochrome P-450 reductase). Conversion of the Cw androgens is thought to 
occur by three sequential reactions at C-19, each requiring 1 mole of NADPH and 1 mole of 
molecular oxygen, culminating in the elimination of the C-19 atom as formic add and the 
aromatization of ring A of the steroid molecule (Brodie and Njar, 2000).
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The aromatase mRNA is composed of 10 exons and is transcribed from a 75 kb gene 
which contains five major promoter regions in it’s 5’-untranslated end. The enzyme is 
expressed in the brain, in testis Leydig cells, muscle, adipose tissue (including that in the 
breast), ovarian granulosa cells and the placental syncytiotrophoblast cells, where 
fetal/maternal adrenal androgens are converted to estrogens. The presence of aromatase 
enzyme proximal to or within breast tumors which are estrogen-dependent/sensitive has 
stimulated the development of effective strategies to inhibit this rate-limiting enzyme 
(Brodie and Njar, 2000).
Aromatase inhibitors fall into two major categories; steroidal inhibitors and 
nonsteroidal inhibitors. Steroidal inhibitors compete with androstenedione for the active site 
and include 4-hydroxyandrostenedione (4-OHA), exemestane, atemestane and 10-propagyl- 
androstenedione. The nonsteroidal inhibitors possess a nitrogen-containing heterocyclic 
moiety which binds with the iron atom of hemoprotein P^SOmn and excludes substrate 
androstenedione from the active site. The two major nonsteroidal aromatase inhibitors are 
triazole compounds; anastrozole (arimidex, ZN1033) and letrozole (femara, CGS20267). 
Clinical trials with CGS 20267 have demonstrated no clinically relevant changes in blood 
chemistry arid hematology tests (Trunet et al., 1993; Iveson et al., 1993). Serum cortisol 
and aldosterone levels were not affected. As expected, there were dose-dependent increases 
in T«, LH and FSH. Both inhibitors (Albrecht et al., 2000) are highly potent, competitive 
and reversible and have been recently approved as treatments for postmenopausal breast 
cancer (Brodie and Njar, 2000).
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PHYSICAL AND ANATOMICAL CONSIDERATIONS OF THE BABOON
The baboon (Papio anubis) is a considerably large animal with the adult females 
averaging about 22-33 pounds. Yet, the animal is docile, easy to handle and extremely 
adaptable. Because of its size, blood and other tissue samples can be collected repeatedly 
during gestation and surgical procedures. As in humans, the baboon possesses a 
hemochorial and monodiscoid placenta, which becomes the major source of estrogen and 
progesterone around 30 days post ovulation (Albrecht and Pepe, 1988). Fetal adrenal 
androgen precursors are used for placental estrogen synthesis (Albrecht et al., 1980). The 
growth and maturation of both the human and baboon fetal adrenal glands exhibit similar 
developmental patterns (Pepe et al., 1977; Pepe and Albrecht, 1990). As in women, the 
baboon placenta syncytiotrophoblast cells synthesize and secrete unique proteins 
including chorionic somatomammotropin (Musicki et al., 1997), pregnancy-associated 
plasma protein A (Pepe et al., 1994a) and insulin-like growth factors (Putney et al., 1990,
1991).
ENDOCRINOLOGICAL CONSIDERATIONS OF THE BABOON
The maternal pattern of placental steroid hormone production exhibited in pregnant 
baboons is similar in many important aspects to that in pregnant women. The rate of 
progesterone (P4) production (Albrecht and Townsley, 1976b) and serum progesterone 
concentrations (Albrecht and Townsley, 1976a) are elevated during pregnancy in baboons as 
in women (Lin et al., 1972), although the absolute amounts of progesterone are less in 
baboons (about 12 ng/ml the last two-thirds of gestation in baboons and 145 ng/ml in 
women). Additionally, placental progesterone production in both baboons and women is 
dependent upon low density lipoprotein (LDL) cholesterol, not de novo synthesis (Albrecht
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and Pepe, 1990). Recent studies in the baboon have demonstrated an estrogen-dependent 
developmental increase in the receptor-mediated uptake ofLDL cholesterol substrate as well 
ss estrogen-induced increases in the mRNA for the LDL receptor and P450scc in baboon 
placental syncytiotrophoblasts. Finally, the metabolism of progesterone is also similar in 
these two species during pregnancy, pregnanediol being the major metabolite (Waddell et 
a/.,1996).
The concentrations and secretory pattern (Albrecht and Townsley, 1978) of 
estradiol (E2) and estrone (Ei) in the maternal and fetal circulation of pregnant baboons 
are similar to those in pregnant women. Estrone is secreted preferentially into the fetus 
whereas estradiol is secreted primarily into the maternal circulation (Waddell et al.,
1992). Moreover, the absolute amounts of E2 present in the peripheral circulation at term 
in baboons are in the same order of magnitude as those in women (i.e., 5-10 ng/ml). In 
the baboon however, the major urinary estrogen is Ei and in women, estriol (E3).
Maternal serum estradiol levels during baboon pregnancy have been demonstrated 
(Figure 1).
The metabolism of cortisol and cortisone in the adult female baboon is also very 
similar to that in women. In both species, adrenals of adult animals secrete only cortisol and 
99% of serum cortisone levels are derived from secreted cortisol (Pepe and Townsley,
1978). During pregnancy, the pattern of cortisol-cortisone metabolism is altered in both 
species (Pepe and Townsley, 1975) and an increase in corticosteroid binding globulin is 
observed, without a significant increase in the production rate of cortisol (Oakey, 1975;
Pepe et al., 1976). The metabolic clearance rate of cortisol exceeds that of cortisone and the 
type and degree of conjugation and formation of tetrahydrocortisol and tetrahydrocortisone
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are very similar in baboons and women. Examination of urinary metabolites of cortisol in 
baboon neonates revealed a pattern very similar to that in human neonates; a low cortisol 
production rate, reduced glucuronidation and an increase in production of highly polar 
compounds such as 63-hydroxycortisol (Pepe and Townsley, 1976). Development, function 
and morphological zonation of the fetal adrenal in the human and the baboon are similar and 
distinct from those in other species.
BABOON HUSBANDRY
A colony of baboons (Papio anubis) was established in 1978 at the Eastern Virginia 
Medical School in the Central Animal Facility. Female baboons weighing 13-16 kg, are 
housed individually in aluminum-stainless-steel primate cages (32.5" x 36" x 56", LC-l106 
baboon cage, Research Equipment Co, Bryan, TX) in air-conditioned rooms with 12 hours 
on/12 hours off light/dark lighting schedule. Baboons receive Purina monkey chow 
(Ralston Purina Co., St. Louis, MO) twice daily, fresh fruit and vitamins once a day and 
water ad libitum. Baboons are cared for and used strictly in accordance with USDA 
regulations and the N1H Guide for the Care and Use of Laboratory Animals (Publication 
85-23, 1985). The experimental protocols employed in this study were approved by the 
Institutional Animal Care and Use Committee of the Eastern Virginia Medical School. 
BABOON MENSTRUAL CYCLE
The menstrual cycle of the baboon resembles that of the human in all major phases. The 
pattern of expression and levels of E2 (range 20 -  280 pg/ml) and P4 (range 1 -13  ng/ml), 
as well as, FSH and LH are very similar to those in women. In our colony the average 
length of the menstrual cycle, as determined by the first day of bleeding of one cycle up to 
the onset of bleeding in the following cycle is 29 days. Changes in the perineum
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(sex skin) are used to determine various stages of the menstrual cycle. They are the 
proliferative, ovulatory, luteal, and involution phases. These stages of the cycle are 
correlated with changes in the perineum area and offers a visual indication of hormonal 
activity and sexual receptivity.
The changes in the sex skin can be described as: a) perineal turgescence b) 
maximum turgescence c) perineal deturgescence, and d) perineal rest (Hendrickx, 1967). 
During the perineal turgescence stage, the perineum begins to swell and the color deepens 
from a dull pinkish red to a brighter red. The turgescence of the perineum continues 
through the postmenstrual and preovulatory phases. This period lasts from 4 to 8 days. 
During the maximum turgescence period, which is associated with maximum estrogen 
production, the perineum becomes fully distended and reaches its deepest and most 
intense color, a bright red. The entire perineum is devoid of wrinkles and has a smooth, 
shiny appearance. The period of maximum turgescence encompasses the latter part of the 
preovulatory phase, the entire ovulatory phase, the transition period and in most instances 
the postovulatory phase. Usually there is a brief period of near-maximum turgescence 
followed by another brief period of about five days when the perineum reaches its 
maximum size. Ovulation seems to occur during the last half of the maximum- 
turgescence period. The entire period lasts between 5 and 15 days. During the perineal 
deturgescence stage, the sex skin area shrinks rapidly and occurs because of a decrease in 
ovarian estrogen production and a concomitant increase in progesterone production by 
the newly formed corpus luteum. This menstrual cycle period coincides with the 
postovulatory and luteal phases. The onset of deturgescence is indicated by the 
beginning of wrinkles on the outer border of the sex skin and by a change in color from a
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bright red to a pinkish red. The duration of this period is between 4 and 14 days. 
Following this, the perineum is at rest. This coincides with the latter part of the luteal 
phase and the onset of a new menstrual cycle, marked with endometrial shedding and 
subsequent bleeding. The epithelial surface of the perineum is dull compared to the 
bright and shiny surface during maximum turgescence. This period lasts from 5 to 15 
days. In the pregnant baboon, the perineum remains at rest throughout the gestation 
period although the color changes to a magenta red (Hendrickx, 1967). Females are 
paired with male baboons (25-40 kg) for five days at the anticipated time of ovulation. 
Pregnancy is confirmed 30 days post ovulation by determining the presence o f chorionic 
gonadotropin in urine using the nonhuman primate pregnancy test kit supplied by Gabe 
Bialy and the National Institute of Health and/or by measuring serum E2 levels.
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CHAPTER H
DEVELOPMENTAL REGULATION OF PROTEIN fONASE-A AND -C  
ACTIVITIES IN THE BABOON FETAL ADRENAL GLAND 
INTRODUCTION
Pepe and Albrecht have previously demonstrated that the estrogen-regulated change 
in transuteroplacental metabolism of cortisol (F) and cortisone (E) from preferential 
reduction (E to F) at midgestation to oxidation (F to E) near term results in activation of 
the hypothalamic-pituitary adrenal axis o f the baboon and the ontogenesis of rate-limiting 
steroidogenic enzymes culminating in de novo F secretion (Pepe and Albrecht, 1984; 
Pepe and Albrecht, 1990; Pepe et al., 1990; Pepe and Albrecht, 1991). Our present 
investigations have been directed at elucidating the subcellular mechanisms in the 
hypothalamic-pituitary-adrenal axis that have been activated by estrogen-induced 
alterations in placental corticosteroid metabolism. With regard to adrenal function, it is 
well established (Simpson and Waterman, 1988) that translation of messages activated by 
peptide-mediated binding to membrane receptors can occur via cyclic AMP (cAMP) 
dependent protein kinase A (PK-A) and/or phospholipid/calcium dependent protein 
kinase C (PK-C). Our present understanding of the respective roles of these kinases in 
fetal adrenal function, however, is incomplete. Recently, it has been demonstrated in 
human fetal adrenal cells in culture, that activation of PK-C by phorbol esters blocked 
increases in 17a-hydroxylase-C2o lyase (17a-OHase) activity (McAllister and Hornsby, 
1988) and mRNA (Ovesmaki and Voutilainen, 1991) elicited by activators of cyclic AMP 
including ACTH and forskolin. In contrast, activation of PK-C increased the activity of 
A5-3 p-hydroxysteroid dehydrogenase (3|3-HSD) elicited by forskolin (McAllister and 
Hornsby, 1988) and also activated the mRNA for this enzyme following long-term 
treatment alone (Voutilainen et al., 1991). Therefore, it appears that the pattern of fetal 
adrenal steroidogenesis can be modulated by the relative abundance and subsequent 
activation of PK-A and PK-C. Although PK-C has been measured in the human fetal
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adrenal at 12-18 weeks of gestation and protein content decreased substantially in tissue 
of near term human anencephalics (Rainey et al., 1988), studies o f the ontogenetic 
development and regulation of PK-C and PK-A in the human and nonhuman primate 
fetal adrenal have not been performed. The present study was designed therefore, to 
determine whether the basal levels and/ or ratio of PK-A and PK-C in the fetal adrenal 
change with advancing baboon gestation and whether basal activities of PK-A/PK-C are 
regulated by estrogen-induced alterations in placental corticosteroid metabolism and thus 
could provide the mechanism(s) by which the increase in fetal adrenal 17a-OHase and 30 
-HSD is mediated with advancing gestation and maturation of the fetus.
MATERIALS AND METHODS
Blood sampling
Between day 70 - 100 or day 130 - 170 of gestation blood samples were obtained from 
pregnant baboons at 1300 - 1430 h every alternate day. Animals were briefly sedated by 
intramuscular administration of 100 mg Ketamine HCL (Parke-Davis, Detroit, MI) and 5 ml 
blood samples (3 - 7 ml) were obtained from the maternal saphenous or antecubital vein via 
a 21-gauge scalp vein needle. Serum was stored at -20 °C until assayed and serum E* P4, 
DHA, DHAS and F concentrations determined by solid phase 125I radioimmunoassay (Coat- 
A-Count, Diagnostic Products Corp, Los Angeles, CA) or by means of an automated 
chemiluminescent immunoassay system (Immulite; Diagnostic Products Corp, Los Angeles, 
CA). Blood samples were also collected at the time of the cesarean section and stored at -20 
°C until assayed.
Operative procedure: anesthesia and general surgical method
The endocrine system is sensitive to the potential effects of various anesthetics. 
Therefore, it was essential to use anesthetic agents that produce the fewest possible
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confounding effects. Various anesthetics, including ketamine and halothane, and their 
effect on serum concentrations of various hormones secreted by the hypothalamus, pituitary 
and adrenals of female baboons has been investigated (Walker et al., 1987). Administration 
of ketamine (Ketalar, Parke-Davis, Morris Plains, NJ) was found to maintain anesthesia and 
had no effect on serum levels ofPRL, F and DHA. DHAS levels rose slightly, but only 
after 75 min of ketamine administration. Halothane had no effect on hormones of the 
adrenocortical system but acetylpromazine increased PRL secretion and also induced a 
marked rise in androgen production (Walker et al., 1987).
Accordingly, ketamine was used as an intravenous anesthetic in this study. Ketamine 
alone, however, is not considered an effective agent in attaining analgesia to visceral pain 
(Walker et al., 1987). Halothane, an inhalant anesthetic agent, depresses the secondary 
afferent system as well as the subcortical structures that regulate somatic and viscerai 
functions. Therefore, in the present study ketamine was used for restraint and 
halothane/nitrous oxide for induction of anesthesia and sedation.
Baboons were restrained by intramuscular injection o f200 mg ketamine. Twenty 
minutes after the onset of ketamine, animals were placed in a supine position and 
intubated with an endotracheal tube through which a mixture of gases (nitrous oxide; 
N2O2, 25%, 1 liter/min; and O2, 75%, 3 liters/min) were passed. Between 0 and 30 min 
1.5% halothane (Fluothane, Ayerst Laboratories, NY) and N2O2 were administered.
From 30 min until termination of treatment, the concentration of the halothane was 
reduced to 1.0% in the presence of N2O2 carrier. Maternal heart rate was monitored 
throughout the period of anesthesia and maintained at 90 -100 beats/min. At the 
indicated times of pregnancy, animals were restrained and sedated with an intramuscular
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injection o f ketamine (10 mg/kg body weight). Anesthesia was achieved as indicated 
above. The uterus was exposed by an abdominal incision, a transverse incision was then 
made in the uterus and the umbilical cord clamped and the fetus and/or placenta removed. 
Blood samples were taken at numerous times during the surgery. The mother received 
approximately 250 ml dextrose-5%-in-water via saphenous canula.
Baboon treatment with estrogen and harvesting of fetal adrenal glands
Female baboons (Papio anubis) weighing 10-15 kg, were housed individually in 
metabolic cages in air-conditioned quarters under standardized conditions (Albrecht, 
1980). Females were paired with males for 5 days at the anticipated time of ovulation as 
estimated by menstrual cycle history and turgescence of the external sex skin. Baboons 
were used strictly in accordance with USDA regulations and the NIH Guide for the Care 
and Use of Laboratory Animals (Publication 85-23, 1985). The experimental protocol 
employed was approved by the Institutional Animal Care and Use Committee of Eastern 
Virginia Medical School.
Fetal adrenal glands were obtained on day 100 (n=8) and day 165 (n=6) of gestation 
(term = day 184) from untreated baboons and on day 100 from baboons treated daily with 
a maximal dose of 0.5 (n=2), 1.0 (n=3), or 2.0 mg (n=5) estradiol benzoate (Sigma 
Chemical Co., St. Louis, MO) suspended in 0.5 ml sesame oil and injected sc in 
increasing concentrations (0.25 to 2.0 mg/day, doubling the dose every 5 days between 
days 70 and 100 of gestation; i.e. 0.25 mg on days 70-74; 0.5 mg on days 75-79; etc). In 
two additional baboons studied on day 100, pellets of the aromatizable androgen 
androstenedione (50 mg; Innovative Research Products, Toledo, OH) were administered 
in increasing concentrations between days 70 and 94 of gestation (i.e., two on day 70;
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four on day 78; six on day 86 and eight on day 94) as described previously (11). In an 
additional study group, 2 baboon fetuses were treated in utero with ACTH (Cortrosyn) 
delivered continuously into the fetal leg muscle between days 70 and 100 via an Alza 
osmotic pump (0.3S fig ACTH/100 pi saline/day) and adrenal kinase activity determined 
on day 100. At 2 day intervals between days 80 and 100 or days 145 and 165 of 
gestation, all baboons were sedated with ketamine-HCl (10 mg/kg BW; Parke Davis, 
Detroit, MI), and a maternal saphenous blood sample (4-7 ml) collected. Serum was
stored at -20°C until assayed for estradiol by a solid phase ^ 1  r j a  (Coat-A-Count, 
Diagnostic Products Corp., Los Angeles, CA) as described previously (Pepe et al., 1988).
Adrenals were also available from four adult female baboons euthanized with 
Beuthanasia-D (Butler Corp., Fredricksburg, VA) at random times during apparently 
normal menstrual cycles and from three pregnant baboons on day 80 of gestation and 
treated 48, 24 and 2 h prior to recovery of adrenal tissue with 3 mg betamethasone 
(Celestone Soluspan; Schering Corp., Kenilworth, NJ). Fetal and adult adrenal tissue 
were placed in ice-cold saline, trimmed of fat and mesentery, and weighed to the nearest 
0.1 mg on a Mettler balance prior to preparation for analysis of PK-A and PK-C activity. 
Analysis of PK-A
All procedures were conducted at 4°C unless stated otherwise. Alter removal of 
visible chromaffin medullary tissue, approximately 25-40 mg of adrenal cortical tissue 
was placed into a 7 ml all glass tissue grinder (Wheaton, Milville, NJ) to which had been 
added 1 ml of 10 mM potassium phosphate (Sigma) buffer (pH 6.8) containing 250 mM 
sucrose (Sigma), 2 mM ethylenediaminetetraacetic acid (EDTA, Sigma), and 5 fil of a 
protease inhibitor cocktail composed of chymostatin, leupeptin, pepstatin A (1 mg/ml;
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Peninsula Laboratories, Torrence, CA) and antipain (0.0S mg/ml; Peninsula). Adrenal 
tissue was gently dounced (10-12 strokes) using a large clearance glass pestle (Wheaton), 
the homogenate transferred to a 1.5 ml eppendorf tube and cell cytosol obtained by 
centrifugation for 10 min at 12,000 x g using a refrigerated Jouan Microfiige (Jouan Inc., 
Winchester, VA). After removal of duplicate 10 pi samples for subsequent determination 
of protein concentration (Lowry et al., 1951), cytosol was diluted 3, 10, 30 and 100-fold 
with homogenization buffer to which had been added bovine serum albumin (1 mg/ml;
Sigma). The activity of PK-A was determined by measuring the incorporation of 32p 
into the PK-A specific peptide, kemptide (Roskoski, 1983). Briefly, 30 pi of a test 
mixture composed of 50 mM Tris-HCl (Sigma) pH 7.4, 25 mM magnesium acetate 
(Sigma), 20 mM potassium fluoride (KF; Sigma), 0.2 mM 3-isobutyl-1 -methylxanthine 
(MIX; Sigma), 0.25 mM adenosine 5'-triphosphate (ATP; Boehringer Mannheim,
Indianapolis, IN), 3 pg kemptide (Sigma), and 1x10^ dpm [y-32p]ATP (SA 6000 
Ci/mmol; New England Nuclear Corp., Boston, MA) was placed into 12 x 75 mm glass 
tubes. After addition of 10 pi distilled water (dH20) or 10 pi 0.025 mM cyclic 
adenosine-3'5'-monophosphoric acid (cAMP; Boehringer Mannheim) in dH20, tubes 
were placed in a 30°C shaking water bath and 10 pi of adrenal cytosol dilutions (0.3 to 30 
pg protein) added in duplicate. Following incubation for 10 min, 35 pi of reaction 
mixture was transferred to 1 x 3 cm P81 phosphocellulose strips (Whatman Lab Sales, 
Hissboro, OR) which were immersed immediately in 10 ml 75 mM phosphoric add 
(Mallinckrodt Chemical Co., Paris, KY). Strips were washed 4 times in 75 mM 
phosphoric add, rinsed in 10 ml 95% ethanol (Quantum Chemical Corp., Tuscola, IL), 
air dried, placed into liquid scintillation vials containing 7 ml Beckman Ready-Sol
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(Beckman Corp., Fullerton, CA), and radioactivity quantified in a Beckman LS 8000 
liquid scintillation spectrometer with automatic external quench correction. Preliminary 
studies confirmed that less than 10% of total enzyme activity was present in detergent 
solubilized adrenal membranes (12,000 x g). In addition, reaction velocity was linear 
with time and with protein concentrations ranging from 0.3 to 10 pg cell cytosol and was 
not altered by increasing the concentration of kemptide or ATP 2-fold (data not shown). 
Analysis of PK-A Subtypes I and II
Analysis of PK-A subtypes in selected adrenal cytosol preparations was determined 
following diethylaminoethyl-cellulose (DEAE) column chromatography (4°C). Briefly, 
freshly isolated cytosol (300-800 pg protein) was applied to a 3.1 ml DE-S2 anion 
exchange gel (Whatman) equilibrated in 20 mM Tris-HCl, pH 7.S, 1 mM ethylene glycol 
bis-(b-aminoethyl ether) N,N,N,N,tetraacetic acid (EGTA, Sigma), 1 mM dithiothreitol 
(DTT, Sigma; TESH buffer) in a 10 ml Bio-Rad poly-prep column (Bio-Rad 
Laboratories, Richmond, CA). The column was washed with 10 ml TESH buffer and then 
eluted with a sodium chloride gradient (25-350 mM NaCl in TESH). Fractions (0.5 ml) 
collected into glass centrifuge tubes containing 2.5 pi protease inhibitor cocktail and 10 p 
15% BSA in dHjO were assayed for PK-A activity as described above and for NaCl 
content using an IL943 Flame Photometer (Instrumentation Laboratory, Lexington, MA). 
Analysis of PK-C
Sections (20-40 mg) of adrenal tissue were dounced (4°C) in 1 ml 20 mM Tris-HCl, 
pH 7.5, containing 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and 5 pi 
protease inhibitor cocktail. The homogenate was centrifuged for 60 min (4°C) at 105,000 
x g and the cytosol diluted 3,10 and 30-fold in Tris buffer containing 1% BSA. The
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microsomal pellet was resuspended in 1 ml Tris buffer containing 0.2% Triton-X (Sigma) 
and solubilized on ice with agitation for 4S min and then diluted with Tris buffer-1% 
BSA. PK-C activity was measured (Noland and Dimino, 1986) by determining the rate
of incorporation of 3^p from [y-^pjATP into Histone IDS (Sigma). Briefly, 20 pi of 
Tris buffer alone or 10 pi Tris-buffer without EGTA to which had been added S mM 
calcium chloride and 10 pi Tris buffer containing an emulsion of 1.0 pg 1,2-dioleoyl-rac- 
glycerol (C18:l, cis9; DG; Sigma) and 10 pg L-a-phosphatidyl-L-serine (PS; Sigma) 
were added to 55 pi of a test mix containing 20 mM Tris-HCl, pH 7.5, 10 mM
magnesium acetate, 0.02 mM ATP, 50 pg Histone IIIS and 1 x 106 dpm [y-32p]ATP 
(NEN; 6000 Ci/mmol). After addition of 25 pi of buffer or 25 pi of adrenal cytosol or 
membrane dilutions (0.3-30 pg protein), reaction mixtures were incubated for 5 min in a 
shaking water bath (30°C) after which 50 pi was removed and transferred to 1 x 3 cm 
P81 phosphocellulose strips and processed as described for PK-A. Preliminary studies 
confirmed linearity of product with time. In selected experiments, cytosolic preparations 
were applied to a 1.0 ml DE-52 anion exchange gel and PK-C activity determined after 
column chromatography as described above for PK-A
Mean adrenal weights, serum estradiol concentrations and specific activities of PK- 
A and PK-C were analyzed by Analysis of Variance with post-hoc comparison of the 
means (Duncan, 1955).
RESULTS
Maternal serum estradiol concentrations (Table I) were similar in animals treated at 
midgestation either with androstenedione (1.2 ng/ml) or with estradiol benzoate at daily 
doses o f 0.5 mg (1.3 ng/ml) or 1.0 mg (1.5 ng/ml). The overall mean (± SE) serum
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Table L Maternal serum estradiol (E2) concentrations and fetal adrenal weight in 
baboons at mid- and late gestation and at midgestation after treatment with androstene- 
dione or E2 . Baboons delivered on days 100 and 16S Gate) of gestation (term = day 
184) to mothers untreated or treated sc with increasing numbers of SO-mg implants of 
androstenedione or with various maximal doses of E2 benzoate injected sc daily in 







Control 6 0.7 ±0.1b 104 ± 8 b
Androstenedione 2 l.2 c 109 b
E2 (0.5 mg) 2 1.3C 107 b
E2 (1.0 mg) 3 1.5 ±0.2C 98 ± 14 b
E2 (2.0 mg) 5 3.6 ± 0.5 d 102 ± 11b
Late Gestation
Control 5 1.9 ± 0.3c 374 ± 27c
* Serum E2 (mean ± SE) was determined in maternal saphenous venous samples obtained 
at 1- to 2-day intervals on days 80 -  100 or days 145 -  165 of gestation. b,c,d Values with 
different superscripts differ from each other (by ANOVA and Duncan’s multiple range 
test, P=0.05).
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MID-GESTATION TERM ADULT ADULT
CONTROL ACTH ESTRADIOL CORTISOL
Figure 8. Mean (± SE) PICA activity (picomoles of 32P incorporated into kemptide 
protein per min/mg protein) in adult adrenal glands, adult adrenal glands treated in vivo 
with betamethasone and fetal adrenal glands obtained at mid (day 100)- and late (day 
165) gestation (term = day 184) from untreated baboons and on day 100 from baboons in 
which estradiol concentrations in the mother were increased by maternal treatment with 
estradiol or estrogen precursor androstenedione (Mid Estradiol; n = 12; see Table I and 
Materials and Methods for details). PKA activity was also analyzed in two baboon 
fetuses (day 100) treated in utero with ACTH for 30 days. PKA was determined in the 
presence o f0.025 mM cAMP. Individual data points for PKA activity determined at the 
various protein concentrations assayed were similar (± 5%) and, thus, were averaged for 
each adrenal preparation to yield a representative value for each animal. The asterisk 
indicates that the mean value differs (P<0.05) from that in the control at midgestation (by 
analysis of variance and Duncan’s multiple range test, P=0.05). The # indicates that the 
mean value differs (P<0.05) from the adult control (by paired /-test, P=0.05).
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estradiol concentration in these baboons (1.3 ± 0.2 ng/ml) was 2-fold greater (P<0.05) 
than that in untreated baboons on day 100, but similar to that of late gestation (Table I)- 
Estradiol concentrations were further increased (P<O.OS) by administration of 2.0 mg 
estradiol benzoate to a mean value which was also greater (P<0.05) than that on day 165 
(Table I)- Although fetal adrenal weight was 2-3 fold greater (P<0.05) at term than at 
midgestation, adrenal weight was not changed significantly by any of the treatment 
regimens (Table I)-
Despite apparent dose-dependent increases in serum estradiol following treatment 
with estradiol-benzoate (Table I). mean (± SE) specific activity of PK-A was similar in 
adrenals of animals treated with 0.5 mg estradiol-benzoate or androstenedione (3660 ± 
892 pmoles/min/mg protein), 1.0 mg estradiol-benzoate (4028 ± 668 pmoles/min/mg 
protein), or 2.0 mg estradiol-benzoate (3117 ± 666 pmoles/min/mg protein). Therefore, 
data for these treatment groups were combined and are presented as an overall mean for 
analysis of the effects of estradiol at mid-gestation (mid-estradiol, Figure 8). PK-A 
activity at mid-gestation was increased (P<0.05) nearly 2-fold by treatment with estrogen 
to levels which were similar to those measured in animals delivered near term. The data 
in Table II, when compared with that in Figure 8, indicates that kinase activity measured 
in the absence of cAMP was always less (P<0.001, paired /-test) than in the presence of 
cAMP
In all groups, the specific activity of PK-C in adrenal cytosol was similar to that 
measured in the triton-x solubilized membrane fraction and was always 3 to 4-fold lower 
(P<0.001; paired /-tests) than that of cytosolic PK-A. In contrast to PK-A, cytosolic PK- 
C activity was similar at mid- and late gestation and was not influenced by treatment at 
mid-gestation with estradiol or androstenedione in vivo (Figure 9). Similar results were 
observed for PK-C activity associated with adrenal membranes (Figure 9). Basal kinase 
activity measured in the absence of calcium and phospholipids was minimal in all 
treatment groups (Table II). Addition of calcium and phospholipids resulted in a 5 to 12-
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Table D. PKA and PKC activities in fetal baboon adrenal cytosols o f mid- and late 
gestation and assayed in the absence of cAMP (PKA -  cAMP) or phospholipid/calcium 
(PKC -  lipids). Baboons delivered on day 100 (Mid) and day 165 (Late) of gestation 
(term = day 184) to mothers untreated or treated with androstenedione or estradiol (E2) 
between days 70 -  100 of gestation (see Table I for details). The number of determin­
ations is given in parentheses.










Mid Control 204 ±35 13.6 ±3.0 52 ±48 5.6 ±2.0
(n=8) (n=4)
Mid + E2 544 ±120c 9.0 ± 1.6 35 ±22 6.2 ± 1.2
(n=12) (n=7)
Late Control 358 ±73 12.4 ±2.3 27 ± 18 12.9 ±6.5
(n=6) (n=4)
* PKA assayed in the absence of cAMP. Values are
from adrenal cytosols simultaneously assayed for PKA in the presence of cAMP (see 
Figure 8 and Materials and Methods for details). b PKC assayed in adrenal cytosols in 
the absence of exogenous lipids or Ca2+. e Mean (± SE) value different from the 
control value at midgestation (P<0.05, by analysis of variance and Duncan’s multiple 
range test, P=0.05).

















Figure 9. Mean (± SE) PKC activity (picomoles of 32P incorporated into Histone IDS 
per min/mg protein) in baboon fetal adrenals obtained at mid (day 100)- and late (day 
16S) gestation (term = day 184) from untreated baboons and on day 100 from animals 
treated with estradiol or the estrogen precursor androstenedione (Mid Estradiol; see 
Table I and Materials and Methods for details). Kinase activity was measured in 
adrenal cytosolic and membrane fractions (105,000 x g) incubated at two protein 







( N « 4 )  ( N - 4 )  ( N - 7 )  (N « 4 )
Term Mld-C Mld-E. Term
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Figure 10. DEAE-cellulose chromatography of baboon fetal adrenal cytosolic PKA 
(A-C) and PKC (D) activities. Approximately 350-700 til adrenal cytosol (300-800 
tig protein) obtained at mid (day 100;A)- or late (day 1653) gestation from untreated 
animals at midgestation from a baboon treated with estradiol (C and D) were applied to 
DEAE-Sephacel columns (A-C, 3.1 ml; D, 1.0 ml), and protein was eluted with a 0-350 
mM NaCl linear gradient. Fractions (500 til) were collected, and aliquots were assayed 
for PKA (10 til) or PKC (25 til) activity in the presence or absence of cAMP (PKA) or 
Ca2+ and phospholipids (PKC), as outlined in Materials and Methods.
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fold mean stimulation of histone m s phosphorylation, a degree of activation that was 
similar in all three treatment groups (Table II).
The data in Figure 10 indicate that there are two types of PK-A in the baboon fetal 
adrenal, one which is eluted from DEAE cellulose at approximately 50-100 mM NaCl 
and presumed to be PK-A type I and a second which elutes at a higher salt concentration 
(175-225 mM NaCl) and presumed to be PK-A type II. Approximately 65% of PK-A 
activity (area under curve) is associated with PK-A n  and 35% with PK-A I. The 
distribution of PK-A types appears to be similar at mid- and late gestation and unaffected 
by estradiol treatment at mid-gestation (Figure 10, panels A  B and C). The data in panel 
D of Figure 10 indicate that PK-C activity is eluted as a single peak from DEAE at a salt 
concentration of approximately 100-150 mM NaCl, or intermediate between that of PK-A 
types I and n. This profile of PK-C was also observed at mid- and late gestation and 
following treatment with estradiol (data not shown).
The specific activity of PK-A in adrenals obtained from adult nonpregnant regularly 
menstruating female baboons was similar to that measured in adrenals of baboon fetuses 
delivered late in gestation (Figure 8). In addition, adult adrenal cytosol was comprised of 
a similar pattern of PK-A type I and type II as determined by DEAE cellulose 
chromatography (data not shown). Adrenal PK-A activity in adult baboons on day 80 of 
gestation in which betamethasone was administered daily to the mother 48,24 and 2 
hours prior to removal of the adrenal to block endogenous ACTH production was (1310 ± 
270) approximately 20% of that in untreated nonpregnant baboons (Figure 8). In these 
animals, maternal cortisol concentrations on day 80 (< 5 pg/lOOml; data not shown) were 
60-80% lower than those (18-30 pg/100 ml) normally observed in our colony of baboons 
at this time in gestation (Pepe and Albrecht, 1991).
DISCUSSION
The results of the present study indicate that fetal adrenal PK-A activity was greater 
in late gestation, when estrogen levels are elevated, than at mid-gestation. Moreover,
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activity of this kinase was experimentally increased at mid-gestation by prematurely 
elevating estrogen to levels typically observed late in pregnancy. We previously 
demonstrated that de novo cortisol production by (Pepe et al., 1990) and the specific 
activities of 30-HSD and 17a-OHase within (Pepe and Albrecht, 1991) the fetal adrenal 
were also greater late in gestation than at midgestation and elevated early in pregnancy by 
the same experimental paradigms utilized in the present study to increase maternal 
estrogen levels at midgestation. Therefore, based on our previous studies and the results 
of the present investigation, we suggest that activation of fetal adrenal steroidogenic 
maturation late in pregnancy and at midgestation after an experimental increase in 
estrogen is due, in part, to an increase in the activity of the cyclic AMP-dependent second 
messenger system involving PK-A. Although basal adenylate cyclase activity has been 
shown to be present in the human fetal adrenal early in gestation and absent in 
anencephalics near term (Carr, 1986), the present study is the first to demonstrate an 
ontogenetic increase in fetal adrenal PK-A in the nonhuman primate and to indicate the 
important role of estrogen in the regulation of the development of this physiologically 
important cell signaling enzyme system. Our studies also indicate that baboon fetal 
adrenal protein kinase-A is composed of two subtypes classically identified as type I and 
type II (Beebe and Corbin, 1986; Corbin et al., 197S). Based on our examination of 
selected adrenal cytosolic extracts, it would appear that the distribution of type I and n  
PK-A in the baboon fetal adrenal was not altered during gestation and was comparable to 
that in the adult adrenal. Thus, we suggest that the estrogen-regulated ontogenetic 
increase in total protein kinase A activity in the fetal adrenal does not reflect an alteration 
in kinase subtypes, as appears to occur with follicular maturation and luteal formation in 
the pig ovary (Dimino et al., 1981) and in various steroidogenic responsive tissues of the 
male rodent following castration and subsequent treatment with dihydrotestosterone 
(Fuller et al., 1978).
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In preliminary studies recently conducted in our laboratories (Pepe, Davies, and 
Albrecht, in progress), we demonstrated that daily administration of 0.35 tig ACTH to the 
fetus between days 75 and 100 of gestation enhanced fetal adrenal PK-A activity and the 
specific activities of fetal adrenal 30-HSD and 17a-OHase to levels previously obtained 
in animals in which the mother was treated with estradiol or androstenedione to increase 
estrogen production (Pepe and Albrecht, 1991). These findings support the suggestion 
that the increase in fetal adrenal PK-A, elicited in estrogen-treated baboons of the present 
study, is the result o f an increase in fetal ACTH production which we have proposed 
(Pepe and Albrecht, 1991) results from the activation of the hypothalamic-pituitary axis 
by an estrogen-induced increase in placental oxidation of maternal cortisol to its inactive 
metabolite cortisone prior to entry into the fetus.
Although it remains to be demonstrated that estrogen-induced alterations in 
placental metabolism activate ACTH production by the fetus, the results of the present 
study as well as of others, provide indirect evidence consistent with this hypothesis.
Thus, in our study, PK-A activity in adrenals of adult pregnant baboons treated with 
betamethasone to reduce maternal ACTH secretion was only 20% of that measured in 
adrenals of nonpregnant animals. In human fetal adrenal cells in culture, 17a- 
hydroxylase activity (McAllister and Hornsby, 1988) and mRNA concentrations 
(Voutiiainen et al., 1991) are increased when cells are cultured in the presence of 
activators of cAMP, such as forskolin, but not by activators o f protein kinase C such as 
phorbol esters. Moreover, basal adenylate cyclase activity in human fetal adrenals 
obtained at 10-12 weeks gestation is stimulated in vitro by ACTH, but not by several 
other factors including MSH, prostaglandins and HCG (Carr et al., 1985). Although 
studies of the human fetal adrenal have focused on the adenylate cyclase component of 
the PK-A signal transduction pathway, it has been clearly demonstrated that ACTH plays 
an important role in regulating PK-A activity in adrenals of adult animals and that the 
effects of ACTH are both acute and chronic. Thus, using immunoreactive gold (Murray
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et al., 1987) and fluorescein-coupled immunocytochemical techniques (Murray et al., 
1985), Murray and colleagues demonstrated that ACTH treatment for 30 min increased 
the concentrations of PK-A catalytic subunit in the nucleus and cytoplasm of Y1 adrenal 
cells in culture. Additionally, it has been demonstrated that short-term treatment with 
ACTH increased the amount o f cyclic AMP bound to the regulatory subunit o f PK-A at 
all concentrations in which ACTH concomitantly elicited an increase in rat adrenal 
steroidogenesis in vitro (Sala et al., 1979). Finally, it was confirmed that the long term 
action of ACTH on maintenance of synthesis and activity of key steroidogenic enzymes 
in cultures of bovine adrenal cells was mimicked by analogs of cyclic AMP (Kramer et 
al., 1984). Thus ACTH appears to maintain, as well as enhance, steroidogenesis in the 
adult adrenal by regulating the basal levels and the activation of cAMP-dependent 
processes including protein kinase A. We propose that this role of ACTH is also 
apparent in the fetus.
It seems unlikely that the increase in PK-A activity observed in estrogen-treated 
animals of the present study is the result of a direct effect of the steroid on the fetal 
adrenal. Thus, at midgestation, estrogen did not stimulate baboon fetal adrenal 
steroidogenesis in vitro (Albrecht and Pepe, 1987) and inhibited 17a-OHase activity in 
the human fetal adrenal by acting as a competitive substrate (Couch et al., 1986) and 
inhibited 30-HSD activity in human fetal (Fujieda et al., 1982) and neonatal cells (Byrne 
et al., 1986). Although estradiol has been demonstrated to increase protein kinase C 
activity in the pituitary gland of the rat (Drouva et al., 1990), fetal adrenal PK-C activity 
was not affected by treatment with estrogen in our study. Therefore, it is more likely that 
the increase in PK-A in estrogen-treated animals of the present study is the result of 
activation of the fetal hypothalamus-pituitary axis and increased ACTH secretion 
secondary to estrogen-induced alterations in placental F-E metabolism as we have 
proposed previously (Pepe et al., 1990; Pepe and Albrecht, 1991).
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It has been proposed that activation of protein kinase C may play a pivotal role in 
regulating growth of the fetal adrenal. Thus, it has been demonstrated that the phorbol 
ester 12-O-tetradecanoyl phorbol acetate (TPA), which activates protein kinase C by 
substituting for the physiological activator diacylglycerol (Castagna et al., 1982), was a 
mitogen for human fetal adrenal definitive cells in culture (McAllister and Hornsby,
1987). Moreover, protein kinase C activity can be modulated by IGF I, IGF n , and EGF 
(McAllister and Hornsby, 1988; Naaman et al., 1989), growth factors which have been 
demonstrated to enhance fetal adrenal cell growth in culture (Naaman et al., 1989; 
Simonian and Gill, 1981; Crickard and Jaffe, 1981). Because IGF-I has the capacity to 
stimulate protein kinase C via increased hydrolysis of glucosyl-phosphatidyl inositols 
(Low and Saltiel, 1988), factors regulating growth factor production, or activating PK-C 
directly such as EGF and FGF (McAllister and Hornsby, 1988), in the human fetal 
adrenal may have profound effects on growth and differentiation. Because fetal adrenal 
PK-C activity was similar at mid and late gestation and was not altered following 
estrogen treatment in baboons of the present study, we suggest that the appearance and/or 
concentrations of growth factors rather than the absolute level of PK-C may play a more 
significant role in regulating fetal adrenal growth.
In human fetal adrenal cells in culture (McAllister and Hornsby, 1988; Dvesmaki 
and Voutilainen, 1991), it has been demonstrated that while activation of PK-A by ACTH 
or forskolin can induce mRNAs for and activities of key steroidogenic enzymes, these 
effects can be abolished and/or enhanced by concomitant treatment with factors which 
activate and/or down regulate PK-C. Therefore, the relative abundance of these two 
second messenger systems and their respective localization in compartments of the fetal 
adrenal in conjunction with the appearance of peptide growth factors may play a 
significant role in orchestrating the steroidogenic and growth pattern of this complex
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endocrine gland as has been suggested previously (Pepe and Albrecht, 1990; McAllister 
and Hornsby, 1988; Voutilainen et al., 1991; McAllister and Hornsby, 1987). The results 
of the present study are consistent with this suggestion and document that the ratio of PK- 
A to PK-C in the primate fetal adrenal increases with advancing gestation and that this 
change occurs concomitant with the ability of the fetal adrenal to synthesize cortisol de 
novo.
In summary, we have demonstrated that fetal adrenal PK-A activity is greater in 
late gestation when estrogen levels are elevated than at mid-gestation. Moreover, PK-A 
activity was experimentally increased at mid-gestation by prematurely elevating estrogen 
to levels typically observed late in pregnancy, treatment paradigms which we previously 
demonstrated (Pepe and Albrecht, 1991) altered placental cortisol metabolism and 
activated the fetal hypothalamic-pituitary-adrenal axis resulting in increased 3|3-HSD and 
17a-OHase activities and the onset of de novo cortisol production by the fetus (Pepe et 
al., 1990). On the basis of our previous and present results, we suggest that activation of 
fetal adrenal steroidogenic maturation involves an ACTH-induced increase in the cAMP- 
dependent second messenger system involving PK-A.
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CHAPTER HI
ACTIVATION OF THE BABOON FETAL PITUITARY-ADRENOCORTICAL 
AXIS AT MIDGESTATION BY ESTROGEN: ENHANCEMENT OF FETAL 
PITUITARY PRO-OPIMELANOCORTIN mRNA/PROTEIN EXPRESSION 
INTRODUCTION
The steroidogenic maturation of the fetal adrenal gland leading to the onset of de 
novo production of cortisol late in gestation is important to fetal development and 
adrenocortical self-sufficiency in the perinatal period in human and non-human primates 
(Liggins, 1976; Jaffe etal., 1988; Pepe and Albrecht, 1990). Using in vivo experimental 
paradigms, we have demonstrated that estrogen, via regulation of placental metabolism of 
maternal corticosteroids, regulates the timing of fetal adrenal cortisol production 
presumably via modulation of hypothalamic-pituitary function. Thus, during early to 
mid-gestation, 11 [3-hydroxysteroid dehydrogenase (11 P-HSD)-catalyzed metabolism of 
cortisol and cortisone across the baboon placenta favors the formation of cortisol (Pepe 
and Albrecht, 1984; Pepe et at., 1988) resulting in cortisol being the dominant 
corticosteroid arriving within the fetus. We have suggested that this cortisol blocks the 
fetal hypothalamic-pituitary axis and thus ACTH production and/or release thereby 
preventing de novo cortisol synthesis by the fetal adrenal gland. With advancing 
gestation, the increase in estrogen production (Albrecht and Townsley, 1978) enhances 
placental NAD*-dependent 11P-HSD oxidase activity (Baggia et at., 1990a; Baggia et at., 
1990b), resulting in increased placental conversion of cortisol to cortisone (Pepe et at.,
1988). We further propose that this change in placental corticosteroid metabolism results 
in a decline in fetal cortisol levels of maternal origin and leads to activation o f the fetal 
hypothalamic-pituitary axis culminating in increased ACTH production required to 
initiate adrenal steroidogenic maturation. In support of this hypothesis, we (Pepe and 
Albrecht, 1991) have demonstrated that the ontogenetic increase in the specific activities 
of the rate-limiting steroidogenic enzymes 17a-hydroxylase/17-20 lyase (17a-OHase)
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and A5-3 P-hydroxysteroid dehydrogenase (3P-HSD), the cell-signaling enzyme protein 
kinase A (Davies et al., 1993), and the initiation of de novo cortisol synthesis near term 
(Pepe et al., 1990) in the baboon fetal adrenal gland could be induced at mid-gestation in 
animals in which transplacental oxidation of cortisol was enhanced prematurely 
following maternal estrogen administration to values normally seen late in pregnancy.
Our present studies are directed at determining whether the activation of fetal adrenal 
maturation following maternal estrogen treatment at mid-gestation and normally at term 
reflects activation of the fetal hypothalamic-pituitary axis.
Developmental studies conducted in the chronically instrumented sheep fetus have 
demonstrated that the concentrations of ACTH increase with advancing gestation (Challis 
and Brooks, 1989). Comparable studies have not been performed in humans or 
subhuman primates, although single point determinations of fetal (i.e., umbilical) ACTH 
have been reported in these species at the time of elective cesarean section late in 
gestation (Pepe and Albrecht, 1990). Because of the multiple sites of secretion and 
potential pulsatile nature of ACTH, however, the latter may not accurately reflect 
hypothalamic-pituitary function in vivo. It is well established that the ACTH molecule is 
contained within the large precursor peptide, proopiomelanocortin (POMC) and in fetal 
sheep (Yang et al., 1991; Myers et al., 1993) and rats (Rundle and Funder, 1988; Scott 
and Pintar, 1993), measurement of POMC mRN A has been utilized to study ontogenetic 
maturation of pituitary corticotroph function. Therefore, in the present study we utilized 
in situ hybridization histochemistry to quantify fetal pituitary POMC mRNA levels in 
order to test our hypothesis that maturation of the baboon fetal adrenal normally near 
term and prematurely at mid-gestation following estrogen-induced alterations in placental 
corticosteroid metabolism reflects enhanced fetal pituitary ACTH production.
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MATERIALS AND METHODS 
Baboon treatment with estrogen and harvesting of fetal pituitary glands
Fetal pituitary glands were obtained on day 100 (n=7) and day 165 (n=5) of 
gestation (term = day 184) from untreated baboons and on day 100 from baboons (n=6) 
treated daily with a maximal dose of 1.0 mg estradiol benzoate (Sigma Chemical Co., St. 
Louis, MO). Estradiol was suspended in 0.5 ml sesame oil and injected sc in increasing 
concentrations (0.25 to 1.0 mg/day, doubling the dose every 5 days between days 70 and 
100 of gestation; i.e. 0.25 mg on days 70-74; 0.5 mg on days 75-79; etc). At 2 day 
intervals between days 80 and 100 or days 145 and 165 of gestation, all baboons were 
sedated with ketamine-HCl (lOmg/kg BW; Parke Davis, Detroit, MI), and a maternal 
saphenous blood sample (4-7 ml) collected. Maternal serum and serum from umbilical 
venous blood samples collected at the time of cesarean section were stored at -20°C until
assayed for estradiol by a solid phase ^ ^ 1 RIA (Coat-A-Count, Diagnostic Products 
Corp., Los Angeles, CA) as described previously (Pepe et al., 1988).
Pituitaries were also obtained from 3 adult female baboons euthanized with 
Beuthanasia-D (Butler Corp., Fredericksburg, VA) at random times during apparently 
normal menstrual cycles. One of these baboons was treated with 3 mg betamethasone 
(Celestone Soluspan; Schering Corp., Kenilworth, NJ) 48, 24 and 2 h prior to recovery of 
pituitary tissue to determine the effect of exogenous corticosteroid on pituitary POMC 
expression.
POMC in situ hybridization
Pituitaries were placed in sterile 15x15x5 mm Tissue Tex II Cryomolds (Miles 
Scientific, Elkhart, IN) containing OCT Embedding Medium (Miles), frozen solidly on
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dry-ice, wrapped in parafilm and stored at -80°C. Within 2-4 weeks, frozen tissues were 
positioned in a Leica-Reichart-Jung (Bethesda, MD) precision microtome cryostat 
(-1S°C), sectioned (12pm) and mounted onto Superfrost Plus (Fisher Scientific,
Arlington, VA) microscope slides which were sequentially numbered, placed in RNAase- 
free slide boxes and stored at -80°C until processed for in situ hybridization 
histochemistry.
The procedures for in situ hybridization detection and quantification of POMC 
mRNA expression were adapted for use in our laboratory using previously published 
methods of others (Young et al., 1986a; Lightman and Young, 1988; Lewis et al., 1978). 
Purified POMC antisense and sense oligodeoxynucleotide probes complimentary to 30 
bases of the human POMC mRNA (Chang et al., 1980) and which encode amino acids 2- 
11 of the ACTH molecule (Chang et al., 1980; Drouin and Goodman, 1980) were 
purchased from Oligos Etc. Inc (Wilsonville, OR). Approximately 0.1 pM probe was 3' 
end-labeled with [^S]dATP (SA > 1000 Ci/mmol; Dupont-New England Nuclear, 
Boston, MA) and terminal deoxynucleotidyl transferase (20 U; Promega, Madison, WI) 
to a specific activity of approximately 5000 Ci/mmol.
At the time of hybridization, sections of the fetal pituitary (20-40/animal) were 
selected, equilibrated (10 min) to room temperature, then fixed (10 min) in freshly 
prepared 4% paraformaldehyde in phosphate buffered saline (pH 7.4). Slides were rinsed 
in 2X SSC (IX  SSC = 0.15M NaCl, 0.015M sodium citrate buffer, pH 7.2), then placed 
(10 min) in freshly prepared 0.25% acetic anhydride in 0.1 M triethanolamine 
hydrochloride-0.9% NaCl (Sigma). Sections were dehydrated through an ethanol series 
(70%, 1 min; 85%, 1 min; 95%, 1 min; 100%, 1 min), delipidated in chloroform (5 min),
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rehydrated in ethanol (100%, 1 min; 95%, 1 min) and then air-dried. Sections were then 
prehybridized for 3 h (50°C) in 50pl hybridization buffer consisting of 4X SCC, 50% 
(vol/vol) formamide, 10% (wt/vol) dextran sulfate, 250pg/ml yeast transfer RNA (Gibco 
BRL), 500pg/ml sheared single stranded salmon sperm DNA (Gibco, BRL), IX 
Denhardt's solution (Sigma), 1% Na2 S2 C>3 , 5mM NaPPi and 50mM freshly prepared
dithiothreitol (DTT; Sigma). Slides were rinsed in 2X SCC and then 40pl labeled 
antisense or sense probe in hybridization buffer added to alternating pituitary sections, 
and incubated overnight (50°C) under glass cover slips in humidified chambers. Sections 
were rinsed with 2X SSC and washed twice (2X SCC, 50% formamide) at 60°C 
(approximately 19C below calculated Tm), then twice in more stringent conditions (0.5X 
SSC, 60°C). After the last wash, slides were rinsed with 2X SCC (30 min; 22°C), dipped 
in double distilled water twice, then in ethanol (70% and 95%) and air-dried. 
Autoradiography
Slides were placed against Kodak X-Omat film in X-ray film holders and exposed 
for 5-7 days. After film exposure, representative slides were dipped in fresh Kodak NTB- 
2 nuclear track emulsion (Eastman Kodak, Rochester, NY) diluted 1:1 with distilled 
water, placed in light-tight boxes and exposed for 10-20 days. Slides were developed in 
Kodak D-19 (5 min; 14°C), rinsed in distilled water, fixed (Kodak Fixer, 5 min, 14C), 
rinsed in running tap water, and counter-stained with 0.7% hematoxylin.
Quantification of POMC mRNA
POMC mRNA expression in the fetal and adult pituitary was determined by 
densitometric analysis of exposed X ray film using an LKB Bromma Ultroscan XL 
Enhanced Laser Densitometer (Pharmacia LKB, Piscataway, NY). Areas of film exposed
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to pituitary sections labeled with antisense or sense probe were circumscribed and the 
average density of film determined by computer after subtraction of background which 
was determined by densitometric analysis of an area of film adjacent to the area of 
interest. For each animal, an average of 16-22 sections of pituitary were analyzed for 
POMC antisense expression, while 8-14 sections were concomitantly analyzed for non­
specific expression (e.g. sense message). Individual values were combined and an 
average value for POMC mRNA calculated as the difference between the average 
antisense and average sense message. Although preliminary studies confirmed that 
densitometric analysis was being performed in the linear range, to control for potential 
variance between treatment groups, for each in situ analysts pituitary sections from adult, 
untreated and estradiol-treated mid-gestation and term animals were hybridized 
concomitantly using the same labeled antisense/sense probes and X ray film exposure 
time, and concurrently developed and analyzed densitometrically. Finally, to ensure that 
densitometric analyses of film were not compromised by nonspecific binding not 
attributable to sense message (i.e., tissue folding), slides of pituitary sections were also 
examined by light microscopy.
The mean specific (antisense minus sense) number of silver grains/.025mm2 in fetal 
pituitary glands from 3 animals in each of the treatment groups was quantified using an 
Optiphot 2 microscope attached to a Video Based Image-1 Analysis System (Universal 
Imaging Corp., West Chester, PA). Spatial calibration of the imaging system using a 40x 
objective was 512 pixels along the horizontal axis and 480 pixels along the vertical axis. 
For each animal, 4 sections of fetal pituitary and an average of 8 randomly selected areas 
(140jun x 180 |im)/slide were analyzed.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
82
ACTH immunocytochemistry
To determine whether POMC mRNA cellular expression was associated with 
concomitant expression of ACTH peptide, localization of ACTH product was determined 
by peroxidase immunocytochemistry using a rabbit polyclonal antibody to human ACTH 
and Avidin-Biotin Cytochemicals provided by the manufacturer (Biomeda Corporation, 
Foster City, CA). Briefly, fetal pituitary sections (n=3-4) adjacent to those in which 
POMC mRNA was determined were selected from 3-4 animals in each of the 
experimental groups, brought to room temperature (10 min), fixed for 10 min with 
freshly prepared 4% paraformaldehyde in phosphate buffered saline (PBS), rinsed twice 
in PBS (3 min) and treated with pre-immune serum (control) or primary antibody at 
concentrations recommended by the manufacturer. After incubation at room temperature 
for 30 min, sections were rinsed twice with PBS, and incubated for 30 min with 
biotinylated anti-rabbit secondary antibody. After washing with PBS, sections were 
treated (30 min) with streptavidin peroxidase reagent, washed and incubated (10 min) 
with chromogen substrate solution. After two washes with distilled water, sections were 
counterstained with hematoxylin (90 sec), rinsed with distilled water, and, after addition 
of two drops of crystal mount, baked for 10 min (80°C) for permanent preservation of 
immunostained slides. Specificity of labeling was verified by antibody neutralization 
where the primary anti-ACTH antibody was incubated at room temperature for 30 min 
with 10 mM human ACTH (1-24; Bachem, Inc.) prior to incubation with the pituitary 
tissue section. Red-staining corticotropes were manually counted microscopically using 
the Video Based Image-1 Analysis System mentioned above.
Mean serum estradiol concentrations, POMC mRNA concentrations, and number of 
corticotrophs expressing ACTH peptide were analyzed by analysis of variance with post-
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hoc comparison of the means (Duncan, 19SS).
RESULTS
The mean (± SE) maternal serum estradiol concentration in baboons treated with 
estradiol benzoate at midgestation was 3- to 4-fold greater (P<0.05) than that in untreated 
baboons on day 100 but similar to that in late gestation (Table ID). In umbilical serum, 
estradiol concentrations were S-fold greater (P<0.05) at term than at mid-gestation but 
unlike maternal values, were not significantly increased at mid-gestation following 
treatment of the mother with estradiol.
Figure 11 depicts representative photomicrographs of sections of fetal pituitary 
cells hybridized with -^ S - la b e le d  POMC sense (Panels A and B) or antisense (Panels C- 
F) probes. Specificity of POMC labeling was documented by the relative absence of 
silver grains following incubation of pituitary sections with the sense probe (Figure 11; 
Panels A and B), the absence of grains in the posterior pituitary of sections hybridized 
with antisense (Panel C), and the appearance and apparent selective distribution of silver 
grains over a dispersed population of cells in the anterior pituitary of sections hybridized 
with antisense, at mid (Panel D) and late (Panel F) gestation and at midgestation 
following maternal treatment with estradiol (Panel E). In contrast, silver grains were not 
visible when pituitary sections were pretreated with excess unlabeled antisense probe 
prior to hybridization with 3SS-labeled probe (data not shown).
Densitometric analysis of film exposed to labeled sense probe further confirmed 
applicability of the methods for POMC mRNA quantification. Thus, average sense 
message (0.02-0.20 arbitrary absorbance units; AU) was minimal and always 10-20 fold 
less than that of sections hybridized with labeled antisense probe. Preliminary studies 
confirmed that densitometric analyses of film exposed to sections hybridized with 
radiolabeled antisense probe was performed in the linear range. We also confirmed that 
our analyses were repeatable. Thus, relative intensity of specific labeling (AU antisense
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Table in . Maternal and umbilical venous serum estradiol concentrations and fetal 








Control 7 1.0 ±  0.3* 0.7 ± 0.2* 5.3 ± 0.9*
Estradiol (1.0 mg) 6 2.9 ± 0.4* 1.1 ± 0.2* 4.8 ± 0.5*
Late gestation
Control 5 1.9 ± 0.3d 3.7 ± 0.9* 20.1 ± 1.1*
* Baboons delivered on day 100 and day 16S (late) of gestation (term = day 184) to 
mothers untreated.or treated with estradiol benzoate injected daily between days 70-100 
of gestation. b Serum estradiol (mean ± SE) determined in maternal saphenous venous 
samples obtained at 1- to 2-day intervals on days 80-100 or daysl45-l65 of gestation. 
c,d Values (mean ± SE) with different superscripts differ from respective values at P<0.0S 
(ANOVA and Duncan’s multiple range test at P=0.05).
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Figure I I . Representative photomicrographs (magnification x 600) of sections of 
baboon fetal anterior pituitary cells hybridized with -^ S - la b e le d  POMC sense (A and B) 
or antisense (D-F) oligodeoxynucleotide probes. C, Cells of the neural lobe hybridized 
with 3 5 S -la b e le d  POMC antisense. Pituitaries from untreated animals at mid (day 100; 
A, C, D) and late gestation (day 165; term day 184; B and F) and at mid-gestation after 
maternal treatment with estradiol (E).
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Figure 12. Mean (± SE) POMC mRNA concentrations expressed as specific arbitrary 
densitometric units (AU antisense minus AU sense) following in situ hybridization of 
fetal pituitaries from untreated baboons at mid- and late gestation and at mid-gestation 
after maternal treatment with estradiol. POMC mRNA was also determined in pituitaries 
of adult female baboons (two control and one treated with betamethasone). Values with 
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Figure 13. Localization of ACTH peptide in the adenohypophysis of the fetal baboon 
pituitary gland following immunocytochemistry of frozen sections. A) Photomicro­
graph (200x) o f a midterm (day = 100) control pituitary demonstrating the distribution 
of corticotropes (red chromogen; nuclei counterstained with hematoxylin). B) 
Photomicrograph (200x) of a midterm (day = 100) after maternal treatment with 
estradiol. C) Late gestation (day 165; term day 184) control photomicrograph. D) 
Mid-gestation control adenohypophysis following pre-incubation of the primary 
antibody with lOnM human ACTH for 30 min prior to ICC.
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minus AU sense) was similar in tissue sections analyzed in two separate hybridizations 
performed at different times (data not shown).
Figure 12 depicts mean POMC mRNA concentrations expressed as arbitrary 
densitometric units in fetal pituitary glands obtained at mid and late gestation and at 
midgestation following induction of placental oxidation of cortisol to cortisone by 
maternal treatment with estradiol. POMC mRNA levels at term (0.S7 ± 0.12) were 2-fold 
greater (P<0.05) than at mid-gestation (0.28 ± 0.08) and were significandy (P<0.05) 
increased at mid-gestation in pituitaries from animals in which the mother was treated 
with estrogen (0.43 ± 0.10). Similar data was obtained when POMC mRNA was 
quantified as the specific (antisense minus sense) number of silver grains/0.025mm2 in 
representative sections o f fetal pituitaries from three animals in each of the treatment 
groups (data not shown). Thus, at mid-gestation in the absence of any change in tissue 
weight (Table III), the number of silver grains/0.025mm2 of pituitary tissue from baboons 
treated with estradiol (401 ± 80) was 3-fotd greater (P<0.05) than in the untreated 
controls (101 ± 36). Moreover, despite a S-fold increase in wet weight of the fetal 
pituitary late in gestation, the number of silver grains/0.025mm2 near term (331 ± 64) was 
still greater (P<0.05) than respective values at mid-gestation.
Based on densitometric analysis, POMC mRNA expression in pituitary sections of 
2 adult baboons (2.11,2.07) was 3-4 fold greater than that measured in tissue of the near 
term fetuses (Figure 12). Although only one animal was studied, it would appear that 
POMC mRNA expression was lower in the adult animal treated with betamethasone 
(1.28).
Preliminary studies confirmed the applicability o f the methods for quantification of 
the number of fetal pituitary cells expressing ACTH peptide. Thus, antibody specificity 
was confirmed by the absence of staining in sections of anterior pituitary cells incubated 
with pre-immune control serum or with primary antibody that was neutralized prior to
















Figure 14. Mean (± SE) number of fetal pituitary cells expressing ACTH peptide 
following immunohistochemical analysis at mid (n = 4)- and late (n = 3) gestation and 
at mid-gestation after maternal treatment with estradiol (E2; n = 4). Values with 
different letter superscripts differ from each other at P=0.05 (ANOVA; Duncan’s 
multiple range test).
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incubation with 10 mM human ACTH (Figure 13D). In contrast, anterior pituitary ceils 
expressing ACTH peptide were clearly visible in sections incubated with primary 
antibody at mid and late gestation and at mid-gestation following maternal treatment with 
estradiol (Figure 13A, B, C). As summarized in Figure 14, the mean number of fetal 
pituitary cells, presumably corticotrophs, expressing ACTH peptide was greater (P<0.05) 
at term (424 ± 21) than at mid-gestation (267 ± 13) and increased (P<0.05) at mid­
gestation following maternal treatment with estradiol (3SS ± 8).
DISCUSSION
The results of the present study indicate that POMC mRNA expression in the 
baboon fetal pituitary was greater in late gestation when estrogen levels are elevated than 
at mid-gestation and increased at mid-gestation by prematurely elevating estrogen to 
levels typically observed late in pregnancy. The increase in POMC mRNA at term and at 
midgestation following treatment with estradiol was associated with an apparently 
complementary increase in the number of cells in the fetal pituitaries of these animals 
expressing ACTH peptide as assessed by immunocytochemistry. Therefore, although we 
recognize that post-translational processing of POMC is complex and the role of estrogen 
and advancing gestation on proprotein convertases (Noel and Mains, 1991; Day et al., 
1992) such as PCI and PC2 is unknown at present, we suggest that the estrogen-regulated 
developmental increase in POMC in animals of the present study was probably 
accompanied by increased production of ACTH. This suggestion is consistent with 
previous work on fetal adrenal maturation conducted in our laboratories. Thus, we have 
shown that the specific activities of fetal adrenal 17a-OHase and protein kinase A were 
significantly increased with advancing gestation and prematurely increased at mid­
gestation by treatment of the mother with estradiol as in the present study (Pepe and 
Albrecht, 1991; Davies et al., 1993). Moreover, associated with these alterations in
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enzyme activity, de novo cortisol production which normally is only measurable near 
term in untreated fetal baboons, was initiated by estrogen treatment early in gestation 
(Pepe et al., 1990). Finally, in a recent study, we have shown that cortisol secretion by 
the baboon fetal adrenal in response to ACTH in vitro is greater at term than at mid­
gestation and increased in animals in which estrogen production was enhanced at mid­
gestation (Berghom et al., 199S), results consistent with exposure of the fetal adrenal to 
ACTH in utero. Since ACTH is known to be a critical regulator o f adrenal maturation 
including maintenance and/or enhancement of the enzymes important to steroidogenesis 
and cell-signaling (Pepe and Albrecht, 1990), the onset of adrenal maturation with 
advancing gestation and following estrogen treatment early in pregnancy in the baboon 
are most likely the result of increased ACTH production and secretion. Therefore, we 
conclude that the onset of adrenal steroidogenic maturation and responsivity culminating 
in the onset of de novo cortisol production by the fetus normally near term and 
prematurely at midgestation following estrogen administration is the result of increased 
expression and subsequent production of ACTH by the fetal pituitary.
The mechanism(s) by which anterior pituitary POMC expression is increased in the 
baboon fetus with development and prematurely following estrogen treatment remains to 
be determined. In the fetal sheep, an age-associated increase in fetal corticotroph POMC 
mRNA expression was dependent upon an intact hypothalamus (Ozolins et al., 1990), 
suggesting an important role for hypothalamic input presumably via corticotrophin- 
releasing hormone (CRH). It has been shown that the increase in fetal sheep POMC 
mRNA with advancing gestation was associated with a concomitant increase in 
hypothalamic CRH mRNA expression (Myers et al., 1993). Although implantation of a 
pellet o f dexamethasone in the region of the paraventricular nucleus which reduced CRH 
mRNA, did not have a marked effect on pituitary POMC mRNA expression between 
days 120 and 125 of gestation in the fetal sheep (Myers et al., 1992), fetal ACTH 
response to hypotension was curtailed (McDonald et al., 1990). Whether estrogen treat-
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ment also alters hypothalamic CRH expression in the fetal baboon is presently under 
investigation.
Pepe and Albrecht have previously shown (Pepe et al., 1988; Baggia et al., 1990a) 
that estrogen has a marked direct stimulatory effect on placental 11 (3-HSD oxidase 
activity and via this mechanism regulates the amount of maternal cortisol arriving within 
the fetus. It has been proposed, therefore, that the developmental increase in fetal 
pituitary POMC mRNA expression observed in the present study is regulated by estrogen 
indirectly via its action on placental metabolism of maternal cortisol (Pepe et al., 1988). 
Thus, because maternal cortisol is preferentially secreted into the fetal circulation at 
midgestation, the relatively low level of fetal pituitary POMC mRNA at this time in 
gestation presumably reflects the inhibition of fetal hypothalamic CRH and/or fetal 
pituitary POMC-ACTH expression by maternal cortisol. Indeed, treatment of intact adult 
animals with synthetic corticosteroids reduces POMC mRNA expression in several 
species including the rat (Charron and Drouin, 1986; Bimberg et al., 1983; Jingami et al., 
1985), sheep (Myers et al., 1992) and baboon (Leavitt et al., 1997). The latter probably 
also occurs in the fetus since it has been demonstrated that pituitary POMC mRNA 
expression in fetal sheep can be further increased late in gestation following fetal 
adrenalectomy (McMillen et al., 1990; Myers et al., 1991). In the fetal rat, it was 
demonstrated that by embryonic day 15, POMC transcription is responsive to both CRH 
and dexamethasone and thus functional (Scott and Pintar, 1993). With advancing baboon 
gestation, we have shown that the rise in estrogen generates placental 11P-HSD oxidase 
activity (Baggia et al., 1990a) and thus increased catabolism of maternal cortisol to 
cortisone within the placenta thereby decreasing maternal cortisol transfer to the fetus, 
which we propose releases inhibition and permits ontogenesis of hypothalamic-pituitary 
POMC/ACTH expression. While the results o f our present and previous studies are 
consistent with this hypothesis, the experimental paradigm employed in the present study 
does not exclude the possibility that the increase in pituitary POMC mRNA at term and at
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mid-gestation following maternal estrogen treatment reflects a direct action of estradiol 
on the fetal hypothalamus and/or pituitary. Indeed, estradiol levels in the fetus were 
greater at term and slightly, but not significantly greater at mid-gestation following 
maternal treatment with estrogen than at mid-gestation and there is evidence that estrogen 
can directly modulate hypothalamic/pituitary function. For example, estrogen receptor 
mRNA has been identified in adult human (Stefaneanu et al., 1994) and rat (Pelletier et 
al., 1988) pituitary glands and chronic estrogen treatment of ovariectomized rats 
increases ACTH and corticosterone secretion basally and in response to stress (Burgess 
and Handa, 1992). Moreover, the human CRH gene contains two perfect half- 
palindromic estrogen response elements (Vamvakopoulos and Chrousos, 1993) and it has 
been shown that estrogen enhances the activity of chloramphenicol acetyltransferase 
(CAT) in CV-1 cells in which CRH-CAT constructs were transiently expressed and 
supplemented with a co-transfected estrogen receptor cDNA expression plasmid 
(Vamvakopoulos and Chrousos, 1993). Although the estrogenic enhancement was only 
10-20% of that observed with a Xenopus vitellogenin CAT construct, the effect of 
estradiol was specific and reproducible. In contrast to these apparent direct stimulatory 
effects of estrogen, in studies ongoing in our laboratories, we have shown that the 
responsivity of the baboon fetal pituitary at mid-gestation to a bolus injection of CRH in 
utero was similar in untreated controls and in animals in which maternal and fetal 
estrogen production was increased (Berghom, K.A, Albrecht, E.D., Pepe, G.J., in 
progress). Therefore, it appears unlikely that the increase in POMC mRNA at term and 
at mid-gestation following maternal estrogen treatment is the result of a singular direct 
effect of estrogen on fetal corticotrophs, but rather reflects the effects of estrogen on 
placental metabolism of maternal cortisol-cortisone. Whether the latter is dependent 
upon the presence of estrogen in the fetus, however, remains to be ascertained.
Coincident with its action on placental cortisol oxidation, estrogen also appears to 
modulate cortisol metabolism within the fetus (Albrecht et al., 1981; Waddell et al.,
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1988a). Thus, the overall conversion of cortisol to cortisone (29%) by the baboon fetus 
at midgestation (Waddell et al., 1988b) is increased 2-fold (60%) by the time of delivery 
(Pepe, 1979), increased at midgestation (50%) following maternal estrogen 
administration (Waddell et al., 1988a) and decreased at term (29%) in neonates delivered 
to mothers treated with antiestrogen (Albrecht et al., 1981). Moreover, in contrast to the 
marked ability to catabolize cortisol, the baboon fetus like the rhesus monkey fetus 
(Mitchell et al., 1982), has limited ability to convert cortisone back to cortisol (Waddell 
et al., 1988b) and the latter reaction appears to be increased only after birth, presumably 
as a consequence of metabolic contributions of the lung, a major site of cortisone 
reduction to cortisol (Murphy, 1978). Whether catabolism of cortisol and cortisone 
within the neural/pituitary axis is also an important contributor to the onset of POMC 
mRNA expression remains to be determined, although recent studies in sheep have 
shown that the mRNA for the 11 (3-HSD enzyme is expressed in the fetal hypothalamus 
and pituitary (Yang et al., 1992). Collectively, these observations are consistent with our 
hypothesis for the importance of the process of oxidative metabolism of cortisol within 
the placenta and fetus in activating the hypothalamic-pituitary-adrenal axis. Finally, the 
ability of cortisol to elicit feedback inhibition is dependent upon the presence of receptors 
for the steroid. Although the latter aspect has not been examined in the human and 
nonhuman primate fetus, cortisol receptor binding in the fetal sheep hypothalamus and 
pituitary (Rose et al., 1985) was highest early in gestation, declined with advancing 
pregnancy only to increase paradoxically near term (Yang et al., 1990). Whether the 
expression of cortisol receptors in the brain of the primate fetus is coordinated with that 
for POMC and/or CRH in and also regulated by estrogen remains to be ascertained.
In summary, we have demonstrated that there was a developmental increase in fetal 
pituitary POMC mRNA expression late in baboon pregnancy, which was reproduced in 
part by maternal estrogen administration at mid-gestation, presumably via a direct effect 
o f the steroid on placental corticosteroid metabolism. The increase in pituitary POMC
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mRNA appeared to be associated with a concomitant increase in pituitary ACTH peptide 
production, which we propose is essential to fetal adrenal maturation exhibited normally 
near term and prematurely at mid-gestation in animals in which placental cortisol 
metabolism is altered by experimental increases in estrogen production. Since estrogen 
production depends upon androgens of fetal adrenal origin, it would appear that the fetus 
is ultimately in control of the timing of the maturation of its own hypothalamic-pituitary- 
adrenal axis, culminating in de novo cortisol secretion and adrenocortical self-sufficiency 
in the perinatal period.
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CHAPTER IV
HYPOTHALAMIC CORTICOTROPIN-RELEASING HORMONE (CRH) 
EXPRESSION IN THE BABOON FETUS AT MID AND LATE GESTATION 
INTRODUCTION
Pepe and Albrecht (Pepe et al., 1988; Pepe et al., 1990) have previously 
demonstrated that estrogen induction of the placental 1 1 3 -hydroxysteroid dehydrogenase 
(11P-HSD) enzymes catalyzing oxidation of cortisol to cortisone (Baggia et al., 1990a; 
Baggia et al., 1990b) at term and at mid-gestation following treatment with estrogen 
decreased the amount of maternal cortisol arriving at the fetus. We proposed that this 
change in maternal cortisol secretion to the fetus culminated in activation of the fetal 
hypothalamus and/or the pituitary leading to increased production of ACTH and 
steroidogenic maturation of the fetal adrenal gland (Pepe and Albrecht, 1995). In support 
of this hypothesis we have demonstrated that the increase in expression of the mRNA for 
the ACTH precursor proopiomelanocortin (POMC) and the number of corticotrophs 
expressing ACTH peptide in the baboon fetal anterior pituitary (Pepe et al., 1994) and in 
the specific activity of rate limiting steroidogenic enzymes in the fetal adrenal (Pepe and 
Albrecht, 1991; Davies et al., 1993) normally observed at term were enhanced at 
midgestation by maternal estrogen administration. Although these observations 
confirmed that initiation of fetal adrenal maturation was due to increased fetal pituitary 
POMC mRNA expression/ACTH secretion, it is not known whether the activation of the 
fetal pituitary by estrogen-induced changes in placental oxidation of maternal cortisol 
reflects a concomitant increase in corticotrophin releasing hormone (CRH) mRNA 
expression and/or peptide production by the fetal hypothalamus. Therefore, the present 
study was designed, in part, to determine whether the increase in POMC mRNA
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previously measured in fetal baboons delivered to mothers treated with estradiol at 
midgestation reflected a concomitant increase in the expression of hypothalamic CRH.
During human and nonhuman primate pregnancy, the placenta has also been 
identified as a source of CRH (Shibasaki et al., 1982; Goland et al., 1986; Goland et al., 
1986; Sasaki et al., 1987) which is secreted both into the maternal and fetal circulations 
(Campbell et al., 1987). Although the precise ro!e(s) for placental CRH remains to be 
elucidated, injection of synthetic CRH into the maternal saphenous vein (Goland et al., 
1990) or fetal carotid artery (Berghom et al., 1991) of pregnant baboons rapidly 
increased ACTH concentrations in maternal and fetal circulations, respectively. Because 
our understanding of the role of estrogen on placental CRH production is unclear 
(Vamvakopoulos and Chrousos, 1994), the present study also determined whether 
estrogen treatment at mid-gestation enhanced placental CRH production and thus could 
account, in part, for the increase in POMC mRNA expression previously measured in the 
baboon fetal pituitary following estrogen administration.
MATERIALS AND METHODS
Baboon treatment with estrogen and harvesting of fetal hypothalami
Fetal hypothalami were obtained on day 100 (n=6) and day 165 (n=5) of gestation 
(term = day 184) from untreated animals and on day 100 from baboons (n=4) treated 
daily with a maximal dose of 1.0 mg estradiol benzoate (Sigma Chemical Co., St. Louis, 
MO) suspended in 0.5 ml sesame oil and injected sc in increasing concentrations (0.25 
mg/day, doubling the dose every 5 days between days 70 and 100 of gestation; i.e. 0.25 
mg on days 70-74; 0.5 mg on days 75-79; etc). At 2-day intervals between days 80 and 
100 or days 140 and 165 of gestation, all baboons were sedated with ketamine-HCl (10
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mg/kg BW; Parke-Davis, Detroit, MI) and a maternal saphenous blood sample (4-7 ml) 
collected. Serum was stored at -20°C until assayed for estradiol by a solid phase l25IRIA 
(Coat-A-Count, Diagnostic Products Corp. Los Angeles, C A) as described previously 
(Pepe et al., 1988). On day 100 or 165, animals were sedated with ketamine-HCl then 
anesthetized with halothanemitrous oxide (Pepe et al., 1988), a uterine venous blood 
sample collected, and the fetus delivered. Samples of maternal and uterine venous blood 
were also obtained from a contemporaneously studied group of baboons at mid (n=3) and 
late (n=3) gestation and at mid-gestation following maternal administration of estradiol 
(n=4) as described above. Following injection of an overdose of ketamine to the fetus, 
the fetal brain was quickly removed and the hypothalamus 2 mm rostral to the optic 
chiasm extending caudally to the level of the mamillary bodies and 6 mm on either side 
of the tuber cinereum and 12 mm dorsal to include the paraventricular nucleus (PVN) 
isolated. Tissue was snap frozen in liquid nitrogen for subsequent analysis of CRH 
peptide or placed in sterile cryomolds containing OCT Embedding Medium (Miles 
Scientific, Elkhart, IN) frozen solidly on dry ice, wrapped in parafilm and stored at -80°C 
for subsequent determination of CRH mRNA.
CRH in situ hybridization
Hypothalamic blocks from 3 mid control and 3 term baboons were positioned in a 
Leica-Reichart-Jung (Bethesda, MD) precision microtome cryostat (-15°C), sectioned (18 
|im) in the coronal plane and mounted onto Superfrost Plus (Fisher Scientific, Arlington, 
VA) microscope slides which were sequentially numbered and stored at -80°C until 
processed for in situ hybridization histochemistry. For each individual hypothalamus, 
approximately 15% of the sections collected through the entire PVN (determined by Nissl
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staining) were utilized for analysis of CRH mRNA expression.
The procedures for in situ hybridization detection and quantification of CRH mRNA 
expression were adapted for use in our laboratory using previously published methods of 
others (Young et al., 1986a; Young et al., 1986b; Lightman and Young, 1987). A 48 
base synthetic oligodeoxynucleotide probe complimentary to the coding region for amino 
acids 22-37 of rat CRH (21) and exhibiting 94% base sequence homology with the 
corresponding human sequence (22) was purchased from Oligos Etc. Inc (Wilsonville,
OR). Approximately 0.1 pM probe was 3' end-labeled with [-^S]dATP (SA > 1,000 
Ci/mmol; Dupont-New England Nuclear, Boston, MA) and terminal deoxynucleotidyl 
transferase (20 U; Promega, Madison, WI) to a specific activity of approximately 8,000 
Ci/mmol (Pepe et al., 1994).
At the time of hybridization, sections of the fetal hypothalamus through the PVN 
were selected, equilibrated (10 min) to room temperature, then fixed (10 min) in freshly 
prepared 4% paraformaldehyde in phosphate buffered saline (pH 7.4). Slides were rinsed 
in 2 X SSC (1 X SSC = 0. ISM NaCI, 0.015 M sodium citrate buffer, pH 7.2), then placed 
(10 min) in freshly prepared 0.25% acetic anhydride in 0.1 M triethanolamine 
hydrochloride-0.9% NaCI (Sigma). Sections were dehydrated through an ethanol series, 
delipidated in chloroform (5 min), rehydrated in ethanol (100%, 1 min; 95%, 1 min) and 
air-dried. Sections were prehybridized for 3 h (37°C) in 50 pi hybridization buffer 
consisting of 4 X SSC, 50% (vol/vol) formamide, 10% (wt/vol) dextran sulfate, 250 p 
g/ml yeast transfer RNA (Gibco BRL), 500 pg/ml sheared single stranded salmon sperm 
DNA (Gibco, BRL), 1 X Denhardt's solution (Sigma), 1% NajSjOa, 5 mM NaPPi and 50 
mM freshly prepared dithiothreitol (DTT; Sigma). Slides were rinsed in 2 X SSC and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
100
after addition o f  40 pi labeled probe in hybridization buffer, incubated overnight (37°C) 
under glass cover slips in humidified chambers. Sections were rinsed with 2 X SSC and 
washed three times (2 X SSC, 50% formamide) at 40°C (approximately 19°C below 
calculated Tm), then once in 1 X SSC (40°C). After the last wash, slides were rinsed 
with 2 X SSC (30 min; 22°C), dipped in double distilled water twice, then in ethanol 
(70% and 95%) and air-dried. Slides were placed against Kodak X-Omat film and 
exposed for 5-7 days or dipped in fresh Kodak NTB-2 nuclear track emulsion diluted 1:1 
with distilled water, placed in light tight boxes and exposed for 21-28 days. Slides were 
developed in Kodak D-19 (4 min; 15°C), rinsed in distilled water, fixed (Kodak Fixer, 5 
min, 15°C), rinsed and lightly counterstained with cresyl violet.
Quantification of CRH mRNA
Specific localization of CRH mRNA expression in the PVN of the baboon fetal 
hypothalamus was confirmed by light microscopic examination of X-ray film (Figure 
15 A) and dark-field illumination of hypothalamic sections (Figure 15B-D). 
Quantification of fetal hypothalamic CRH mRNA expression was determined by
*
counting the specific number of silver grains/nucleus (i.e., per cell) and per 0.025 mm 
PVN in three control animals at mid- and late gestation using an Optiphot 2 microscope 
attached to a Video Based Image-1 Analysis System (Universal Imaging Corp., West 
Chester, PA). Spatial calibration of the imaging system using a 4 Ox objective was 512 
pixels along the horizontal axis and 480 pixels along the vertical axis. For each animal, 
an average of 25 different areas (140 pm x 180 pm) of the PVN each comprised of 
approximately 85-120 total nuclei were examined. After establishing a gray level, cells 
with a grain density 10-fold greater than background were considered CRH positive.
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Using this criteria, approximately 15-45% of cells/0.025 mm2 PVN were CRH positive.
All grain counts, per cell and per region (number/0.025 mm2) were averaged and a single 
value for each animal determined and utilized to calculate overall group mean values. 
Tissue extraction/Sephadex chromatography/Purification of CRH protein
Frozen fetal hypothalami from baboons of mid- (n=3) and late gestation (n=2) and 
from mid-gestation baboons in which the mother was treated with estradiol benzoate 
(n=4) were homogenized in 2 ml 0.1M hydrochloric acid containing 0.1% (v/v) Triton X- 
100 (Sigma) and 3,000 cpm [l23I]Tyr0-rat/human CRH (2,200 Ci/mmol; Dupont, NEN, 
Boston, MA) and centrifuged at 6,000 x g, 4°C, for 30 min (Chatelaine et al., 1988). The 
supernatant was then extracted twice with 2 volumes of ice-cold methanol (Ruckert et al., 
1990) and evaporated to dryness using a vacuum centrifuge (Savant Instruments, New 
York, NY). Extract from one of the two late gestation tissues examined was aliquoted 
into 3 fractions and each of these, as well as all other hypothalamic extracts, were applied 
to 35 x 0.9 cm chromatographic columns containing Sephadex G-75 Fine (Pharmacia 
Fine Chemicals, Uppsala, Sweden) equilibrated with 0 .1M HC1 (25). After passage of 
void volume, aliquots were collected at a flow rate of approximately 4 ml/h and I-
Tyr°-CRH content quantified. Fractions 24-28 (Figure 16A) were pooled, extracted with 
methanol which was evaporated to dryness, resuspended in 1.0 ml assay buffer (0.05 M 
sodium phosphate, 0.1M sodium chloride, 0.025M EDTA, 0.1% sodium azide, 0.1% 
bovine serum albumin and 0.05% Triton X-100; pH 7.3) and stored at -20°C. Duplicate 
0.25 ml uterine venous serum samples to which 125I-Tyr°-CRH was added were extracted 
with methanol, dried, resuspended in 250 pi buffer and stored at -20°C until assayed.
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RIA of purified CRH protein
The assay was adapted from that originally described (Vale et al., 1983). Briefly, 
standard doses (5-250 pg/100 pi assay buffer) of rat/human CRH (Bachem Inc, Torrance, 
CA) or duplicate aliquots of extracts of hypothalamus (25, 50,100 pi) or uterine venous 
serum (50 pi) were added to 12 x 75 mm polypropylene tubes immersed in ice-water. 
After addition o f300 pi rabbit anti-human/rat CRH antiserum (1:600,000 in assay buffer) 
generously supplied by Wylie Vale, tubes were vortexed and incubated overnight at 4°C. 
Tubes were incubated (4°C) for an additional 18-24h following addition of 123I-Tyr°- 
CRH (20,000 cpm/100 pi assay buffer) and 100 pi normal rabbit carrier (Linco Research 
Inc., St. Louis, MO). To separate bound/free CRH, 100 pi goat anti-rabbit gamma 
globulin (Linco) and 500 pi 10% polyethylene glycol (Sigma) in assay buffer were added 
to reaction mixtures which were vortexed, incubated for 45 min and then centrifuged at 
3,000 rpm for 30 min. Assay of serum samples to which 100 or 250 pg authentic CRH 
were added yielded CRH levels which were 95-105% of those anticipated. The antibody 
exhibited minimal (<0.5%) cross-reactivity with ovine-CRH, oxytocin, vasopressin, 
endorphins and sauvagine. All hypothalamic extracts, which exhibited parallelism with 
CRH standards (Fig. 16B) were evaluated in the same assay. The coefficient of variation 
for mean CRH value for the 3 aliquots of term fetal hypothalamus was 8.6%.
Mean serum estradiol and CRH concentrations and hypothalamic CRH mRNA and 
peptide levels were analyzed by Student /-tests or by analysis of variance (ANOVA) with 
post-hoc comparison of the means using the Student-Newman-Keuls test (Snedecor and 
Cochran, 1980).
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RESULTS
The mean (± SE) maternal serum estradiol concentration in baboons treated with 
estradiol at mid-gestation was greater (P<0.05) than that in untreated baboons on day 
100, but similar to that in late gestation (Table IV). Fetal hypothalamic wet weight was 
3-fold greater (P<0.05) at term than at mid-gestation and was not altered at mid-gestation 
by treatment of the mother with estradiol.
The steady-state concentration of CRH in the baboon fetal hypothalamus (Figure 17) 
at mid-gestation (1S.S ± 6.0 ng/g tissue) was not altered in fetuses in which the mother 
was treated with estradiol (17.6 ± 0.9 ng/g). Because the apparent wet weight of the 
hypothalamus at mid-gestation (0.S1 ± 0.05 g) was not altered by maternal estradiol 
treatment (0.32 ± 0.07 g), the content of CRH in the hypothalamus also was similar in 
fetuses of control (7.S ± 2.2 ng/gland) and estrogen-treated (S.S ±1.1 ng/gland) animals. 
Although only two fetuses were studied late in gestation, hypothalamic CRH concen­
trations in these baboons (20.4 -21.0 ng/g) were similar to mean CRH values measured at 
mid-gestation. In contrast, due to the marked increase in weight of the fetal 
hypothalamus with advancing pregnancy, the content of hypothalamic CRH in late 
gestation (29.6 and 28.1 ng/structure) exceeded (P<0.01; ANOVA) the mean value (7.S ± 
2.2) and the 95% confidence interval (16.8 ng/ml) for CRH content in hypothalamic 
extracts from control baboons of mid-gestation.
Examination of X-ray film after 7 days exposure revealed a high density of labeling 
of CRH mRNA in the PVN of the fetal baboon hypothalamus (Figure 15 A). At this level 
of exposure, no other areas of the section of neural tissue examined exhibited labeling. 
Specificity of labeling to the PVN was confirmed when sections of slides placed in 
emulsion for 28 days were examined by dark-field microscopy (Figure 15C and D). The 
hybridization signals obtained in the PVN were specific since hybridization of adjacent
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Table IV. Maternal serum estradiol concentrations and fetal hypothalamic weight in 






Control 1.0 ±0.2° 0.51 ±0.05c
(n = 9) (n = 3)
Estradiol (1.0 mg) 2.4 ± 0.4d 0.32 ±0.07*
(n = 8) (n = 4)
Late Gestation
Control 2.0 ± 0.2d 1.40d
(n = 9) (n = 2)
*Baboons delivered on day 100 and day 16S (late) of gestation (term = day 184) to 
mothers untreated or treated with estradiol benzoate injected daily between days 
70-100 of gestation. b Serum estradiol (mean ± SE) determined in maternal saphenous 
venous samples obtained at 1- to 2-day intervals on days 80-100 or days 145-165 of 
gestation. c,d Values (mean ± SE) with different superscripts differ from respective 
values at P<0.05 (ANOVA and Student-Newman-Keuls test).
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Figure 15. Localization of CRH mRNA in the PVN of the fetal baboon hypothalamus 
after in situ hybridization of coronal brain sections (V = third ventricle) with -^S-labeled 
48-mer antisense (A, C, D) or sense (B) oligonucleotide probes. A) Photomicrograph of 
x-ray film showing the distribution of CRH mRNA in the PVN on Day 165 of gestation 
(term = Day 184). B) Darkfield photograph of an emulsion autoradiogram of PVN on 
Day 165, labeled with sense probe and counterstained with cresyl violet. C and D). 
Darkfield photographs of emulsion autoradiograms showing cells in the PVN on Day 
100 (C) and Day 165 (D) of gestation labeled with antisense probe.
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Figure 16. Al Representative Sephadex chromatography o f hypothalamic extracts 
containing [ I]-Tyr°-CRH. B) RIA of CRH in representative serial dilutions of fetal 
hypothalamic extracts on day 100 (open circles) and day 16S (open triangles) in 
untreated baboons and on day 100 after maternal treatment with estradiol (open 
squares) compared with synthetic rat/human CRH standards (solid circles). B/Bo, 
amount of [12T]-Tyr°-CRH bound relative to that at zero hormone concentration.
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Figure 17. Mean (± SE) fetal hypothalamic CRH concentrations and CRH content 
determined by RIA at mid (day 100; n = 3)- and late (day 165; n = 2) gestation 
(term = day 184) and at mid-gestation in baboons treated with estradiol (E2, n = 4). 
See Materials and Methods for methodological details. Content of CRH (ng CRH/ 
hypothalamus) in late gestation differs from that at mid-gestation (P<0.05; ANOVA 
and Student Newman Keuls Test).

















sections with a labeled sense probe under identical conditions as described for the 
antisense probe gave no hybridization signal (Figure 1SB). As seen in Figure 18, mean 
levels of CRH mRNA at mid-gestation, when expressed per cell (17.4 ±1.3 grains/ cell) 
or per unit area of PVN (3S0 ± 55 grains/area), were similar to respective values in late 
gestation (18.3 ±1.1 grains/cell; 375 ± 20 grains/area).
Mean CRH levels in uterine vein (Table V) were similar at mid- and late gestation 
and not significantly altered at mid-gestation by maternal treatment with estradiol. In 
umbilical serum samples of three mid-gestation baboons in which sufficient serum was 
available for assay, CRH levels were below the minimal detectable dose (< 50 pg/ml; 
data not shown).
DISCUSSION
The present study demonstrated that the steady-state concentration of CRH peptide 
in and CRH mRNA expression within the PVN of the baboon fetal hypothalamus were 
similar at mid- and late gestation. These findings support the suggestion that the increase 
in fetal pituitary POMC mRNA expression and ACTH peptide previously reported 
normally between mid-gestation and term are not associated with a concomitant increase 
in hypothalamic CRH peptide or CRH mRNA concentrations. The absence of change in 
fetal hypothalamic CRH peptide concentrations with gestational age has also been noted 
in humans studied between 12 and 27 weeks of gestation (Ackland et al., 1986). 
Interestingly, the concentration of CRH measured in hypothalamic extracts of human 
fetuses (9.2 ± 11.4 ng/g) was similar to that measured in fetal baboons of the present 
study. In the sheep, fetal hypothalamic CRH concentrations, although relatively low very 
early in gestation, appear to be similar (Brooks et al., 1989; Myers et al., 1993) or rise 
only slightly (Watabe et al., 1991; Brieu et al., 1989) between days 100 and 135 of 
gestation. The present study also showed that CRH peptide concentrations were not
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Figure 18. Mean (± SE) expression of CRH mRNA determined by in situ hybrid­
ization in sections of the paraventricular nucleus (PVN) of the fetal baboon hypo­
thalamus at mid (day 100; n = 3)- and late (day 165; n = 3) gestation. See 
Materials and Methods for methodological details.
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Table V. Mean (± SE) CRH levels (pg/ml) in uterine vein in baboons at mid- and late 
gestation and at mid-gestation after treatment with estradiol4.
MIDGESTATION LATE GESTATION
Control + Estradiol Control
572 ±21 479 ± 50 509 ±59
(n=7) (n=8) (n=7)
aUterine venous blood samples obtained on day 100 (mid) and day 16S from 
untreated animals and on day 100 from baboons treated between days 70 and 100 
of gestation with a maximal dose of 1 mg estradiol benzoate.
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altered at mid-gestation in animals in which the mother was treated with estradiol. In our 
previous studies, we demonstrated that the concentration of fetal pituitary POMC 
mRNA/ACTH expression was increased at term and at mid-gestation following maternal 
estrogen administration (Pepe et al., 1994). It is possible therefore, that the estrogen- 
dependent increase in fetal pituitary POMC mRNA/ACTH peptide reflects activation of 
the fetal pituitary and not the hypothalamus. Additional studies are required to establish 
this point particularly since the total level of hypothalamic CRH at term was 2-3 fold 
greater than at mid-gestation. Nevertheless, it would appear, that by mid-gestation 
hypothalamic CRH is available in adequate concentrations to “drive” the fetal pituitary 
and that it is the levels of maternal cortisol arriving within the fetal circulation, as 
dictated by estrogen-regulated placental 11 P-HSD-oxidase activity (Pepe and Albrecht, 
1995), which establishes the extent to which the fetal pituitary responds to CRH. Our 
findings do not imply that fetal hypothalamic CRH is unimportant to fetal pituitary 
function and/or maturation. Indeed, in addition to the fact that CRH content in the fetal 
hypothalamus in late gestation was 2-fold greater than that at mid-gestation, in the 
absence of CRH as presumably occurs in anencephalic human fetuses, fetal pituitary 
corticotrophs appear to be less in number and smaller in size (Begeot et al., 1977) and 
fetal adrenal growth and steroidogenic maturation essentially abolished (Pepe and 
Albrecht, 1990). In addition, in the sheep fetus, hypothalamic-pituitary disconnection 
(Antolovich et al., 1990) or lesions of the hypothalamic PVN greatly retard maturation of 
fetal anterior pituitary corticotrophs (McDonald et al., 1992) and prevent the increase in 
fetal ACTH levels associated with advancing gestation (McDonald et al., 1992). Finally, 
although factors in addition to CRH (e.g. arginine vasopressin) have been shown to elicit 
release of ACTH from the fetal and adult pituitary in vivo (Hargrave and Rose, 1986; 
Berghom et al., 1991) and in vitro (Blumenfeld and Jaffe, 1986), it appears that CRH
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primarily modulates POMC mRNA expression (Bruhn et al., 1984). Although the 
ontogenesis and potential role of arginine vasopressin on fetal baboon pituitary function 
remains to be determined, we suggest that it is the level of cortisol in fetal blood which 
dictates the responsivity of the pituitary (e.g. POMC mRNA expression) to CRH.
Indeed, the negative feedback action of cortisol on CRH-induced increases in fetal ACTH 
can occur directly at the fetal pituitary (Ozoiins et al., 1990). Moreover, infusion of 
cortisol into the sheep fetus blocked CRH- or hypotension-induced secretion of ACTH 
(Rose et al., 198S). In the adult rat, adrenalectomy elicited a 2-fold increase in 
hypothalamic CRH mRNA expression whereas POMC mRNA expression was increased 
by more than 9-fold. Moreover, while treatment of the adrenalectomized rat with 
dexamethasone reduced CRH mRNA to levels which were similar to those in intact rats, 
POMC mRNA was reduced to a level which was only 19% of that in the controls 
(Jingami et al., 1985). Thus, it is possible that the negative feedback effects of cortisol 
on the pituitary are exerted at the level of transcription. Consistent with this suggestion, 
it has been shown in AtT20 ceils that glucocorticoids have a direct inhibitory effect on 
ACTH precursor mRNA levels (Nakamura et al., 1978; Roberts et al., 1979) and inhibit 
the transcription rate of the ACTH precursor gene (Bimberg et al., 1983; Eberwine and 
Roberts, 1984). Thus, as suggested (Jingami et al., 1985), glucocorticoids exert their 
negative feedback effect at the level of gene expression more dominantly on pituitary 
corticotrophs than on hypothalamic CRH neurons. It is likely therefore, that in the 
baboon fetus the developmental expression of POMC mRNA is regulated, in part, by 
cortisol and its direct effects on the fetal pituitary.
Because cortisol appears to play a significant direct role in regulating pituitary 
POMC mRNA/ACTH expression, it remains to be demonstrated by what 
means/mechanisms fetal pituitary POMC mRNA expression is increased late in gestation
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concomitant with an increase in fetal adrenal maturation measured as increased 
production of cortisol. In this regard, we have shown that estrogen in addition to its 
action on placental cortisol metabolism also enhances cortisol oxidation to cortisone by 
the fetus (Albrecht et al., 1981; Waddell et al., 1988a) presumably by modulating tissue 
specific activity of 110-HSD (Pepe and Albrecht, 1995). In sheep, the mRNA for 11(3- 
HSD type 1 is present in several fetal tissues including the fetal pituitary (Yang et al., 
1992) while in human fetal tissues 11P-HSD type 2 is predominantly expressed (Pepe 
and Albrecht, 1995). It is possible, therefore, that the maintenance of POMC mRNA late 
in gestation presumably reflects increased fetal conversion of cortisol to its inactive 
metabolite cortisone which does not bind to the glucocorticoid receptor.
The human CRH gene contains both a consensus glucocorticoid response element 
and two half-palindromic estrogen response elements (Vamvakopoulos and Chrousos, 
1994). Estrogen can enhance the activity of chloramphenicol acetyltransferase (CAT) in 
CV-1 cells in which CRH-CAT constructs were transiently expressed and supplemented 
with a co-transfected estrogen receptor cDNA expression plasmid (Vamvakopoulos and 
Chrousos, 1993). Conversely, estrogen has been shown to decrease hypothalamic CRH 
expression in ovariectomized rats (Grino et al., 1995). Despite the fact that estrogen 
production and secretion into the fetus is increased with advancing gestation in baboons 
as in humans (Albrecht and Pepe, 1990), it seems unlikely that estrogen elicits a negative 
effect on CRH production in the baboon. Thus, although the concentration of 
hypothalamic CRH was not altered with advancing gestation, the total amount of CRH 
peptide and mRNA expressed was elevated. Consistent with this suggestion, results of 
the present study also showed that CRH concentrations in the uterine vein, and
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presumably placental CRH production were similar at mid- and late gestation. Moreover, 
despite the fact that estrogen can enhance uterine blood flow, and the observation that the 
baboon does not synthesize a CRH binding protein (Pepe and Albrecht, 1995), uterine 
vein CRH concentrations in baboons of the present study were not decreased following 
treatment with estradiol. Indeed, estrogen did not alter CRH mRNA expression of CRH 
peptide released by human trophoblast cells/fragments studied in vitro (Jones et al., 1989; 
Robinson et al., 1988).
In summary, we have demonstrated that the concentration of CRH peptide and 
mRNA in the fetal baboon hypothalamus was similar at mid- and late gestation and that 
CRH peptide levels were not increased at mid-gestation following maternal treatment 
with estradiol. Therefore, we suggest that the increase in pituitary POMC mRNA and 
ACTH peptide expression at term and following maternal estrogen administration of 
estradiol is regulated, in part, by cortisol, the fetal serum levels of which are controlled by 
estrogen-regulated 113-HSD-catalyzed oxidation to cortisone within placental and fetal 
tissues.
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CHAPTER V
CLONING AND EXPRESSION ANALYSIS OF THE 110-HYDROXYSTEROID 
DEHYDROGENASE (110-HSD) - I  AND -2  GENES IN THE BABOON:EFFECTS 
OF ESTRADIOL ON PROMOTER ACTIVITY IN PLACENTAL JEG-3 CELLS 
INTRODUCTION
Pepe and Albrecht have shown that estrogen, via regulation of placental 1 ip- 
hydroxysteroid dehydrogenase (11P-HSD) catalyzed metabolism of cortisol and cortisone 
(Pepe et al., 1988) determines the amount of maternal cortisol arriving within the fetus 
(Pepe and Albrecht, 1990) and thus regulates the function of the fetal hypothalamic- 
pituitary-adrenocortical axis (Pepe and Albrecht, 1990; Pepe et al., 1990; Pepe et al., 
1994). It is now known that cortisol-cortisone interconversion is regulated by two 
different 1 lp-HSD enzymes (Tannin et al., 1991; Agarwal et al., 1994; Monder and 
White, 1993; Pepe and Albrecht, 199S). The 11P-HSD type 1 originally cloned from the 
rat liver (Lakshmi and Monder, 1988) possesses both oxidative and reductive activity, 
prefers NADP/NADPH as a cofactor and has a relatively low (pM) affinity for 
glucocorticoid substrates. In contrast the 11P-HSD type 2 is unidirectional possessing
only oxidative activity, uses only NAD+ and has a high affinity (nM) for substrate 
cortisol (Browne/al., 1993; Brown etal., 1996a). While the Up-HSD-1 gene appears to 
be expressed in several tissues (Tannin et al., 1991; Monder and White, 1993; Pepe et al., 
1996b), the 11P-HSD-2 is expressed only in a few tissues including the kidney cortex, 
placenta and perhaps the fetal adrenal (Albiston et al., 1994; Brown et al., 1996b; Pepe et 
al., 1996a). The molecular/ biochemical basis for selective tissue expression remains to 
be determined.
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Recently, Pepe and Albrecht demonstrated that the mRNA and peptide levels of 
both 1IP-HSD-1 and -2 in syncytiotrophoblast of the baboon placenta increased with 
advancing gestation (Pepe et al., 1996a) and that baboon placental NAD+-dependent 11(3 
-HSD-2 activity was regulated by estrogen (Baggia et al., 1990a). Because of the 
important role that both 1IP-HSD-1 and -2  enzymes play in regulating fetal-placental 
function in the baboon (Pepe and Albrecht, 1995; Pepe et al., 1996b), our more recent 
studies have been directed at elucidating the molecular basis by which syncytio­
trophoblast expression of 1IP-HSD-1 and -2 is regulated. The genes for 1ip-HSD-1 and 
-2 have been isolated from several species (Tannin et al., 1991; Agarwal et al., 1994; 
Agarwal et al., 1995; Cole, 1995) and sequence analysis indicates that although there is 
little homology between 1 ip-HSD-1 and -2, there is a high degree of inter-species 
homology of both genes. Because of the distinct tissue expression of the 11P-HSD 
genes, elucidation of the cell-specific transcription factors contributing to 1 1 P-HSD-1 
and -2 expression may require gene-transfection studies using primary cell culture in 
addition to analyses in transformed cell-iines. For example, the cAMP-responsive 
elements of placental growth hormone variant gene are preferentially activated in second 
and third trimester trophoblasts, a time when endogenous gene expression is elevated 
(Golos et al., 1994). Because the promoter regions of 1 1 P-HSD-1 and 11 P-HSD-2 in the 
baboon have not been determined, the present study was designed to isolate both 11P- 
HSD-1 and 11 P-HSD-2 genes from a baboon genomic library and sequence the promoter 
regions which would subsequently permit examination of the tissue specific factors 
contributing to the regulation o f I lp-HSD-l and 11 P-HSD-2 gene expression in the 
baboon placenta. Moreover, we also produced luciferase reporter constructs o f the
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baboon 11 P-HSD-1 and 11 p-HSD-2 genes to determine whether the promoter regions of 
these two genes were activated in human placental JEG-3 cells and whether expression 
could be modified by estradiol. Finally, adenovirus constructs containing antisense 
human 11 P-HSD-2 cDNA was analyzed for potential expression inhibition upon co­
transfection with the cloned baboon sense 1 iP-HSD-2/luciferase construct.
MATERIALS AND METHODS 
Isolation of genomic clones and sequence analysis of baboon lipHSDs
Approximately 1.3 x 106 plaques of a baboon kidney genomic library (Stratagene, La 
Jolla, CA) were screened by hybridization with the human cDNA for 11 P-HSD-1 
(generously supplied by Carl Monder and Perrin White) labeled with [a-32P] dCTP 
(Dupont-New England Nuclear Corp., Boston, MA) to a specific activity of 109 dpm/|ig 
using the Random Primed DNA labeling kit (Boehringer Mannheim, Indianapolis, IN) as 
outlined by Feinberg and Vogelstein, 1983. An additional 1.3 x 106 plaques of a baboon 
kidney genomic library (Stratagene, La Jolla, CA) were screened in the same fashion 
with the human cDNA for 11 P-HSD-2 (generously supplied by Zygmunt Krozowski). 
DNA from positive clones was isolated and analyzed by restriction endonucleases. The 
S’-flanking region of the baboon 11 P-HSD-1 gene was isolated by hybridization with a S’ 
end-specific human 11 P-HSD-1 probe generated by EcoRI digestion of the human 1 ip- 
HSD-1 cDNA (+1 to +165bp) and subcloned into pBluescript SK (Stratagene). DNA 
sequences of both strands were determined by the dideoxy nucleotide chain termination 
method using a Sequenase (version 2) kit (United States Biochemical, Cleveland, OH). 
Based on the DNA sequence information obtained, new oligonucleotides were 
synthesized (Bio-Synthesis Inc, Lewisville, TX) and used as primers to continue the
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sequencing process. In similar fashion, the S’-flanking region of the baboon 11 P-HSD-2 
gene was also isolated by hybridization with a S’ end-specific human 11 P-HSD-2 probe 
generated by restriction enzyme digestion of the human 11 P-HSD-2 cDNA and 
subcloned into pBluescript SK (Stratagene). Again, DNA sequences of both strands were 
determined by the dideoxy nucleotide chain termination method above and new oligo­
nucleotides were synthesized and used as primers to continue the sequencing process. 
Northern analysis
Total RNA from term placenta as well as fetal and adult baboon liver and/or heart 
was isolated (Albrecht et al., 1995). Briefly, tissues were homogenized in 4M guanidine 
isothiocyanate (Sigma Chemical Co., St. Louis, MO) containing 0.83% 2-mercapto- 
ethanol (Sigma), extracted with chloroformiisoamyl alcohol (24:1), layered over a 5.7M 
cesium chloride gradient and RNA pelleted by centrifugation (Chirgwin et al., 1979). 
Following size-fractionation by electrophoresis in 1% agarose-formaidehyde gels, 30 |ig 
total RNA was transferred to nylon membrane (Micron Separations, Inc., Westboro, MA) 
and samples hybridized with either the full-length (1368 bp) human I ip-HSD-1 cDNA (1 
x 106 cpm/ml) or the full-length (1871 bp) human 11 P-HSD-2 cDNA (1 x 106 cpm/ml) at 
65°C in 6 x SSC, 2 x Denhardt’s, 0.5% SDS overnight. The membranes was washed 
under stringent conditions (Pepe et al., 1996) and then exposed (-70°C) for 96 h to Kodak 
X-AR film (Eastman Kodak, Rochester, NY).
Primer extension analysis
Primer extension analysis of the transcriptional start site(s) of the baboon 1 ip- 
HSD-1 clone was conducted using a baboon-specific 22 base DNA primer 
(5’- ACCTGGTCTGAATTCCTATATG -3’) located at the 3’ end of exon I. The primer
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was end-labeled with [y-32P] ATP (Dupont-NEN) and purified from unincorporated label 
by separation on a Chroma Spin-10 Column (Clontech Laboratories, Inc., Palo Alto, CA). 
To analyze the start site(s) of baboon 11 P-HSD-2, a 22 base DNA primer 
(5’-GGATCGGGGAGAAAGAGTCTGG-3’) and a 23 base primer 
(5’-AGCGCGCGGGCAGCCACGAGCAG-3’> located at the 3’ end of exon I of our 
baboon 11 P-HSD-2 clone, were end-labeled and purified as above. Approximately 30 pg 
of baboon liver total RNA and 30 |ig yeast tRNA were precipitated with 32P labeled 11P- 
HSD-1 primer (S.2 x 10s cpm) and resuspended in hybridization buffer composed of 40 
mM PIPES, 1 mM EDTA (pH 8.0), 0.4M NaCl, and 80% formamide. In similar fashion, 
approximately 30 pg of baboon kidney and placenta total RNA and 30 pg yeast tRNA 
were precipitated with the two 32P labeled 11 P-HSD-2 primers (1.2 x 106 and 1.7 x 106 
cpm) and resuspended in hybridization buffer as above. After heating to 8S°C, the 
mixtures were incubated overnight at 30°C. Hybridized duplexes were precipitated and 
resuspended in reverse transcription buffer composed of 50 mM Tris-HCl (pH 8.3), 60 
mM KCI, 10 mM MgCfe, 1 mM dithiothreitol, 1 mM each dNTP, 20U RNasin (BRL Life 
Technologies Inc., Gaithersburg, MD) and 400 units Molony mouse leukemia virus 
reverse transcriptase (BRL). After incubation for 2 h at 37°C, reactions were terminated 
by addition of I pi 0.5 M EDTA (pH 8.0) and 1 pi RNase-A (20 U/ml; BRL) and 
incubation for 30 min at 37°C. The samples were extracted with phenol-chloroform, 
precipitated and then resuspended in 6 pi sequencing gel loading buffer, and 
electrophoresed on an 8M urea-acrylamide-DNA sequencing gel. A set of 
dideoxynucleotide DNA sequencing reactions were run alongside the samples to 
accurately size the extended product.
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Solution hybridization -  RNA nuclease protection assay
A 262 bp Bam Hl-Eco R1 fragment of the S’-flanking region of the baboon 110- 
HSD-1 gene (-91 to +171 nt; Figure 20) encompassing both the upstream and 
downstream transcription start sites was isolated, purified and subcloned into pBluescript 
SK (Stratagene). After confirmation of orientation of the sequence by DNA sequencing 
analysis, probe and reference (sense) RNAs were transcribed and transcription terminated 
by digesting the template with RNase-free DNase (BRL). Solution hybridization-RNase 
protection was performed (Jakubowski and Roberts, 1992). Briefly, approximately 10 ng 
of RNA probes labeled with [a-32P] UTP (Dupont-NEN) were mixed with 5 or 30 pg 
total RNA isolated from adult baboon liver or term baboon placenta in a final volume of 
25 pi of hybridization buffer (4M guanidinium thiocyanate, 0.1 M EDTA, pH 7.5). 
Standard curves were established by mixing the probe with increasing amounts (0-37 pg) 
of the reference RNA. After hybridization overnight at 30°C, the mixture was incubated 
(30°C) for 60 min with 300 pi of a RNase solution composed of 10 mM Tris-HCl, pH 
8.0, 300 mM NaCI, 40 pg/ml RNase A (BRL) and 2 pg/ml RNase T1 (BRL). After 
treatment with proteinase K for 15 min at 45°C, samples were extracted with phenol- 
chloroform and the duplex RNA fragments protected from RNase digestion precipitated 
with ethanol and electrophoresed through a 6% nondenaturing polyacrylamide gel. Gels 
were dried, exposed to Kodak X-AR film for 12 h and bands quantified densitometrically 
(Pepe et al, 1994).
Luciferase reporter constructs and transient transfection assay
The 1.7 kb fragment of the 5’-flanking region of baboon 11 P-HSD-1 and the 1.2 kb 
fragment of baboon 11 P-HSD-2 were each subcloned into promoter-less luciferase
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
121
reporter pGL3-Basic vectors (Promega Corp., Madison, WI). Constructs were then 
transiently-transfected into human choriocarcinoma JEG-3 cells, 293 human embryonic 
kidney cells, Chang adult liver cells and HEP-G2 human adolescent liver hepatoblastoma 
cells (American Type Tissue Culture, Bethesda, MD) using calcium phosphate 
precipitation procedure. Briefly, cells were cultured on 60 mm plates in Dulbecco’s 
Modified Eagle’s medium (DMEM) containing phenol red and 10% fetal bovine serum 
(FBS). After washing, cells were transiently transfected in triplicate with 5 pg of 
plasmid-DNA construct in DMEM-10% FBS. Control cells were transiently transfected 
with the promoter-less pGL3-Basic vector. Following incubation for 12-14 h, all cells 
were washed three times with phosphate buffered saline (PBS) and then incubated in 
DMEM without phenol red and 10% charcoal-stripped FBS for an additional 16-18 h. 
Cells were scraped from dishes and then lysed in 25 mM glycylglycine (pH 7.8) buffer 
containing 15 mM MgSC>4, 4 mM EGTA, 1 mMdithiothreitol, 1% Triton-X 100. 
Following centrifugation (13,000 x g, 4°C, 5 min), supernatants were diluted in 25 mM 
glycylglycine (pH 7.8) buffer containing 15 mM KPO4, 15 mM MgS0 4 , 4 mM EGTA, 2 
mM ATP, and 11 mM luciferin and immediately assayed for luciferase activity. Protein 
concentrations in cell lysates were determined by the bicinchoninic acid method (Sigma). 
To study the role of estrogen, JEG-3 cells were transfected with 11 P-HSD-1/-2 
constructs, washed and incubated overnight with lxlO*8 M 173-estradiol or 1x10*® M 
17a-estradiol. To augment the low level of estrogen receptor (ER) in JEG-3 cells 
(Radovick et al., 1991; Wierman et al., 1992), studies of 11 P-HSD-1 and -2 promoter 
activity were also performed in JEG-3 cells co-transfected with I pg of an expression 
vector containing the human ERa cDNA (pSG5ER, gift of P. Chambon) essentially as
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described previously (Wierman et al., 1992; Dong et al., 1996). Control cells were co­
transfected with 1 pg of an expression vector containing a beta galactosidase cDNA 
(Promega). Further analyses utilizing the membrane-permeant, lipophilic cAMP analog, 
CPT-cAMP, 8-(4-chlorophenylthio)-cAMP, were conducted on JEG-3 cells to determine 
the effect, if any, of c AMP-dependent protein kinase activation on the promoter 
regulation of 11 P-HSD-1 and -2. Finally, the role of steroidogenic factor 1 (SF-1) was 
assayed using a human SF-1 expression vector cDNA (kindly donated by S. J. Beebe).
To more accurately determine SF-l’s role on 11 P-HSD-1 and -2 promoter activity, 
cotransfections and luciferase determinations were conducted in 293 kidney cells, which 
do not contain endogenous SF-1 as do JEG-3 cells.
Adenovirus / 11PHSD-2 antisense construction
The University of Iowa Viral Vector Core laboratory constructed the adenovirus / Up 
HSD-2 vector using non-oncogenic adenovirus serotype 5. The El gene region was 
deleted rendering it replication deficient and was replaced with the 1.9 kb human 11P 
HSD-2 cDNA inserted in an inverted fashion, i.e. antisense orientation. A 1.0 kb Rous 
Sarcoma Virus promoter was ligated S’ to the inverted 1 lpHSD-2 sequence to ensure 
proper nuclear targeting and high transcriptional expression. Constructed viruses were 
subsequently propagated in the El-gene complementary 293 human embryonic kidney 
cell line. Prospective recombinant viral clones were screened by isolating and digesting 
their DNA to verify the presence of the 1.9 kb insert. Recombinant adenovirus clones 
containing the antisense human 1 ipHSD-2 cDNA insert were propagated and isolated to 
yield I x 1012 particles / ml.
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Antisense gene therapy in JEG-3 cells
JEG-3 cells at 80% confluence on 60 mm plates were cotransfected either 
simultaneously with antisense human 1IPHSD-2 cDNA adenovirus and calcium- 
phosphate-precipitated sense baboon 11 PHSD-2/luc construct (as described above) or 
transfected with adenovirus alone 24 hrs prior to transfection via calcium phosphate 
precipitation with the sense baboon 1 ipHSD-2/luc DNA construct. With these later 
transfections, the adenovirus was introduced onto cells in DMEM and incubated for I hr 
before adding FBS to 10%. As a control, JEG-3 cells were cotransfected simultaneously 
with the adenovirus and calcium phosphate precipitated sense baboon 1ipHSD-1/luc 
construct DNA to determine what role, if any, the adenovirus might play in transfection 
efficiency, luciferase expression and/or cell viability. The adenovirus was stored at -  
80°C and aliquots were thawed quickly just prior to use. Only adenovirus thawed once 
or twice were utilized.
RESULTS
The 11 P-HSD-1 genomic DNA was isolated from a baboon kidney genomic library 
using the human 11 P-HSD-1 cDNA as a probe. After three screenings, 7 recombinant 
phage exhibited strong hybridization to the human type I 11 P-HSD cDNA The 5’- 
flanking region of the baboon 11 p-HSD-1 gene was isolated using a portion of the 5’ end 
of the human 11 P-HSD-1 cDNA (+1 to +165 bp) prepared by restriction digestion with 
EcoRI. Using this probe, 2 of the 7 recombinant phage exhibited an extensive 
hybridization signal. A 1.7 kb fragment was subsequently isolated and subcloned into a 
pBluescript SK vector.
The 11 P-HSD-2 genomic DNA was isolated from a baboon kidney genomic library 
using the human 11 P-HSD-2 cDNA as a probe. After three screenings, 5 recombinant 
phage exhibited strong hybridization to the human type 2 11 P-HSD cDNA. The 5’-
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flanking region of the baboon 11 P-HSD-2 gene was isolated using a Nco I fragment 
(+108 to +420 bp) containing a portion of the S’ end of the human 11 P-HSD-2 cDNA. 
One of the 5 recombinant phage exhibited an extensive hybridization signal. A 1.2 kb 
Not I-Hind III fragment was subsequently isolated and subcloned into a pBluescript SK 
vector for DNA sequencing analysis.
To determine the transcription initiation site(s) of the baboon 11 P-HSD-1 gene, 
primer extension analysis was performed using total RNA from adult baboon liver 
annealed with an antisense primer located at the 3’ end of exon I 
(ACCTGGTCTGAATTCCTATATG). The location of the extended products was 
determined by parallel genomic sequencing reactions with the same primer. Two 
extended products 93 nucleotides apart were observed in baboon liver RNA but not in 
yeast transfer RNA indicating that two transcriptional start sites are present in baboon 
liver (Figure 19; A; upstream start site; B; downstream start site). The nucleotide 
sequence of the baboon 11 P-HSD-1 and comparison with that for the published sequence 
in the human (Tannin et al., 1991) is outlined (Figures 20 and 21). The nucleotide 
sequence of the cloned fragment (approximately 1737 bp) contains 440 bp of the 5’- 
flanking region, 183 bp of exon I (from the upstream transcription initiation site), 829 bp 
of intron I, 131 bp of exon II and 129 bp of intron II. Approximately 25 bp in the middle 
of intron I was not sequenced due to significant internal secondary structure. Repeated 
attempts to sequence this region via both manual and automated means were 
unsuccessful. DNA sequence comparison analysis confirmed a high degree of homology 
between the baboon and human 11 P-HSD-1 in exons I and U (>95%) and in the proximal 
promoter (>98%). Overall similarity between the genes of these two species was >95%.
In order to verify the two transcriptional start sites of baboon 11 P-HSD-1, as well as 
to compare the level of mRNA transcribed, ribonuclease protection assays were 
performed. Figure 22 shows the autoradiogram (Panel A) used to calculate a standard 
curve for the reference RNA (Panel C) and the two protected hybrids (Panel B) from
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Figure 19. Mapping of the transcriptional start sites of baboon 11 P-HSD-1 by 
primer extension of baboon liver RNA. Primer extension was performed using 
a 22 bp oligodeoxynucleotide probe complementary to nucleotides +164 to +185 
o f the 5’-flanking region. The arrow in panel A marks the upstream transcription 
start site; the arrow in Panel B marks the downstream transcription start site.
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B AAATGGTGTTAAGAGTAAGATGGACTtGGGTAGGGATGCTCAGGAATCCAGTCCTGT - 1 9 4
H AAATGGTGTTAAGAGTAAGATGGACTcGGGTAGGGATGCTCAGGAATCCAGTCCTGT - 1 9 2
B ACAGTCATGAGCTTGGCCATCTGGAAGTCTCCTCTTGCTCAATGAAATGGAGTAAAC - 1 3 7
H ACAGTCATGAGCTTGGCCATCTGGAAGTCTCCTCTTGCTCAATGAAATGGAGTAAAC - 1 3 5
B ATTGTCCATTATGAAATCCACCACACAGGCTGCCAGGgACGAATGGGATCCCACCCA - 8 0
H ATTGTCCATTATGAAATCCACCACACAGGCTGCCAGG-ACGAATGGGATCCCACCCA - 7 9
B AAGCCAATCGCTGCTCTGACAGGGAAATTGGCTAGCACTGCCTGAGACTACTCCAGC - 2 3
H AAGCCAATCGCTGCTCTGACAGGGAAATTGGCTAGCACTGCCTGAGACTACTCCAGC - 2 2
b c tc c c c c c g tc c c tg a tg tc acA t t c a g a g g c tg c tg c c tg c tta g g a g g ttg ta g  + 35
H CTCCCCC-GTCCCTGATGTCACAATTCAGAGGCTGCTGCCTGCTTAGGAGGTTGTAG + 35
B AAAGCTCTGTAGGTTCTCTCTGTGTGTCCTACAGGAGTCTTCAGGCCAGCTCCCTGT + 92
H AAAGCTCTGTAGGTTCTCTCTGTGTGTCCTACAGGAGTCTTCAGGCCAGCTCCCTGT +92
B cdE~ATGGCTTTTATGAAAAAATATCTCCTCCCCATTCTGGGGCTCTTCATGGCCTA + 148
H CGG ATGGCTTTTATGAAAAAATATCTCCTCCCCATTCTGGGGCTCTTCATGGCCTA + 148
ZMTRON I
B CTACTACTATTCTGCAtAtGAGGAATTCAGACCAG GTAAGTACC- 7 1 3 + 2 5 b p  -  + 1 9 2  












B-------GTT CTTATATATGCT CACATATAGACAGAAGCTAGCATATCGCAGAT C-----
H GTT CTTATATAT GCT CACATATACACAGAAGCTAGCATAT C GCAGAT C-----
Figure 20. Sequence of the baboon 11 P-HSD-1 promoter. The nucleotide sequence of 
the 5’-flanking region of the 11 P-HSD-1 gene in the baboon (B) and human (H) were 
aligned by GCG computer program. The transcriptional start sites are shown as a bent 
arrow. The CAAT boxes, the putative TATA box and putative glucocorticoid (-197 to 
-190) and estrogen-like (+60 to +65) response elements are underlined. The numbering 
is relative to die upstream transcription site; lower case symbols indicate a nucleotide 
difference between the two species.
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ATTTTGCTGT TTTGTGCTGT TATTTTTAAT TGCTTCCGAC TGGGTAGGGG AGTAGGGGGA CTGAAAGTGA -371
GATTTGGCTT GAGTTTGGCT CTCTTTGCTA TTACTCACAT ttccccccag AAGCCCTACA TGCACTCCTC -301
TCTCTCTGTC TTTGACAAAT CACTTTTGAA AGATCATTGA TCCCTGGCGT AAATGGTGTT AAGAGTAAGA -231
TGGACTTGGG TAGGGATGCT CAGGAATCCA GTCCTGTACA GTCATGAGCT TGGCCATCTG GAAGTCTCCT -161
CTTGCTCAAT GAAATGGAGT AAACATTGTC CATTATGAAA TCCACCACAC AGGCTGCCAG GGACGAATGG -91
GATCCCACCC AAAGCCAATC GCTGCTCTGA CAGGGAAATT GGCTAGCACT GCCTGAGACT ACTCCAGCCT -21
r ~ BXOM Z
CCCCCCGTCC CTGATGTCAC_ AATTCAGAGG CTGCTGCCTG CTTAGGAGGT TGTAGAAAGC TCTGTAGGTT +50
CTCTCTGTGT GTCCTACAGG AGTCTTCAGG CCAGCTCCCT
▼
GTCGGATGGC TTTTATGAAA AAATATCTCC +120
MetAl aPheMetLys LysTyrLeuL
ro n to n  i
TCCCCATTCT GGGGCTCTTC ATGGCCTACT ACTACTATTC TGCATATGAG GAATTCAGAC CAGGTAAGTA +190
euProIleLe uGlyLeuPhe MetAlaTyrT ycTyrTyrSe rAIaTycGlu GluPheArgP coG
CCCATGTGTC TCACTTTGGA GGAATAGGTT TTAAAAACAC AGGGGTGCTT AGTGTTCCTG AGGACCAAGA +260
TGGTTCTTGA TCCTCAAAGT TGGTGAAAAT GAGGGAACCC TGAAGTAAAA CAGTACTTTT GTGTCCTCCA +330
GCTACAGGCT GTGGGCAGGG GGGAATGTGT AGGGAGGGTA ATCGTGTAGC CAAAATCTTG CCAAATAGGC +400
CATGCTTTAT TTGGCACCCT TAATGGAAAG CAATTTCAAA TATTCTACAA AAATGAGAGT AATACCCAAA +470
TTCACAACTC AGCCAGCTAA TTGGGCTCTA TGAAGAGACT GATAAGTGGG AGGCAAAGAA AAAAAAAAAT +540
CTCTGGAGAT GATGACTACA TAGAAGTGAG GGAAAATCCC TGGAATTTCT ATGAACACAT GTTGTTTTGA +610
TTCCTTGTTA AATATACTTT CAATTGGCAA AACTGAAAGA GTCCAGAAAT GTTCTGGAAC TCCA-25bp-
TGGAGCAAAA TGAAAGGATC CAGAAATTTT GGGAATTCAG CATTTTAGGT GGAACCATGT ATGAATTTCT
GGGCTTCATC CTATGAATTT CTTTCCATGG GAGGTmTA GGAAATGACA GTAGGGAGGC TGTCAGCCCA
AAACTTCCCA ATTCAGAGCA TGTTTATGAA AGACGTGGCC TGTTCCCAAC AGTGATTTAA CAACAGTTTG
TGACAAACTG ATCTGGGCTC ATAACCTTTA AGTTACAAAT TGAGATAAGC CTGCCTATAT CCAGAGAGGG
IXOM IX
AGAAGGAATT TTGCTGCCAA CTTGGGTATG GTCCTCACTT CCTTTTGGGG TTCCTCAGAG ATGCTCCAAG
lu MetLeuGlnG
GAAAGAAAGT GATTGTCACA GGGGCCAGCA AAGGGATCGG AAGAGAGATG GCTTATCATC TGGCGAAGAT
lyLysLysVa HleValThr GlyAlaSerL ysGlylleGl yArgGluMet AlaTyrHisL euAlaLysMe
IHTMH XI
GGGAGCCCAC GTGGTGGTAA CAGCGAGGTC AAAAGAAACT CTACAGAAGG TGAGGGTTCC ATGCCCGCAG
CGlyAlaHis ValValValT hrAlaArgSe rLysGluThr LeuGlnLys
ATACATGTAC CCTCACATGC CCAGATGTGT TCTTATATAT GCTCACATAT ACACAGAAGC TAGCATATCG
CAGATCCGAA TTCTTCGCCC TATAGTGAGT CGTATTAC
Figure 21. DNA sequence of the baboon 11 P-HSD-1 gene. A 1.7 Kb Hind ID/Not 1 frag­
ment containing the 5’-flanking region, Exon 1, Intron 1, Exon II, and Intron II of the baboon 
11 p-HSD-1 gene was sequenced using the dideoxy nucleotide chain termination method.
The transcriptional start sites are shown as a bent arrow. The CAAT boxes, the putative 
TATA box, and the putative glucocorticoid (-197 to -190) and estrogen-like (+60 to 
+65) response elements are underlined. The numbering is relative to upstream 
transcriptional start site of the baboon 11 P-HSD-1 gene.
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extracts of adult liver and near term baboon placenta. As can be seen, solution 
hybridization-RNase protection confirmed that 2 transcriptional start sites were utilized in 
the near term baboon placenta as well as in adult liver. In the liver, however, transcripts 
emanating from the upstream start site were more than 6-fold greater than those 
originating from the downstream transcription start site (Figure 22, Panel D). In contrast, 
in the placenta, transcripts originated primarily from the downstream start site.
To determine the transcription initiation site(s) of the baboon 1 lp-HSD-2 gene, 
primer extension analysis was performed using total RNA from adult baboon kidney and 
placenta annealed with two antisense primers located at the 3’ end of exon I (311-332 and 
207-229 bases upstream from the 3’ end of exon I respectively). The location of the 
extended products was determined by parallel dideoxynucleotide DNA sequencing 
reactions. When the first antisense primer (311-332) was used, two major extended 
products, which migrate at approximately 219 nt and 244 nt, and a minor extended band 
migrating at 23S nt were observed both in baboon kidney and placenta RNA, but not in 
yeast transfer RNA, indicating that multiple transcriptional start sites are present in 
baboon kidney and placenta (Figure 23). To verify this observation, another antisense 
primer (207-229) 82 bases downstream from the first one was used for primer extension 
analysis. Again three extended bands of identical size were observed confirming 
multiple transcriptional initiation sites in the baboon 11 P-HSD-2 gene. The nucleotide 
sequence of the cloned fragment (1,220 bp) of baboon 11 P-HSD-2 contains 167 bp of the 
S’-flanking region, 554 bp of exon I, and 499 bp of intron I (Figure 24). DNA sequence 
comparison analysis confirmed a high degree of homology between the baboon and 
human 11 P-HSD-2 (Agarwal et al., 1995) in exon I (96%) and in the proximal promoter 
(>90%). Overall similarity between the genes of these two species was >95%.
The expression of 11 P-HSD-1 in different baboon tissues was assessed by Northern 
blot analysis using 30 pg total RNA prepared from adult heart and liver, liver from a 
fetus delivered at mid-gestation and from whole villous placenta of an animal delivered
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Figure 22. Mapping and quantification of the upstream and downstream transcriptional 
start sites of the baboon 11 P-HSD* 1 gene by ribonudease protection assay. Panel A: 
Autoradiogram of a ribonudease protection assay of total RNA from baboon liver and 
term placenta hybridized with a radiolabeled 262 bp probe. The mRNA protected from 
the upstream and downstream start sites are shown as protected bands of 171 bp and 78 
bp, respectively. The standard reference (sense) RNA is shown as a protected 262 bp 
hybridized product. Panel B: The scheme of the 262 bp S’-flanking region of 11 P-HSD 1 
gene. The transcriptional start sites are shown as bent arrows and the protected sequence 
emanating from the upstream start site shown as a 171 bp product and that from the 
downstream start site as a 78 bp product. Panel C: Standard curve generated from the 
autoradiogram in Panel A. The relative density o f the reference product plotted against 
the pg of reference added. Panel D: Levels (pg/pg total RNA) of the mRNA transcribed 
from the upstream and downstream transcription start sites in baboon liver and placenta.
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near term. The mRNA for 11 P-HSD-1 was detected as a single species of approximately 
1.5 kb in adult liver and term placenta, but not fetal liver or adult heart (Figure 25). In all 
samples, P-actin mRNA was detected as a strong band of 2.0 kb (data not shown) 
indicating that our failure to find the 11 P-HSD-1 mRNA in fetal liver and adult heart 
reflected minimal 11 P-HSD-1 gene expression and not RNA degradation. This 
distribution of 11 P-HSD-1 expression is similar to that seen in the human (Tannin et al., 
1991), sheep (Yang et al., 1992) and rat (Moisan et al., 1990) and confirms our previous 
observations (Pepe et al., 1996b) demonstrating abundant expression of 11 P-HSD-1 
mRNA in baboon placenta, decidua and adult liver but not fetal liver of mid-gestation.
The expression of 11 P-HSD-2 in different baboon tissues was assessed by Northern 
blot analysis using 30 pg total RNA prepared from adult heart, kidney and liver, as well 
as fetal Uver and kidney and whole villous placenta of an animal delivered near term.
The mRNA for 11 P-HSD-2 was detected as a single species of approximately 1.9 kb in 
adult and fetal kidneys and near term placenta, but not adult and fetal Uver or adult heart 
(Figure 26). The hybridization signal appeared highest in the adult kidney and lowest in 
the fetal kidney. In all samples, P-actin mRNA was detected as a strong band of 2.0 kb 
(1.8 kb in heart) indicating that absence of 11 P-HSD-2 mRNA expression in fetal Uver 
and adult heart and liver reflected minimal 11 P-HSD-2 gene expression and not RNA 
degradation. This distribution of 11 P-HSD-2 expression is similar to that seen 
in the human (Agarwal et al., 1995) and sheep (Agarwal et al., 1994) and confirms our 
previous observations (Pepe et al., 1996a) demonstrating abundant expression of 1 ip~ 
HSD-2 mRNA in baboon placenta.
The promoters of both 11 P-HSD-1 and -2 were activated following transient 
transfection into JEG-3 cells (Figure 27 and Figure 28, Panel A). In the independent 
experiments performed, basal activity of the 11 P-HSD-2 promoter (87 ± 21 RLU/pg 
protein) always exceeded (P<0.05) that of 11 P-HSD-1 (37 ± 7) by approximately 2-fold 
(n=5). Similar promoter activation patterns (P<0.05) were demonstrated in 293
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Figure 23. Mapping of the transcriptional start sites of baboon 113-HSD-2 by primer 
extension of baboon placental and adult kidney total RNA and yeast tRNA. Primer 
extension was performed using a 22 base oligodeoxynucleotide probe complementary 
to nucleotides 311 to 332 bp away from the 3’ end ofExon I. The arrows mark the 
transcription start sites.
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GGCGGTGCGA TCAGCAAAGG GCACCGGGAT GCCGGTTGTG CGTGTCCTCA GGTGTCCCGA ACAAGCGTGA -98
GTGGCATGTG CTCACCTGAG CGCGGCGGCT TGCCAGCCCC GGGCGCGTGG GTGCTGCAGC CAGGCGGCTC -28
1,
CTCTAGCGCA GCAACTTTGG GACTTTGTTC CGGCTTTTTC CAAATCGAAT CTGGTCGAGG GGGCGGGGCG +43
CACCTGCCTG CAGGNGTNCC GGGAGAGAAG TGGAGGAAAT CCCCTGCCCC TCCCCGCCCG CTCCCCGCCC +113
BXOH t
TCTCCCCCGC CCCCGGGGCT CTTTATAAGC TCGGCCCGAG GGCGAGCAGA GGAAGCCTGT GTCCCTCCCG +183
CGCCTGAGGC CGGTGTTCCC CCGCACTCCG CGCCCGGGCC CAGACTCTTT CTCCCCGATC CCCGGCCCGG +253
CCCCCGCCCC GCCCCGCCCC AGCCCGCTGG GCCGCCATGG AGCGCTGGCC TTGGCCGTCG GGCGGCGCCT +323
MetG luArgTrpPr oTrpProSer GlyGlyAlaT
GGCTGCTCGT GGCTGCCCGC GCGCTGCTGC AGCTGCTGCG CTCAGACCTG CGTCTGGGCC GCCCGCTGCT +393
rpLeuLeuVa lAlaAlaArg AlaLeuLeuG InLeuLeuAr gSerAspLeu ArgLeuGlyA rgProLeuLe
GGCGGCGCTG GCGCTGCTGG CCGCGCTCGA CTGGCTGTGC CAGCGCCTGC TGCCCCCGCC GGCCGCACTC +463
uAlaAlaLeu AlaLeuLeuA laAlaLeuAs pTrpLeuCys GlnArgLeuL euProProPr oAlaAlaLeu
GCCGTGCTGG CCGCCGCTGG CTGGATCGCG TTGTCCCGCC TGGCGCGCCC GCAGCTCCTG CCGGTGGCCA +533
AlaValLeuA laAlaAlaGl yTrpIleAla LeuSecArgL euAlaArgPr oGlnLeuLeu ProValAlaT
timou x
CTCGCGCGGT GCTCATCACC GGTGAGTGGC GGGTGCGGAG CGCGGGGACT CCAGGCTCGA GGGCGGGACT +603 
hrArgAlaVa lLeuXleThr
AGACACTCAC AGGACTGACT CCTCATGGCA CGGCCAAGGC GGGCTCCCCA GTGCAAGAGT GGGAGAGTTC
TCCTCCCCGG GGTGCAGGGA GCGAGCCAAG TAGGGAGCGC CGGGCACCTC CCCAAGTCCG GGTTCACTAC
CTGCTGCTGC AGGGAGTGTT GGAGGGAAAG TGAGACAGGG AGTGGGCAGG TTCAAGAAGG AAACTGACTG
CTGGCTGAGA AGAGGGAGCC TCCTGGAGTT TGAGAGTTTA TGCCATTCCC TTCCCCAAGA GAGCAGTTTC
AGGGGACTTC GGAGGCTTTG AGAAGGGAGG ATCGTTACCC CTTGAACGCT GCCTGACATC CCCACCTGAG
ACACCCCATC TCCCATTCCT GGGGCCAGAG GGAAGAGCTT AGATGGGGAA CTTCCCCACC CGACCCAACC
CCCACTGGCT GGGATCCTTG GAGTTCAGAA
Figure 24. DNA sequence of the baboon 113-HSD-2 gene. A 1.2 Kb Not 1/Hind m  
fragment containing the S’-flanking region, Exon 1 and Intron 1 of the baboon 11(3- 
HSD-2 gene was sequenced using the dideoxynucleotide chain termination method. 
The transcriptional start sites are shown as bent arrows. The ATG codon, TATA box 
and putative GC box are underlined.
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Figure 25. Northern blot analysis of 11 P-HSD-1 mRNA expression in baboon 
term placenta, adult liver, adult heart and fetal liver of midgestation. Total RNA 
was isolated and probed with a human cDNA to 11 P-HSD-1.
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p-actin
Figure 26. Northern blot analysis of 11 P-HSD-2 mRNA expression in baboon term 
placenta and adult liver and adult heart and near term fetal liver and kidney. Total 
RNA was isolated and probed with a human cDNA to 11 P-HSD-2 and then to p-actin.
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embryonic kidney cells (1344 ± 810 RLU/ng protein for type 2 and 280 ± 139 RLU/pg 
protein for type 1; n=3) and Chang human adult liver cells (420 ± 381 RLU/pg protein 
for type 2 and 64.3 ± 35.6 RLU/pg protein for type 1; n=3; P<0.01). In three tissue 
culture cell lines, luciferase expression utilizing the promoter-less pGL3-Basic vector 
was minimal (13 ± 4 in JEG-3, 23 ± 0.5 in 293 and 9 ± 4 in HEP-G2; activity in Chang 
was not done; Figure 27). Repeated attempts (n=3) to transiently transfect HEP-G2 
human adolescent liver hepatoblastoma cells with CaPC>4-precipitated-DNA were 
unsuccessful. In Panels B and C of Figure 28, the effects of estradiol in the presence or 
absence of a cotransfected ERa on 11 P-HSD-1 and -2 in a representative of three 
experiments is described. As indicated, in the absence of cotransfected ERa, basal 
promoter activities of both 11 P-HSD-1 and -2 were not altered by 17P-estradiol. 
Although the promoter activities of 11 P-HSD-1 and -2 were enhanced by approximately 2- 
fold in cells co-transfected with pSG5ER alone, these increases were not statistically 
significant. However, in cells co-transfected with the ERa, incubation with 17P- 
estradiol, but not 17a-estradiol, increased (P<0.05) promoter activity of 11 P-HSD-1 (177 
±12) and 11 P-HSD-2 (1309 ± 203) by approximately 4-fold over respective values in 
cells incubated with no steroid (or with 17a-estradiol). These results are presented in 
Panels D and E (Figure 28), as the fold induction of basal promoter activity, which was 
designated as 1.
Thus, in the presence of a co-transfected ERa, 17P-estradiol but not 17a-estradiol 
stimulated (PO.05) the basal activities of the 11 P-HSD-1 and 11 P-HSD-2 promoters by 
8.1 ± 1.5 and 8.3 ± 2.0 fold respectively, values which also exceeded (P<0.05) those in 
cells transfected with the ERa and incubated with no steroid or with 17a-estradiol. Basal 
activity of the promoterless pGL3 Basic vector (12 ± 3 RLU/^g protein; n = 3) was not
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Figure 27. Luciferase activity in JEG-3 human choriocarcinoma cells, 293 human 
embryonic kidney cells, Chang human adult liver cells and HEP-G2 human adolescent 
liver hepatoblastoma cells of the 1.7 kb baboon 11 (3HSD-1/luciferase construct (I) and 
the 1.2 kb baboon 1 ipHSD-2/luciferase construct (II) after CaP0 4 -precipitated-DNA 
transfection. Values (mean ± SE) expressed as luciferase promoter activity RLU / pg 
cell protein and were determined 18 h after incubation of constructs in cells (n = 4). 
Basic luciferase activity was determined following transient transfection under similar 
conditions with the promoter-less pGL3-Basic luciferase reporter vector (B). Values 
(mean ± SE) with different letter superscripts differ from each other at P=0.01 (by one­
way ANOVA). Basic luciferase was not done in Chang cells.
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Figure 28. Promoter activity of the 1.7 and 1.2 kb fragments of the S’-flanking regions 
of baboon 1 ip-HSD-1 and -2 subcloned into a luciferase promoter vector (pGL3) and 
transfected without (-) or with (+) a human estrogen receptor (ERa) cDNA (pSGSER) 
into JEG-3 cells. Luciferase activity expressed as relative light units (RLU)/pg cell 
protein was determined 18 h after incubation of cells without or with I x 10** M 173- 
estradiol (173-E}) or 17a-estradiol (17a-E2). (A) Basal promoter activities corrected for 
luciferase activity in cells co-transfected with a promoterless pGL3 vector. Asterisk 
indicates values (mean ± SE of four experiments) differ at P < 0.05; paired /-test. (B, C) 
Effects of estradiol alone or in the presence of a co-transfected ERa on 1 IP-HSD-1 (B) 
and llp-HSD-2 (C) promoter activities. Values (mean ± SE) of cell replicates (n = 2-5) 
in one representative experiment. (D, E) The effect of estradiol in the presence or 
absence of a co-transfected ERa on 1 IP-HSD-1 and 11P-HSD-2 promoter activities. 
Values expressed as the fold induction (mean ± SE of 3 experiments; where indicated, 
n=2) of basal promoter activity (Panel A) which was designated as 1. In panels B-E, 
values with different letter superscripts differ from each other at P < 0.05 (ANOVA; 
Neuman-Keuls multiple comparison test).
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altered by 173-estradiol in the presence or absence of a cotransfected ERa (data not 
shown).
Additional studies into the activation of the lip-HSD-l and 110-HSD-2 promoters 
were undertaken using CPT-cAMP in JEG-3 cells. Initial studies demonstrated a linear 
increase in luciferase expression as CPT-cAMP increased from 5 nM to SO pM (data not 
shown). It was decided to use SO |oM CPT-cAMP in subsequent treatments. As shown 
(Figure 29), CPT-cAMP significantly (P<0.01) increased 1 lp-HSD-1 promoter activation 
in JEG-3 cells almost 3-fold (2.S4 ± 0.21; n = 8) over respective values in cells incubated 
with no CPT-cAMP, whereas 11P-HSD-2 promoter activity increased slightly (1.30 ± 
0.07; n=6).
Finally, the basal promoter activities of 1 IP-HSD-1 and -2 with cotransfected 
steroidogenic factor 1 (SF-1), an orphan nuclear receptor, were investigated. Since SF-1 
is expressed in adrenal, ovary, testes and placenta (Parker and Schimmer, 1997), 293 
embryonic kidney cells, instead of JEG-3 choriocarcinoma cells, were used to determine 
the basal effect of SF-1. SF-1 in 293 kidney cells (Figure 30), decreased the basal 
promoter activity of 11(5- HSD-1 by 24% RLU/pg protein (n=l) and increased the basal 
promoter activity of 11P-HSD-2 by 25% RLU/pg protein (n=l). The cAMP-stimulated 
activity of SF-1 was not investigated.
To determine the degree inhibition of luciferase expression by the adenovirus/1 1 3 
HSD-2 antisense construct, JEG-3 cells were cotransfected with the adenovirus human 
antisense 11PHSD-2 cDNA construct and CaPC>4-precipitated baboon sense 113HSD- 
2/luc DNA. As indicated (Figure 31), 20% inhibition (n=3) of luciferase activity was 
demonstrated in JEG-3 placental cells when the antisense and sense constructs were
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Figure 29. Luciferase activity in JEG-3 cells of the 1.7 kb baboon 11PHSD-1 /luciferase 
construct and the 1.2 kb baboon 11 (3HSD-2/luciferase construct following treatment with 
CPT-cAMP (50 nM) 24 hr after CaPO«-precipitated DNA transfection. Values (mean ± 
SE) expressed as % change in basal (110HSD-1 or -2/luciferase DNA alone = 100%) 
luciferase promoter activity RLU / pg cell protein and were determined 18 h after 
incubation of CPT-cAMP in JEG-3 cells. The asterisk indicates that the mean value 
differs from the respective basal value (P<0.001, by unpaired /-test).
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Figure 30. Luciferase activity in 293 embryonic kidney cells of the 1.7 kb baboon 
1 ip-HSD-l/luciferase construct and the 1.2 kb baboon 11 PHSD-2/luciferase 
construct following simultaneous CaPCVprecipitated cotransfection with human 
cDNA Steroidogenic Factor 1 expression vector (n = 1). Values expressed as % 
change in basal (110HSD-1 or -2/luciferase DNA alone = 100%) luciferase promoter 
activity RLU / |ig cell protein and were determined 18 h after incubation of expression 
vectors in 293 cells.
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cotransfected concomitantly. When the adenovirus/11(3HSD-2 antisense construct was 
administered one day prior (in order to allow cellular accumulation of antisense mRNA), 
51% inhibition (n=3) of luciferase expression/activity was demonstrated. As evidenced, 
(Figure 32), there was a consistent (n=4) linear decrease in luciferase expression as the
adenovirus/11 (3HSD-2 antisense construct concentration increased. At the highest virus
concentration tested (30 x 10^ particles per 60 mm plate at 80% cell confluence), 
luciferase expression was reduced 51%. The virus particle to cell concentration ranged 
from approximately 10:1 to 100:1. At high virus concentrations when administered 24 
hrs prior to the sense DNA there was a diminution of total cellular protein by an average 
of 50% (data not shown). The ceils did not lift off the plate but apparently did not 
replicate during the 72 hour incubation as rapidly as the controls. Even though there was 
a reduction in total cellular protein at high virus titers, the RLU/pg protein (Figure 32) 
were still significantly diminished (P<0.05). This decrease in total cellular protein did 
not occur when the adenovirus and sense 1 l(3HSD-2/luc constructs were cotransfected 
concomitantly (data not shown) perhaps because the virus-infected cells were incubated 
for a shorter period of time (48 hrs vice 72 hrs). As a control (n = 2), baboon sense 11(3 
HSD-l/luc construct DNA was cotransfected with the adenovirus/1 ipHSD-2 antisense 
construct. There was actually a 20% increase in luciferase expression (RLU/pg protein 
(data not shown). This increase in luciferase expression is most likely attributable to 
adenovirus enhanced uptake of CaPCVprecipitated DNA In light of this increased 
luciferase expression in the control cotransfections, the luciferase inhibition values as 
evidenced with the antisense gene are particularly striking.
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Figure 31. Luciferase activity in JEG-3 cells of the 1.2 kb flanking region of baboon 
1 ip-HSD-2/luciferase construct following simultaneous transfection with adenovirus 
containing human 11J3HSD-2 antisense cDNA and CaPCVprecipitated sense 11PHSD- 
2/luciferase DNA (n = 3) or when the antisense adenovirus was administered one day 
prior to the addition of CaPCVprecipitated sense 11 (3HSD-2/luciferase DNA (n = 3). 
Values (mean ± SE) expressed as reduction in basal (11 PHSD-2/luciferase DNA alone 
= 100%) luciferase promoter activity RLU / pg cell protein (12K x g cytosol) and were 
determined 18 h after incubation of cells with adenovirus and baboon 11(3HSD- 
2/luciferase construct. Values (mean ± SE) with different superscripts differ from 
respective values at PO.OOl (by one-way ANOVA).
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Figure 32. Luciferase activity in JEG-3 cells of the 1.2 kb flanking region of baboon 
11 P-HSD-2/luciferase construct following concomitant transfection with adenovirus 
(0 -  30 x 109 particles per 60 mm plate at 80% confluence) containing human 11 (3- 
HSD-2 antisense cDNA and CaPCVprecipitated sense 11 PHSD-2/luciferase DNA. 
Values (mean ± SE) expressed as reduction in basal (110HSD-2 antisense cDNA 
alone = 100%) luciferase promoter activity RLU / jig cell protein (12K x g cytosol) 
and were determined 18 h after incubation of cells with adenovirus and baboon 110- 
HSD-2/luciferase construct (n = 4). Values (mean ± SE) with different superscripts 
differ from respective values at P<0.001 (by one-way ANOVA).
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RT-PCR confirmed that estrogen receptor a  mRNA was expressed in trophoblast and 
nontrophoblast cells of the late gestation baboon placenta at levels that appeared lower 
than in baboon uterus (Figure 33). In placenta, estrogen receptor mRNA expression was 
lowest in the syncytiotrophoblast.
DISCUSSION
In the present study, a baboon kidney genomic library was screened with a full 
length cDNA of the human 110-HSD-l to isolate and characterize the S’-flanking region 
as well as to identify the transcriptional start sites for baboon 110-HSD -1. Screening of 
1.3 x 106 plaques followed by three rounds of plaque purification, yielded seven verified 
genomic clones which were partially mapped with restriction enzymes and confirmed to 
contain insert DNA of 12-19 kb which hybridized with the human 1 10-HSD-l cDNA 
Additional results indicated that only two clones hybridized to the exon I cDNA fragment 
and it was the 1,737 bp Hind m-Not I fragment which we subsequently subcloned and 
sequenced. Overall, the nucleotide sequence of the S’-flanking region of baboon 110- 
HSD-1 analyzed in this study was more than 9S% homologous to that in the human 
(Tannin et al., 1991). This high degree of homology was particularly striking in the 
region of exons I and II and in the proximal promoter region (>98%). Using baboon liver 
RNA and a 22 bp primer complimentary to nucleotides +164 to +185 exon I, primer 
extension studies confirmed that the baboon 110-HSD-l gene has two transcriptional 
start sites 93 nucleotides apart. Similarly, as in the human gene, the S’-flanking region of 
the baboon 110-HSD-l does not contain a TATA box but there are two consensus CAAT 
boxes. Because there is no consensus TATA box, this transcriptional start site is 
presumably regulated by the consensus CAAT box 70 bp upstream from the start of
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Figure 33. Relative distribution of estrogen receptor (ERa) mRNA in baboon placenta. 
Total RNA (3 |ig) from syncytiotrophoblast (Lane 1), a heterogeneous non-trophoblast 
cell population (Lane 2), cytotrophoblasts (Lane 3) and whole villous tissue (Lane 4) 
from a late gestation baboon placenta were reverse transcribed and amplified in the 
presence of primers specific for ERa. The 417 bp ERa PCR product from nonpregnant 
baboon uterus (75 ng total RNA) is shown in Lane 5. RT was omitted from the reaction 
in Lanes 6, 7, and 8. RNA was omitted from the reaction in Lane 9. M = lkb ladder.
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transcription. Significantly, this upstream transcription start site is identical to that of the 
human 11P-HSD-1 gene in both its sequence and its location (Tannin et al., 1991). The 
second transcription start site is 93 bases downstream from the first one and this site is 
two bases up-stream from the translation initiation site for the human/ baboon 11P-HSD- 
1 gene. This data indicates that the transcripts from both transcription initiation sites may 
encode the same 1 ip-HSD-1 protein. Again, there is no TATA box in the up-stream 
region of the second promotor, rather there is a typical CAAT box 90 base pairs up­
stream from the second start site. Our studies also indicated that in the baboon, as in the 
rat and human (Tannin et al., 1991; Agarwal et al., 1989), there is a TATA box in intron I 
which may serve to regulate an alternative translation initiation site at Met 31 (Met 27 in 
the rat) of exon II. Indeed, in the rat kidney it has been demonstrated that as a result of 
differential promoter utilization, multiple 1 Ip-HSD-1 mRNAs and presumably proteins 
are expressed in vivo (Krozowski et al., 1990). Whether the utilization of this initiation 
site plays any role physiologically seems unlikely since transcripts originating in Intron I 
of the rat I ip-HSD-1 apparently encode a truncated polypeptide(s) that is enzymatically 
inactive (Obeid et al., 1993). Finally, a glucocorticoid response element and an estrogen- 
like-response-element (86% homology) were identified in the S’-flanking region of the 
baboon 1 ip-HSD-1 gene as has been reported for the human gene (Tannin et al., 1991), 
as well as the rat gene (Moisan et al., 1992).
Solution hybridization RNase protection assays confirmed that baboon 1 ip-HSD-1 
mRNA transcripts emanated from both transcription start sites in the near term baboon 
placenta as well as the liver. We have recently demonstrated that in the baboon placenta 
as in the human, the protein and mRNA for 1 lp-HSD-l are expressed primarily in the
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syncytiotrophoblast and not in non-trophoblast cells (Pepe et al., 1996a). Therefore the 
observation that the relative abundance of mRNA transcripts produced in the adult liver 
exceeded that produced in the placenta per unit total RNA most likely reflects the fact 
that nontrophoblast cells comprise a large proportion of the primate placenta.
Interestingly, however, our studies are the first to demonstrate that the 1 ip-HSD-1 
mRNA transcripts emanating from the baboon placenta and liver utilize different 
transcriptional start sites. Thus, mRNA transcripts originating from the upstream 
initiation start site dominated in the liver whereas in the placenta these transcripts 
originated primarily from the downstream initiation start site. Since these transcriptional 
start sites are only 93 bp apart, it remains to be determined using, for example, DNA 
sequence knock-out studies whether the two transcripts are transcribed from one or two 
promoters.
The observation that the 11J3-HSD-1 promoter exhibits glucocorticoid and estrogen­
like response elements would suggest that these hormones play a role in regulating cell- 
specific expression of 11 (3-HSD-1. However, the regulatory effects of these two 
hormones appear extremely complex and highly dependent upon the physiologic status of 
the animal. For example, in sheep, 1 IP-HSD-1 mRNA expression is enhanced in adult 
liver but reduced in fetal liver following glucocorticoid administration in vivo (Yang et 
al., 1994), whereas in the hippocampus, glucocorticoids and chronic-stress up-regulate 
neural 1 IP-HSD-1 (Low et al., 1994a). In the rat, hepatic 110-HSD-l is down-regulated 
by estrogen directly and/or via growth hormone (Low et al., 1994b; Low et al., 1993). 
The hormonal milieu to which a cell is exposed in vivo is not only complex but also 
modified during various physiologic states (i.e., pregnancy). This factor, plus the
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observation that the two transcriptional start sites of baboon 110-HSD-l are utilized in a 
tissue-specific manner, suggests that the exclusive utilization of immortalized cell lines 
for the study of regulation of the 110-HSD-l promoter, although valuable, may not 
permit unequivocal extension of findings to the in vivo situation. Thus, cultures of 
primary cells obtained from animals under varying physiologic situations or following 
treatment in vivo with selected secretogogues may provide a necessary adjunct to 
elucidate the factors operating to modulate to regulate the cell-specific factors important 
to the activation of the 110-HSD-l gene.
Additionally, a baboon kidney genomic library was screened with a full length 
cDNA of the human 110-HSD-2 to isolate and characterize the S’-flanking region as well 
as to identify the transcriptional start sites for baboon 110-HSD-2. Screening of 1.3 x 106 
plaques yielded five verified genomic clones that were confirmed to contain insert DNA 
of 12-19 kb, which hybridized with the human 110-HSD-2 cDNA. One clone hybridized 
to the exon I cDNA fragment and it was the 1220 bp Not I fragment which we 
subsequently subcloned and sequenced. Overall, the nucleotide sequence of the S’- 
flanking region of baboon 110-HSD-2 analyzed in this study was more than 9S% 
homologous to that in the human (Agarwal et al., 199S). This high degree of homology 
was particularly striking in the regions of exon I and the proximal promoter.
Using RNA from adult baboon kidney and near term placenta, primer extension 
studies confirmed that transcription is initiated at -311 nt from the ATG encoding 
methionine. In both the baboon placenta and adult kidney a second transcription 
initiation site was identified at -286 nt while a minor transcription initiation site was 
observed at -306 nt. Interestingly, a GC box, which typically regulates multiple
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transcription start sites, was identified 41 and 72 bases upstream from the first and second 
major transcription initiation sites respectively in the baboon 11J3-HSD-2 gene. Multiple 
start sites were also identified for 11P-HSD-2 in the human placenta (Agarwal et a I.,
199S) although the major start site was at *74 nt and the minor one at -116 nt. In the 
human kidney, however, only the -116 nt start site was observed (Agarwal et al., 199S). 
The transcription start site for 11P-HSD-2 in the sheep kidney (Agarwal et al., 1994) also 
appears to differ slightly from that in the human (Agarwal et al., 1995) and baboon (Pepe 
et al., 1999). Despite the fact that the first initiation transcription site of baboon 1ip- 
HSD-2 is approximately 263 bases upstream from that in the human, the size and 
nucleotide composition of the 11 P-HSD-2 encoded by baboon and human tissues is 
virtually identical. Although we have not determined the amino acid composition of the 
baboon 1I P-HSD-2 protein, the deduced structure of this protein is highly conserved in 
several mammalian species (Agarwal et al., 1994; Agarwal et al., 1995; Cole, 1995; 
Campbell et al., 1996).
Although we have only sequenced a relatively small component of the 5’-flanking 
region of both 11(3-HSD genes, the promoters of both 113-HSD-l and -2 were activated 
when transfected into JEG-3 cells. Moreover, the results of the current study also 
indicate that estradiol in the presence of estrogen receptora enhances the promoter 
activity of the 5’-flanking regions of the genes for baboon 1 ip-HSD-1 and 11P-HSD-2.
In the baboon, 1 IP-HSD-1 and -2 mRNA and protein are expressed in and localized 
specifically to the syncytiotrophoblast (Pepe et al., 1996a). The fact that the promoter 
activities of both 1 ip-HSD-1 and -2 were enhanced by approximately 2-fold in cells co­
transfected with pSG5ER alone in the absence of 17P-estradiol (Figure 28), supports the
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finding that these increases may be attributable to ER phosphorylation. ER 
phosphorylation occurs as part of both ligand-induced activity and ligand-independent 
transcriptional activation (Pettersson and Gustafsson, 2001). It has been shown that ER, 
in the absence of ligand, can be activated following phosphorylation by growth factors 
(EGF) or kinases (PKA, MAPK or CDK2; Hall and McDonnell, 1999)
Moreover, syncytiotrophoblast expression of both genes increases with advancing 
gestation in association with the progressive rise in estrogen (Albrecht and Pepe, 1990). 
The results of the present study also demonstrated that estrogen receptora is expressed in 
the cytotrophoblast and syncytiotrophoblast of baboon placenta, results consistent with 
previous observations of estrogen receptora mRNA (Chibbar et al., 1995) and protein 
(Billiar et al., 1997) expression in human placental trophoblast. Collectively, these 
results support the hypothesis that estrogen regulates the developmental expression of 
both 1 ip-HSD-1 and -2 in baboon syncytiotrophoblast. However, because putative 
transcription factor binding sites may also be present outside the most proximal regions 
of these genes, it remains to be determined whether the estrogen-estrogen-receptora 
activation of 1ip-HSD-1 and -2 reflects the magnitude of the response of the endogenous 
gene. Moreover, it remains to be determined whether estrogen regulates the promoter 
activity of the 1 IP-HSD-1 and -2 genes following transfection into primary cultures of 
baboon placental trophoblast. Nevertheless, the results of the current study are consistent 
with our previous studies demonstrating that placental NAD-dependent 11 P-HSD-2 
enzyme activity (Baggia et al., 1990a) as well as oxidation of cortisol to cortisone (Pepe 
et al., 1988; Baggia et al., 1990b), were increased at mid-gestation in baboons in which
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placental estrogen production was prematurely elevated in vivo and thus support a role 
for estradiol in regulating 11 P-HSD-2 expression.
However, similar studies in cultured human term placental syncytiotrophoblast 
demonstrated estradiol (l|iM) diminished 11 P-HSD-2 activity and mRNA (Sun et al., 
1998). Progesterone (lpM) and nitric oxide also inhibited 11 P-HSD-2 activity and 
mRNA, whereas the stimulation of the cAMP pathway with forskolin increased 11P- 
HSD-2 activity and mRNA Treatment of these cultured human syncytiotrophoblasts 
with the phorbol ester PMA (PK-C signal transduction pathway activator) had no effect 
on 1 ip-HSD-1 or -2  activity or mRNA (Sun et al., 1998). None of the five 
aforementioned compounds affected 1 ip-HSD-1 activity or mRNA. In vitro analysis of 
baboon syncytiotrophoblast 11 P-HSD-2 activity demonstrated that both progesterone and 
cortisone were enzymatically inhibitory (Baggia et al., 1990a).
Our transient transfection analyses in JEG-3 cells showed cAMP slightly increased 
11 P-HSD-2 promoter activity while 1 ip-HSD-1 activation increased 3 fold. These 
results coincide directly with the number of putative CREs (cAMP Response Elements; 
palindromic octamer TGACGTCA) present in each 5’-flanking region. The promoter of 
the baboon 1 lp-HSD-1 gene contains 5 putative CREs, while the baboon 11 P-HSD-2 S’- 
flanking region contains only 1 putative CRE. The modicum increase in cAMP- 
stimulated 11 P-HSD-2 promoter activity therefore reflects a promoter (i.e., at basal) 
which was approaching maximum possible stimulation, whereas cAMP-stimulated 1 lp- 
HSD-1 promoter activity was more susceptible to increased levels of activation (i.e., by 
cAMP). Perhaps the comparatively high basal activity of 11 P-HSD-2 reflected 
constitutive and/or fetal bovine serum growth factor-related activation and the low basal
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110-HSD-l activity indicates that this promoter required additional stimulants (i.e., 
cAMP). Another interesting note is that the cAMP analog, CPT-cAMP, used in these 
studies has been shown to bind with high affinity to the cAMP-binding site type B (vice 
type A) of the type II (vice type I) regulatory subunit (Ogreid et al., 1985) and perhaps 
the 110-HSD-l promoter is more selectively activated by this specific PK-A form (Rydel 
and Greene, 1988).
Our work demonstrates (Davies et al., 1997) that the 5’-flanking region of the 
baboon 110-HSD-l gene contains an estrogen receptor-like response element thereby 
providing a mechanism for estrogen to regulate expression of this gene. However, the 
promoter region of the gene also contains a glucocorticoid receptor response element and 
others have shown that glucocorticoids modulate 110-HSD-l mRNA expression in liver 
of fetal and adult sheep (Yang et al., 1994) and in rodent neural tissue (Low et al.,
1994a). Although additional studies remain to be performed, perhaps using a larger 
component of the 110-HSD-l promoter region, it is unlikely that cortisol regulates 
baboon placental 110-HSD-l expression since syncytiotrophoblast mRNA and protein 
levels of 110-HSD-l (Pepe et al., 1996a) increase concomitant with increased local 
catabolism of cortisol to cortisone by baboon syncytiotrophoblast (Baggia et al., 1990a; 
Pepe and Albrecht, 1995). It would appear therefore, that the regulation of 110-HSD-l is 
tissue specific. The rat 110-HSD-l gene utilizes tissue-specific differential promoter 
usage as evidenced by the detection of multiple mRNA species in different tissues 
(Moisan et al., 1992). Indeed, we also demonstrated (Davies et al., 1997) that there are 
two transcriptional start sites in the 5’- flanking region of the baboon 110-HSD-l gene
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and that mRNA transcripts emanating from the downstream start site dominated in 
baboon placenta whereas in the liver, transcripts originated from the upstream start site.
The results of the present study also indicate that, in contrast to 1 ip-HSD-1, the 
promoter region of the baboon 11 P-HSD-2 gene, like that in the human (Agarwal et al., 
1995) and sheep (Yang et al., 1994), does not contain an estrogen response element. 
Rather, in the baboon, as in the human, the 5’-flanking region of 11 P-HSD-2 has a high 
GC base content, regions which are known to exhibit binding for transcription factors 
including Spl (Briggs et al., 1986) and AP-2 (Williams and Tjian, 1991). Both Spl and 
AP-2, as well as SF-1, have been shown to be required for cAMP-dependent transcription 
(Liu and Simpson, 1997). Recently, it was demonstrated that native estrogen receptor 
protein or an estrogen receptor mutant lacking the DNA binding domain formed a 
complex with Spl (Porter et al., 1997). However, although these estrogen-receptor-Spl 
complexes resulted in enhanced Spl-binding to DNA in the presence or absence of 
estradiol, transactivation of promoter-reporter constructs was totally estrogen-dependent. 
These authors proposed (Klinge, 2000) the existence of an estrogen-dependent 
transactivation pathway that involves estrogen receptor-protein interaction and which is 
estrogen-response element independent. Although further study is required, the latter 
would provide a mechanism by which estrogen regulates 11 P-HSD-2 expression in the 
baboon placenta.
Steroidogenic Factor-1, (SF-l), an orphan nuclear receptor/transcription factor, has 
emerged as a key regulator of endocrine function (cytochrome P450 enzymes) and sex 
differentiation (Parker and Schimmer, 1997). Because of endogenous SF-1 expression in 
JEG-3 cells, SF-1 expression vector-activation of 1 lp-HSD-1 and -2 were investigated in
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293 embryonic kidney cells. Basal activation of both promoters by SF-1 was minimal, 
perhaps because required endocrine-tissue-specific factors were not present in kidney 
cells. SF-1 ’s promoter activation in response to cAMP was not determined although 
many studies have demonstrated that SF-1 can mediate cAMP responsiveness ( Liu and 
Simpson, 1997).
Finally, we have also demonstrated that a cotransfected adenovirus containing 
antisense cDNA can significantly diminish the expression of the complimentary sense 
cDNA cotransfected via calcium-phosphate precipitation into JEG-3 cells. It is uncertain 
how this inhibition occurs, but it is postulated to concern RNA triplex structures and/or 
increased mRNA destabilization/degradation. Nonetheless, 1 ip-HSD-2/luciferase 
expression diminished in the presence of antisense 11 P-HSD-2 promoter DNA/mRNA. 
Further analyses to determine whether the reduction in luciferase activity was attributable 
to reductions in luciferase mRNA or protein would have proved interesting.
In summary, we have isolated and sequenced the 5’-flanking regions the baboon 11 
P-HSD-1 and 11 P-HSD-2 genes and shown that the baboon genes exhibit extensive 
nucleotide homology to their respective human genes. The baboon 1 IP-HSD-1 gene has 
two transcriptional start sites 93 nucleotides apart and it appears that the upstream start 
site is the major one utilized in liver whereas the placenta appears to utilize the 
downstream start site. The baboon 11 P-HSD-2 gene also exhibited multiple 
transcriptional start sites in placenta and kidney, analogous to that in the human placenta, 
but not the human kidney (Agarwal et al., 1995). The baboon 1 IP-HSD-1 promoter 
contains no TATA boxes, but two consensus CAAT boxes, which presumably regulate 
transcription initiation. The baboon 11 P-HSD-2 promoter contains multiple GC boxes
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that probably regulate transcription. The 5’-flanking region of the baboon 1 lp-HSD-1 
and -2 genes exhibit extensive nucleotide homology to that of the human and are 
activated when transfected into JEG-3 cells. Moreover, it would appear that the S’- 
flanking regions of both the baboon 1 lp-HSD-1 and -2 genes are responsive to 17P- 
estradiol in the presence of a co-transfected estrogen receptora cDNA. Because of the 
importance of placental 11 P-HSD-1 and 11 P-HSD-2 in regulating cortisol transfer to the 
fetus and thus the function of the fetal hypothalamic-pituitary axis in the baboon (Pepe 
and Albrecht, 1995), studies of the regulation of the promoter in primary cultures of 
baboon trophoblasts obtained from animals at various stages of gestation with/without 
hormonal treatment in vivo should enhance our understanding of the mechanism(s) by 
which this gene is regulated in the placenta.
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CHAPTER VI
EXPRESSION OF 1 lP-HYDROXYSTEROID DEHYDROGENASE (UP-HSD) 
TYPES - I  AND -2  IN BABOON PLACENTAL SYNCYTIOTROPHOBLAST: 
EFFECT OF PLACENTAL P450-AROMATASE ENZYME INHIBITION IN  
VIVO
INTRODUCTION
Pepe and Albrecht have shown that estrogen, via regulation of placental 11P- 
hydroxysteroid dehydrogenase (1 lp-HSD) catalyzed metabolism of cortisol and cortisone 
(Pepe et al., 1988), determines the amount of maternal cortisol arriving within the fetus 
(Pepe and Albrecht, 1990) and thus regulates the function of the fetal hypothalamic- 
pituitary-adrenocortical axis (Pepe and Albrecht, 1998; Albrecht and Pepe, 1999). It is 
now known that cortisol-cortisone interconversion is regulated by two different 1 lp-HSD 
enzymes (Tannin et al., 1991; Agarwal etal., 1994; Monder and White, 1993; Pepe and 
Albrecht, 1995). The 11P-HSD type 1 originally cloned from the rat liver (Lakshmi and 
Monder, 1988) possesses both oxidative and reductive activity, prefers NADP7NADPH 
as a cofactor and has a relatively low (pM) affinity for glucocorticoid substrates. In 
contrast, the 113-HSD type 2 is unidirectional, possessing only oxidative activity, uses 
only NAD*, and has a high affinity (nM) for substrate cortisol (Brown et al., 1993;
Brown et al., 1996a). While the 11 P-HSD-1 gene appears to be expressed in several 
tissues (Tannin et al., 1991; Monder and White, 1993; Pepe et al., 1996b), the 11P-HSD- 
2 is expressed only in a few tissues including the kidney cortex, placenta (Hirasawa el al., 
2000) and the fetal adrenal (Albiston et al., 1994; Brown et al., 1996b; Pepe et al., 1996a; 
McMillen et al., 1999). The molecular/ biochemical basis for selective tissue expression 
remains to be determined.
The observation that the baboon and human 1 ip-HSD-1 gene promoter exhibits 
glucocorticoid and estrogen-like response elements would suggest that these hormones 
play a role in regulating cell-specific expression of 11 P-HSD-1. However, the regulatory
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effects of these two hormones appear extremely complex and dependent upon the 
physiologic status of the animal. For example, in sheep, 11 P-HSD-1 mRNA expression 
is enhanced in adult liver but reduced in fetal liver following glucocorticoid 
administration m vivo (Yang et al., 1994), whereas in the hippocampus, glucocorticoids 
and chronic-stress up-regulate 11 P-HSD-1 (Lowe/al., 1994a). Rat hepatic UP-HSD-1 
is down-regulated by estrogen directly and/or via growth hormone (Low et al., 1994b; 
Low et al., 1993) while estrogen upregulates both UP-HSD-1 and -2  expression in the 
rat uterus (Burton and Waddell, 1999). It is unlikely that cortisol regulates baboon 
placental UP-HSD-1 expression since syncytiotrophoblast mRNA and protein levels of 
11 P-HSD-1 (Pepe et al., 1996a) increase concomitant with increased local catabolism of 
cortisol to cortisone by baboon syncytiotrophoblast (Baggia et al., 1990a; Pepe and 
Albrecht, 1995). The rat lip-HSD-1 gene exhibits tissue-specific differential promoter 
usage as evidenced by the detection of multiple mRNA species in different tissues 
(Moisan et al., 1992). Indeed, we also demonstrated (Davies et al., 1997) that there are 
two transcriptional start sites in the 5’- flanking region of the baboon 1 lp-HSD-1 gene 
and that mRNA transcripts emanating from the downstream start site dominated in 
baboon placenta whereas in the liver, transcripts originated from the upstream start site.
It would appear therefore, that the regulation of 11 P-HSD-1 is tissue specific.
In cultured human term placental syncytiotrophoblast, studies demonstrated that 
estradiol (lpM) diminished 11 P-HSD-2 activity and mRNA levels (Sun et al., 1998). 
Moreover, progesterone (lpM) and nitric oxide also inhibited 11 P-HSD-2 activity and 
mRNA in vitro, whereas stimulation of the cAMP pathway with forskolin increased 11P- 
HSD-2 expression. In contrast, treatment of cultured human syncytiotrophoblasts with 
the phorbol ester PMA, a PK-C signal transduction pathway activator, had no effect on 
11 P-HSD-2 activity or mRNA (Sun et al., 1998) and none of the five aforementioned 
compounds affected 11 P-HSD-1 expression. Studies of baboon syncytiotrophoblast 1 ip~ 
HSD-2 enzymatic activity showed that both progesterone and cortisone were competitive
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inhibitors for substrate cortisol (Baggia et al., 1990a). Our transient transfection analyses 
in JEG-3 cells showed cAMP slightly increased 11 P-HSD-2 promoter activity while 1 lp- 
HSD-1 activation increased 3 fold (Figure 29).
Our recent study (Pepe et al., 1999b) also indicated that, in contrast to 11 P-HSD-1, 
the promoter region of the baboon 11 P-HSD-2 gene, like that in the human (Agarwal et 
al., 1995) and sheep (Yang et al., 1994), does not contain an estrogen response element. 
Rather, in the baboon, as in the human, the 5’-flanking region of 11 P-HSD-2 has a high 
GC base content, regions which are known to exhibit binding for transcription factors 
including Spl (Briggs et al., 1986) and AP-2 (Williams and Tjian, 1991). The S’- 
flanking regions of both the baboon UP-HSD-1 and -2 genes are responsive to 17P- 
estradiol in the presence of a co-transfected estrogen receptora cDNA (Pepe et al., 
1999b; Figure 28).
Because of the importance of placental 11 P-HSD-1 and 11 P-HSD-2 in regulating 
cortisol transfer to the fetus and thus the function of the fetal hypothalamic-pituitary 
adrenal axis (Pepe and Albrecht, 1995), it is essential to ascertain whether the 
developmental increase in mRNA of these two enzymes in baboon syncytiotrophoblast is 
regulated by estrogen. This study was therefore undertaken to determine the levels of 11 
p-HSD-1 and -2  mRNA in syncytiotrophoblast isolated from placenta of baboons 
following treatment on day 100 -  day 170 with CGS-20267, a highly-specific placental 
P450-aromatase enzyme inhibitor.
MATERIALS AND METHODS
Baboon treatment with aromatase inhibitor CGS-20267
Baboons were randomly selected to receive CGS-20267 (4,4’-[ 1,2,4-triazol-1 -yl- 
methyIene]-6/5-benzonitrite, Letrozoe; Novartis Pharma AG, Basel, Switzerland) injected
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subcutaneously beginning on either day 30, day 60 or day 100 of gestation with a dose of 
0.1 mg/d in sesame seed oil. The dose of CGS-20267 was gradually increased by 0.1 
mg/d increments to a maximum of 2.0 mg/d, the level of which was maintained until 
cesarean-section delivery on days 160 through 178 of gestation. Other randomly 
assigned baboons received either no treatment or CGS-20267 (0.1 -  2.0 mg/day as above) 
plus estradiol benzoate (0.1 -  2.0 mg/d subcutaneously in sesame seed oil) at doses 
comparable to the normal ontogenetic pattern of maternal serum estradiol concentration. 
Placenta harvesting and syncytiotrophoblast cellular RNA purification
Syncytiotrophoblast-enriched and cytotrophoblast-enriched fractions were isolated by 
collagenase dispersion (Kliman et al., 1986) as modified by Baggia et al., 1990b and 
Pepe et al., 1999a. Essentially, the placenta was weighed immediately upon harvest and 
placed in a baked steel tray (8” x 12” x 2”) and rinsed repeatedly with sterile saline or 
Hanks (GIBCO #310-4185 AJ; filter sterilized) at 4°C on ice to remove as much blood as 
possible. The maternal and fetal membranes were pulled/dissected away while on ice in 
cold Hanks and discarded along with calcifications and any infarcts. The placenta was 
then weighed again (50 g mid-gestation, 80 g term gestation) and Dispersion Media (4 
ml/g tissue) in a 500 ml baked Erlenmeyer flask was prepared. Dispersion Media for 40 
g tissue; add to 160 ml sterile Hanks 1.6 ml FBS, 160 mg collagenase (0. 1%; Sigma 
C9891 or 200 mg Sigma C8051), 160 mg hyaluronidase (0. I %; Sigma H3506), 16 mg 
DNAse (0.01%; Sigma D5025), 40 mg trypsin inhibitor (0.025%; Sigma T9003) and 54 g 
NaHCC>2 (Sigma S5761). The placental tissue was minced 5 g at a time in a petri dish on 
ice with 5 -10 ml cold Hanks using a sharp, curved scissors and then the minces were 
collected/pooled into 50 ml tubes (polypropylene, Fisher #05-539-5 and -6). The tubes
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were filled to the top with cold Hanks (4 tubes mid, 8 tubes term) and spun at 300 x g 
forlO min at 4°C. The pellet was loosened by hitting the centrifuge tube on the counter 
top and then pouring it into wanned Dispersion Media. Digestion occurs at 37°C for 3S 
min with agitation.
Following collagenase dispersion, the digestion was strained through autoclaved 
Nitex cloth into a baked glass beaker on ice. The cloth was squeezed to maximize 
recovery. The cell suspension, now in SO ml tubes, was diluted about 50% with cold 
Hanks and then centrifuged 500 x g 15 min at 4°C. The supernatant was aspirated or 
poured off carefully and the pellets were then resuspended and combined using sterile 
plastic pasteur pipettes to two 50 ml tubes. The volume was brought to 50 ml with cold 
Hanks and then recentrifuged 500 x g 30 min at 4°C. Again the supernatant was carefully 
removed and only the top white and middle pink (not the bottom RBC pellet) placental 
cells layers were collected and resuspended well in cold Hanks. (5-8 ml per Percoll 
gradient)
Trophoblasts were isolated via 5 - 70% Percoll (Sigma P1644) gradient 
centrifugation. Baked 12 x 75 mm glass test tubes were labeled 1 to 14 (3 sets midterm 
placenta, 6 sets for term placenta). 90% Percoll was prepared by adding 6 ml of 10 x 
Hank's to 54 ml of Percoll for a midterm (12 ml 10 x Hanks + 108 ml Percoll for a term). 
A 70% to 5% gradient in 5% increments was prepared using proportions charted below. 
The tubes were vortexed for 3 -  5 sec and the gradient was then prepared in 50 ml conical 
clear polystyrene centrifuge tubes (Coming orange top #25339-50) placed at a 45° angle. 
Starting with tube #1, the Percoll mixture was applied to the 50 ml tube using a Rainin 
Rabbit 8-channel peristaltic pump (Rainin, Woburn, MA) with small diameter tubing
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(Rainin # 39-625) at a rate of 100-150 ml/hr (setting 444). (The tubing was flushed first 
with sterile H2 O then 90% Percoll). This process was repeated for tubes 2 through 14.
Interfaces between each 5% step in the gradient can be seen. 5-10 ml cell suspension was 
carefully pipetted onto the gradient and centrifuged in a Beckman TJ-6, speed 7, 1125 x
g, 2400 RPM, for 20 min at RT; CAPS OFF, BRAKE OFF!
Tube# 90% Percoll (mil 1 x Hank's (mil Final % Percoll
1 2.33 0.67 70
2 2.17 0.83 65
3 2.00 1.00 60
4 1.83 1.17 55
5 1.67 1.33 50
6 1.50 1.50 45
7 1.33 1.67 40
8 1.17 1.83 35
9 1.00 2.00 30
10 0.83 2.17 25
11 0.67 2.33 20
12 0.50 2.50 15
13 0.33 2.67 10
14 0.17 2.83 5
On a 5-70% Percoll gradient, 3 white cell layers were collected and pooled/washed. 
Band 1 (37-32 ml/mark) was veiy thick so it was separated into 2 - 3 50 ml tubes and 
diluted to 50 ml with Hanks. Bands 2 & 3 (32-23 ml/mark) and Band 4 (22-12 
ml/mark) were also collected and diluted a lot with Hanks (at least 3 - 4  tubes). An 
aliquot of band 4 cytotrophobiast was counted as the total # cells recovered per tissue 
weight. 10% of band 1 and 4 cells were saved to -80°C in sterile 15 ml polypropylene 
tubes after snap freezing in liquid nitrogen. The cells were pelleted at 500 x g for 15 min 
4°C. The supernatants were discarded. At this point, one could either snap-freeze cells in 
liquid nitrogen and store them -80°C or proceed.
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Total RNA was isolated as stated above (Chirgwin et al., 1979) using P-mercapto- 
ethanol and guanidine isothiocyanate (prepared as follows: 70.9 g GITC (Gibco) in a 
250-300 ml baked volumetric cylinder. DEPC H2 O was added to the 140 ml mark and 
then 1.25 ml 3M NaAcetate pH 6.0 was added. The volume was brought to 150 ml with 
DEPC H2 O and filter sterilized with a 150 ml Nalgene 125-0080 filter; store room
temperature). To the band 1 cell pellet, 19 ml GITC buffer (plus 158.7 pi pm-EtOH) was 
added. Bands 2/3 cell pellet received 7.2 ml or 10.8 ml GITC + 60 or 90 pi Pm-EtOH. 
The Band 4 cell pellet received 3.6 ml GITC + 30 pi Pm-EtOH. The cell lysate (in 50 ml 
polypropylene tubes) was then vortexed and polytroned (Polytron PT10, Kinematica, 
Switzerland; setting at 9.5) on ice for 15 sec x 4 with a 10 sec rest in between. The tubes 
were then centrifuged 1000 x g for 10 min at RT and the supernatants were poured into 
new polypropylene tubes and extracted with an equal volume of 24:1 chloroform:isoamyl 
alcohol. The tubes were inverted slowly and repeatedly for 1 min and then centrifuged 
2300 x g for 15 min at RT. The top layer was carefully pipetted to new tubes, leaving the 
interface behind. Band 1 was extracted at least once or twice more. Genomic DNA was 
sheared by pulling the supernatants up and down once through a 23 gauge needle. At this 
junction, the lysates could be frozen/stored -80°C or gently layered with a 1 ml 
pipetteman onto 1.8 ml CsCl buffer (prepared as follows: 95.97 g CsCl (Sigma; 5.7 M) + 
830 pi 3M NaAcetate pH 6.0 are added and brought to 100 ml with DEPC H2 O in a 100
ml volumetric cylinder, vacuum filter/sterilize as GITC above) in Beckman tubes 
#344057. Total RNA is pelletted 38.6K RPM (179,000 x g;SW 50.1 rotor), 21 hrs, 23°C.
Following the overnight spin, the supernatants were carefully removed 
incrementally with a plastic transfer pipette. The supernatant to the CsCl shelf was
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discarded and then the CsCl was removed until about O.S ml remained. Then the tube 
was inverted to remove the last O.S ml. The tube was wiped with a sterile cotton Q-tip 
and allowed to dry for a few minutes. The RNA pellet was resuspended in 100 pi 0.3 M 
NaAcetate pH 6.0 by pipetting repeatedly and transferred to sterile 1.5 ml eppendorf 
tubes. This was repeated twice. 750 pi cold EtOH (100%) was then added and the 
eppendorf-containing-RNA preparations were stored indefinitely at -80°C. When 
needed, the RNA was pelletted via centrifugation at 13K x g for 30 min, 4°C, washed 
with 1 ml cold 70% ETOH in DEPC H2 O, repelletted, dried in a Savant Speed Vac 
Concentrator (Savant Instruments, Farmingdale, NY), dissolved in sterile H2 O and 
analyzed spectrophotometrically prior to RT-PCR experimentation.
RT-PCR determination of estrogen receptor a , 11PHSD-1 and 11PHSD-2 mRNA 
and I8S rRNA expression
The expression of ERa, 1I0HSD-1 and -2 mRNA as well as 18S rRNA in sundry 
tissues and in enriched placenta cell fractions were determined by reverse transcription - 
polymerase chain reaction (RT-PCR) using procedures recently developed in our 
laboratories (Albrecht et al., 1995; Babischkin et al., 1997). Oligonucleotide primers 
synthesized by Life Technologies, Inc. were selected from the cDNA sequence of human 
ERa (Green et al., 1986) and flanked a portion of the cDNA sequence that spans exons 
4-7 and overlaps introns D, E and F. ERa forward primer (upstream):
5 ’GATCCTACCAGACCCTTC AG-3 ’ (position 1226-1245). ERa reverse primer 
(downstream): 5 ’-TTCCAGAGACTTCAGGGTGC-3 ’ (position 1642-1623). Position 
numbers correspond to the nucleotide sequence of human ERa (Green et al., 1986) 
cDNA where the initiation codon begins at position 233. The ERa RT-PCR product
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generated should be 417 bp in size. For 1 lp-HSD-1, primers were also selected from the 
human sequence (Tannin et al., 1991) and flanked a portion of the cDNA sequence that 
spans exons 1-5 and overlaps introns A, B, C and D. 11(3-HSD-1 forward primer 
(upstream): 5 ’-GAAAAAATATCTCCTCCCCATTCTG-3 ’ This sequence is 100% 
homologous to the baboon gene sequenced previously (position 107-131; Figures 20 and 
21). 11P-HSD-1 reverse primer (downstream):
5’-GACACTGAATATTCCTTTCTGATGG-3’ (position amino acid 204-196). The 
human sequence predicts an RT-PCR product 600 bp in size. For 110-HSD-2, primers 
were again selected from the human sequence (Agarwal et al., 1995) and flanked a 
portion of the cDNA sequence that spans exons 2-5 and overlaps introns B, C and D. 11 
p-HSD-2 forward primer (upstream): 5’-TGCTGCAGATGGACCTGACCAA-3’ 
(position amino acids 134-141). 113-HSD-2 reverse primer (downstream): 
5’-GTAGTAGTGGATGAAGTACATGAGC-3’ (position amino acids 354-346). The 
human sequence predicts an RT-PCR product 659 bp in size. Finally, for 18S, primers 
were selected from the human 18S ribosomal RNA gene sequence (Torcynski et al.,
1985). 18S forward primer (upstream): 5’-TCAAGAACGAAAGTCGGAGG-3’
(position 1126-1145). 18S reverse primer (downstream):
5 ’-GGACATCTAAGGGCATCACA-3 ’ (position 1614-1595). The human sequence 
predicts an RT-PCR product o f489 bp in size.
Total RNA from sundry samples (1-3  pg) were reversed transcribed at 42°C for 60 
min in a reaction mixture (20 p i)  containing 1 m M  each of dATP, dCTP, dGTP, dTTP 
(Promega) 1 m M  dithiothreitol, 200 U SUPERSCRIPT RNase H RT (Life Technologies), 
40 U RNAguard ribonuclease inhibitor (Pharmacia Biotech Inc., Piscataway, NJ), 50 m M
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Tris-HCl (pH 8.3), 75 m M  KC1, 3 m M  MgCh and 250 ng of Random Primers (Life 
Technologies). After 60 min, the RT mixture was heated to 70°C for 15 min and then 
cooled to 4°C. DNA amplification was carried out in a 100 pi reaction volume 
containing 20 pi of the RT reaction, 0.2 m M  each of dATP, dCTP, dGTP, dTTP, 10 mM 
Tris-HCl (pH 8.3), 50 mM KC1, 1.5 -  2.0 mM MgCh, 1.25 U cloned Thermus aquaticus 
DNA polymerase (Amplitaq, Applied Biosystems, Foster City, CA) and 20 pmoles each 
of the forward and reverse primers. On many occasions, a RNA PCR Core Kit (Perkin 
Elmer #N808-0143, Applied Biosystems, Foster City, CA) was utilized. PCR was 
performed in a PTC-100 Programmable Thermal Controller (MJ Research, Watertown, 
MA). Samples were amplified from 23-40 sequential cycles at 94°C for 20-60 sec 
(melting), 48°-60°C for 30-60 sec (annealing) and 58°-72°C for 30-120 sec (extension), 
depending upon the cDNA amplification parameters. After the last cycle, samples were 
incubated for an additional 7 min at 72°C. Two negative controls, in which either RNA 
or RT was omitted from the reaction, were also performed. The PCR products were 
fractionated by electrophoresis in a 1% agarose gel and stained in ethidium bromide. The 
PCR target products were visualized with a UV transilluminator and photographed using 
type 665 positive/negative film or captured on a Stratagene Eagle Eye II Still Video 
System (Stratagene U.S.A).
All the PCR reactions were preliminarily analyzed kinetically to ensure exponential 
amplification of the PCR product, since it is only in this phase that amplification is 
extremely reproducible (data not shown). The cycle number, [Mg*2] and cycle 
parameters were optimized to ensure all amplification reactions were within the linear 
range and had not entered the plateau phase. The cycle number was also appropriately
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optimized to ensure the PCR product band width was suitable for quantitative SigmaGel 
Gel Analysis (Sigma, St. Louis, MO). SigmaGel Gel Analysis software in the lane 
analysis mode measures and integrates the product lane area “under the curve” 
statistically accurately only if the band-width is appropriately sized and is not saturated. 
Quantitative analysis of the PCR products for 11P-HSD-1 and -2, as a ratio of 18S rRNA 
expression, were determined using SigmaGel Gel Analysis of agarose gel images 
captured on a Stratagene Eagle Eye II Still Video System (Stratagene U.S.A.). PCR- 
generated bands were extracted from the agarose gel (QIAGEN, Chatsworth, CA) and 
verification of the products was accomplished by dideoxy-chain termination sequencing 
(San Diego State University MicroChemical Core Facility, San Diego, CA) using Big 
Dyes Kh with AmpliTAQ SS (Applied Biosystems, Foster City, CA) on an ABI377 
DNA automated sequencer.
RESULTS
Maternal peripheral serum estradiol concentrations in CGS-20267-treated baboons 
decreased to and remained at a level significantly lower (P <0.001) than that in the 
untreated control baboons (Figure 34, A). This decrease was evident within 1 to 3 days 
of the initiation of CGS-20267 administration. The pattern of maternal serum estradiol 
concentrations in baboons treated concomitantly with CGS-20267 and estradiol was 
similar to that demonstrated in control untreated baboons (Figure 34, B). The overall 
level of estradiol, however, was two-fold greater than that in untreated control baboons.
The placental cell fraction obtained by 5 -  70 per cent Percoll gradient centrifugation 
of collagenase-dispersed placenta tissue appeared to be comprised primarily of cellular 
aggregates with small highly basophilic nuclei (data not shown) that was shown to
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Figure 34. Mean maternal serum estradiol concentrations in CGS-20267-treated 
baboons. A. Baboons untreated (n = 20, filled circles) or treated daily subcutaneously 
with CGS-20267 at 0.1 to 2.0 mg/day beginning on day 100 o f gestation (n = 24, open 
circles-, term is 184 days). B. Baboons concomitantly treated subcutaneously with 
CGS-20267 at 0.1 to 2.0 mg/day and estradiol benzoate at 0.1 to 2.0 mg/day beginning 
on day 100 of gestation (n -  9, filled circles).
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Figure 35. Expression of 11P-HSD-1 mRNA and 18S rRNA in placental 
syncytiotrophoblast isolated on day 165 -170  of gestation from baboons which were 
untreated (N = 7) or treated on days 100 -  170 with CGS-20267 (N = 8) or CGS-20267 
plus estradiol (N = 7). Total RNA (1 |ig) was reversed transcribed and 90% of the RT 
reaction mixture PCR-ampiified for 31 cycles with 1 ip-HSD-1 specific primers (600 
bp product), and 10% PCR-amplified for 23 cycles with 18S specific primers (489 bp 
product). The ratios o f the densitometric analyses of 110-HSD-1 to 18S are displayed. 
All amplifications were performed in the exponential phase. Control samples utilizing 
RNA (1 pg) not reverse transcribed were also PCR-amplified with negative results to 
verify the absence of contaminating genomic DNA (data not shown).
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exhibit extensive cytoplasmic immunoreactivity with antisera against SP j (Babischkin et 
al., 1996). In contrast, this cellular fraction showed little of no staining for vimentin 
which labels endothelial cells and fibroblasts or a-antichymotrypsin which labels 
macrophages (Babischkin et al., 1996). These results indicate that syncytiotrophoblasts 
were the predominant cell type isolated by Percoll gradient centrifugation.
Baboon syncytiotrophoblast cells isolated from near-term gestation (day 160-178, 
term = day 184) cesarean-section delivered placentas express the mRNA for 1 lp-HSD-1 
and -2  enzymes, as well as 18S ribosomal RNA, as determined by RT-PCR (Figures 35 
and 36). Using human sequence-specific primers to 1 ip-HSD-1 (Tannin et al., 1991), 
RT-PCR generated a single product o f600 base pairs (bp), the correct size for the 
targeted region. The identity of this product was further confirmed by dideoxy nucleotide 
chain termination sequence analysis (data not shown) of both strands. The sequence 
analysis of the baboon 110-HSD-1 RT-PCR product, in comparison to the published 
human sequence (Tannin et al., 1991) indicated remarkable homology; 99.S % identity at 
the amino acid level (199 o f200) and 98.7 % identity at the nucleotide level (592 o f600).
Similarly, RT-PCR analysis of 110-HSD-2 (Figure 36), using human sequence- 
specific primers (Agarwal et al., 1995), generated a single product o f659 bp. Sequence 
analysis (data not shown) of both strands of this product further confirmed its identity. In 
comparison to the human sequence (Agarwal et al., 1995), the baboon 110-HSD-2 
mRNA in this region is also highly homologous; 98.6 % identity at the amino acid level 
(217 o f220) and 97.9 % identity at the nucleotide level (645 o f659).
Thirdly, RT-PCR amplification of the baboon 18S rRNA, utilizing human sequence- 
specific primers (Torczynski et al., 1985), yielded a single 489 bp product, the size of the
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targeted region. Once again, sequence analysis of both strands of this product (data not 
shown) further confirmed its identity, and, in comparison to the human sequence 
(Torczynski et a/., 198S), the baboon 18S rRNA in this region is 100 % homologous at 
the nucleotide level (489 o f489).
The PCR reactions for both 1 ip-HSD-1 and -2, as well as 18S ribosomal RNA, were 
analyzed ldnetically in preliminary studies to ensure exponential amplification of the 
PCR product (data not shown). The cycle number, [Mg*2] and cycle parameters were 
optimized to ensure all amplification reactions had not entered the plateau phase. Control 
samples utilizing comparable RNA (1 pg) quantities were not reverse transcribed but 
PCR-amplified with negative results to verify the absence of contaminating genomic 
DNA (data not shown). The cycle number was also appropriately optimized to ensure the 
PCR product band width was “under the curve”. SigmaGel Gel Analysis software 
(SIGMA, St. Louis, MO) in the lane analysis mode measures and integrates the product 
lane area “under the curve” statistically accurately only if the band width is appropriately 
sized and is not saturated. A typical RT-PCR reaction, using 18S rRNA as an 
endogenous internal standard, is demonstrated for 1 ip-HSD-1 (Figure 3S) and 11P-HSD- 
2 (Figure 36). As evidenced, the 18S standard remains relatively constant whereas the 11 
P-HSD-1 and -2  RT-PCR product bands demonstrate variability among the sundry 
treatment groups.
Quantitative analyses of the PCR products for 1 lp-HSD-1 and -2, as a ratio to 18S 
rRNA expression, were determined using SigmaGel Gel Analysis of agarose gel images 
captured on a Stratagene Eagle Eye II Still Video System (Stratagene U.S. A ). These 
results were highly reproducible, and therefore the RT-PCR ratios displayed in Figures
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Figure 36. Expression o f 11 (3-HSD-2 mRNA and 18S rRNA in placental 
syncytiotrophoblast isolated on day 165 -  170 of gestation from baboons which were 
untreated (N = 7) or treated on days 100 -170  with CGS-20267 (N = 8) or CGS-20267 
plus estradiol (N = 7). Total RNA (1 pg) was reversed transcribed and 90% of the RT 
reaction mixture PCR-amplified for 32 cycles with 11 p-HSD-2 specific primers (659 
bp product), and 10% PCR-amplified for 23 cycles with 18S specific primers (489 bp 
product). The ratios of the densitometric analyses of 11 P-HSD-2 to 18S are displayed. 
All amplifications were performed in the exponential phase. Control samples utilizing 
RNA (1 pg) not reverse transcribed were also PCR-amplified with negative results to 
verify the absence of contaminating genomic DNA (data not shown).
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35 and 36 were analyzed (Figure 37) using ANOVA with multiple comparison of the 
means by the Student-Newman-Keuls statistic test. When expressed as a ratio to 18S 
rRNA expression, baboon lip-HSD-1 RT-PCR generated products was 0.546 ± 0.096 at 
term control and significantly reduced 5-fold to 0.104 ± 0.027 in syncytiotrophoblasts 
from baboons treated with CGS-20267 (P<0.01). The expression of 11 P-HSD-1 in 
syncytiotrophoblasts from baboons treated with CGS-20267 and estradiol was 0.353 ± 
0.087, a value significantly different from the CGS-20267 treatment alone (P<0.05), but 
not from the control (P>0.05; Figure 37).
Baboon syncytiotrophoblast expression of 11 P-HSD-2 RT-PCR generated products 
was 0.692 ± 0.140 at term control and reduced, albeit not significantly to 0.512 ± 0.237 
upon CGS-20267 treatment (P>0.05). With concomitant CGS-20267 treatment and 
estradiol supplementation, 11 P-HSD-2 expression was 0.794 ± 0.213, again not a 
significant difference from either the CGS-20267 treatment alone (P>0.05) or from the 
control group (P>0.05; Figure 37).
With regard to 11 P-HSD-2, two values, one from the CGS-20267 treatment alone 
(2.15) and the other from the CGS-20267 plus Ej (2.00), appeared to be significantly 
removed from the main body of data (Figure 36). These two extreme observations were 
analyzed and proven to be statistical outliers (P<0.005) and not from the same population 
as the other observations. Upon removal of these two 11 P-HSD-2 values and reanalysis 
of the data (Figure 38), syncytiotrophoblast expression of 11 p-HSD-2 (ratio to 18S) 
mRNA in untreated animals (0.692 ± 0.140) was reduced (P<0.001) more than 2-fold 
(0.279 ± 0.049) in syncytiotrophoblast of baboons treated with CGS-20267. With 
concomitant CGS treatment and estradiol supplementation, 11 P-HSD-2 mRNA
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Figure 37. Relative expression of 11 P-HSD-1 and -2 mRNA in isolated baboon 
placental syncytiotrophoblast cells from the agarose gels displayed in Figures 35 and 36. 
Data expressed as the ratio (mean ± SE) of 11 P-HSD-1 or -2 message compared to its 
corresponding 18S rRNA signal. Baboon placental syncytiotrophoblast preparations 
were each assayed six times and the PCR product band areas densitometrically analyzed 
using SigmaGel Gel Analysis (Sigma, St. Louis, MO) of Stratagene Eagle Eye II Still 
Video System (Stratagene U.S.A)-photographed images. Values (mean ± SE) with 
different letter superscripts differ from each other at P<0.01 (ANOVA with multiple 
comparison of means by Student-Newman-Keuls Test).
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Figure 38. Relative expression of 11 P-HSD-1 and -2 mRNA in isolated baboon 
placental syncytiotrophoblast cells from the agarose gels displayed in Figures 35 and 36. 
Values for 11 P-HSD-1 are the same as in Figure 37. Values for 11 P-HSD-2 are also 
from Figure 37 determined after deletion of statistical outliers. Values (mean ± SE) 
with different letter superscripts differ from each other at P<0.01 (ANOVA with 
multiple comparison o f means by Student-Newman-Keuls Test).
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expression was 0.594 ± 0.084, again a significant difference only from the CGS-20267 
treatment alone (P<0.01), but not from the control group (PX).05).
DISCUSSION
The results presented here are the first to unequivocally demonstrate that estrogen, 
in vivo, is essential for the transcriptional regulation of 11 P-HSD-1 and -2 genes in the 
baboon syncytitrophoblast. CGS-20267, a potent and specific placental P450-aromatase 
enzyme inhibitor, when administered during the latter half of pregnancy, reduced 
maternal estrogen levels from approximately 2 ng/ml to less than 0.1 ng/ml (Figure 34). 
This estradiol diminution was associated with a significant decrease in placental 
syncytiotrophoblast mRNA levels of 11 P-HSD-1 and -2.
Recently, Pepe and Albrecht demonstrated that the mRNA (via Northern analysis) 
and peptide levels (via Western analysis) of both 11 P -H S D -1 and -2 in 
syncytiotrophoblast of the baboon placenta increased with advancing gestation (Pepe et 
al., 1996a) and that baboon placental NAD+-dependent 11 P-HSD-2 activity was 
regulated by estrogen (Baggia et al., 1990a). We also demonstrated that the promoter 
regions of both baboon 11 P -H S D -1 and -2  genes are activated by estradiol in JEG-3 cells 
following transient transfection analyses in vitro (Pepe et al., 1999b; Figure 28). The 
hormonal milieu to which a cell is exposed in vivo is not only complex but also modified 
during various physiologic states (i.e., pregnancy). This fact, plus the observation that 
the two transcriptional start sites of baboon 11 P -H S D -1 are utilized in a tissue-specific 
manner, suggests that the exclusive utilization of immortalized cell lines for the study of 
regulation of the 1 ip - H S D -1  promoter, although valuable, may not permit unequivocal 
extension of findings to the in vivo situation. This in vivo demonstration of diminution of
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baboon 11 P-HSD-1 and -2  mRNA levels following the almost complete absence of 
estrogen is therefore remarkable.
Because of the distinct tissue expression of the 11 P-HSD genes, elucidation/ 
verification of the cell-specific factors (i.e., estrogen) contributing to lip-HSD-1 and -2 
expression in vivo required unique cell-specific isolation/analysis studies to determine 
whether the promoter regions of these two genes are activated in baboon placenta 
following maternal/fetal estradiol reduction and/or enhancement. Because of the 
important role that both syncytiotrophoblast 11PHSD-1 and -2  enzymes play in 
regulating fetal-placental function in the baboon, i.e. activation of the fetal HPAA and 
subsequent fetal adrenal maturation (Pepe and Albrecht, 1995; Pepe et al., 1996b), this 
study provides further amplifying evidence for the regulation of both baboon 11 P-HSD-1 
and -2  genes by estrogen. Following extended matemal/fetal estrogen reduction in vivo 
(day 100 -  day 170) by CGS-20267, a highly-specific placental P450-aromatase enzyme 
inhibitor, semi-quantitative RT-PCR demonstrated a significant reduction in both 1 ip- 
HSD-1 and -2  mRNA in baboon placental syncytiotrophoblasts.
To spite the extremely large reduction in maternal serum estradiol level (about 20 
fold decrease), the concentration of bioactive estradiol remained in the 10*9 mol/L range. 
Because the dissociation constant of estradiol binding to its placental receptor approximates 
10*9 mol/L (Younes et al., 1981), the level of estrogen here in CGS-20267-treated baboons 
may be sufficient to bind its receptor and elaborate a physiologic response (Albrecht et al., 
2000). At least one estrogen receptor, (ERa), has been localized to the baboon placenta 
syncytiotrophoblast (Figure 33). The presence/absence of the second receptor, (ERP), 
has yet to be definitively resolved. Further studies utilizing gel-shift mobility assays
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with/without ERa and/or ERf) antibodies, and DNAse I footprinting analyses of the 11 p- 
HSD-1 and -2 promoter regions would prove valuable.
On the basis o f cofactor preference (i.e., NAD*), 11 P-HSD-2 appears to be the 
major form expressed in the human placenta (Brown et al., 1993; Stewart et al., 1994; 
Stewart et al., 1995; Krozowski et al., 1995; Brown et al., 1996a; Brown et al., 1996b, 
Sun et al., 1996, Sun et al., 1998), baboon placenta (Pepe et al., 1996a; Pepe et al., 
1996b; this research) and rat placenta (Li et al., 1996; Roland et al., 1996; Burton et al., 
1996). Expression of 11 P-HSD-2 has been specifically localized by in situ hybridization 
(Roland et al., 1996; Waddell et al., 1998), immuncytochemistry (Krozowski et al., 1995; 
Sun et al., 1996; Pepe et al., 1996b) and Northern analysis (Pepe et al., 1996a) to 
placental syncytiotrophoblast cells. Despite this clear evidence for 11 P-HSD-2 
expression in the placenta, 11 P-HSD-1 expression in the human placenta remains 
controversial (Burton and Waddell, 1999) and has only been demonstrated by Pepe 
and Albrecht in the baboon and human (Pepe et al., 1996b; Pepe et al., 1999a) and by 
Yang in the sheep placenta (Yang et al., 1992; Yang, 1995). Despite readily apparent 11 
P-HSD-1 bioactivity utilizing NADP* as a cofactor in human placental tissue fragments 
(Lakshmi et al., 1993), Stewart (Stewart et al., 1994b; Stewart et al., 1995a) and 
Sun (Sun et al., 1997) were unable to detect 11 P-HSD-1 immunoreactivity and /or 
mRNA in human placental syncytiotrophoblast or whole villous tissue. Utilizing 
sensitive and specific RT-PCR analysis of human placental cell-enriched fractions, we 
have demonstrated a modicum amount of 11 P-HSD-1 mRNA in cytotrophoblasts and an 
even smaller amount in syncytiotrophoblasts. On the other hand, detection of 11 p-HSD- 
2 in both cell types was readily apparent at significantly larger quantities.
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In summation, utilizing sensitive and reproducible comparative RT-PCR technology, 
we have definitively demonstrated a significant reduction in the in vivo expression of 
both 11 P-HSD-1 and -2  mRNAs in baboon placental syncytiotrophoblast-enriched 
fractions following reduction of maternal serum estrogen by a highly-specific P450- 
aromatase enzyme inhibitor, CGS-20267. This discovery provides further amplifying 
evidence that estrogen, via regulation of placental 1 lP-hydroxysteroid dehydrogenase (11 
P-HSD) catalyzed metabolism of cortisol and cortisone (Pepe et al., 1988), determines 
the amount of maternal cortisol arriving within the fetus (Pepe and Albrecht, 1990) and 
thus regulates the ontogenetic development/function of the fetal hypothalamic-pituitary- 
adrenocortical axis (Pepe and Albrecht, 1998; Albrecht and Pepe, 1999).
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CHAPTER VH 
SUMMARY AND FUTURE DIRECTIONS 
The goal of this research was to determine whether estrogen regulated the 
expression of the 11 (3HSD enzymes controlling secretion o f maternal-derived cortisol 
into the fetus, and whether the latter regulated fetal adrenal maturation by enhancing 
hypothalamic and/or pituitary CRH/ACTH production. One of our studies clearly 
demonstrated that there was a developmental increase in fetal pituitary POMC mRNA 
expression between mid- and late gestation, and this increase could be induced at mid­
gestation by maternal estrogen administration at mid-gestation, presumably via the 
estrogen-induced placental decrease in cortisol release into the fetal compartment. The 
increase in pituitary POMC mRNA was associated with a concomitant increase in 
pituitary ACTH peptide production. Collectively these results support the hypothesis that 
the decrease in placental-derived cortisol removes the feedback inhibition on the fetal 
pituitary and thereby permitting fetal pituitary ACTH to drive fetal adrenal maturation. 
These results also support the phenomenon that feedback inhibition by cortisol on the 
midterm fetal pituitary is a reality.
These results do generate some questions. For example, where and how early in 
fetal development are GRa and/or GRP expressed in the baboon fetal pituitary and are 
the receptors co-localized with POMC? Where and how early in fetal development are 
PCI and PC2 expressed in the baboon fetal pituitary? These questions could easily be 
ascertained by in situ hybridization and/or RT-PCR analysis of laser capture microscopy 
tissue of the fetal adenohypophysis. The absence of ERa and/or ERp could also be 
determined to insure that the upregulation of POMC mRNA/ACTH peptide was indeed
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indirect via the placental 110HSD-1/-2 system. What role, if any, do placental CRH and 
placental ACTH play in the endocrine development of the fetal pituitary and/or adrenal? 
This could be ascertained by determining whether placental peptides are secreted into the 
fetus and whether levels are increased by estrogen.
A second significant discovery was that the concentration of CRH peptide and 
mRNA in the fetal baboon hypothalamus was similar at mid- and late gestation and that 
hypothalamic CRH peptide levels were not increased at mid-gestation following maternal 
treatment with estradiol. This indicated that the increase in pituitary POMC mRNA and 
ACTH peptide expression at term, and following maternal estrogen administration of 
estradiol at mid-gestation, is regulated, in part, by cortisol, acting on the pituitary and not 
the hypothalamus.
Thirdly, it was demonstrated that fetal adrenal PK-A activity is greater in late 
gestation when estrogen levels are elevated than at mid-gestation. Moreover, PK-A 
activity was experimentally increased at mid-gestation following premature elevation of 
estrogen to levels typically observed in late pregnancy, treatment paradigms altered 
placental cortisol metabolism and activated fetal pituitary ACTH release resulting in the 
onset of de novo cortisol production by the fetus (Pepe et al., 1990). Additional studies 
in our laboratories demonstrated (Leavitt et al., 1997; Aberdeen et al., 1998) that 
treatment of baboon fetuses with betamethasone in late gestation suppressed fetal 
pituitary POMC mRNA expression, fetal serum ACTH levels and ACTH-R mRNA 
concentrations and 3 P-HSD expression in the definitive zone of the fetal adrenal gland, 
whereas ACTH administration promoted maturation of the fetal adrenal transitional zone, 
but not the definitive zone (Leavitt et al., 1999). Combined, these results suggest that
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activation of fetal adrenal steroidogenic maturation requires, in part, an estrogen- 
regulated shift in placental conversion of maternal cortisol to biologically inactive 
cortisone, resulting in increased pituitary ACTH elaboration. Moreover, since estrogen 
production depends upon androgens of fetal adrenal origin, it would appear that the fetus 
is ultimately in control of the timing of the maturation of its own HPAA. A future 
research effort would be to investigate which transcription factors are responsible for the 
down-regulation of the ACTH-R mRNA in the fetal zone and the up-regulation of the 
ACTH-R mRNA in the definitive zone.
This work does not definitively preclude a direct effect of estrogen on the fetal 
pituitary corticotropes and/or fetal adrenal cells since fetal estrogen levels do increase 
ontogenetically, and prematurely at mid-gestation following maternal estrogen 
supplementation. Additionally, recent evidence indicates that ERa and/or ERP are 
expressed in the fetal pituitary and adrenal glands (Hirst et al., 1992; Enmark et al., 1997; 
Brandenberger etal., 1997; Albrecht et al., 1999). ERa/p has also been demonstrated in 
the hypothalamic paraventricular nucleus (Couse et al., 1997; Shughrue et al., 1997; 
Hrabovszky et al., 1998). Moreover, it (Albrecht and Pepe, 199S) has been shown that a 
negative feedback system exists in utero whereby placental product estrogen regulates 
maternal and fetal adrenal Ci9-androgen production to maintain a physiologically normal 
balance of estrogen biosynthesis during primate pregnancy. Additionally, estrogen 
suppressed the responsivity of the baboon fetal gland to ACTH with respect to the 
formation of fetal-zone specific DHA, but not of transitional-zone specific cortisol, as 
determined in vitro (Albrecht and Pepe, 1987; Albrecht et al., 1990) and in vivo (Pepe et 
a/., 1989).
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In the second major part of this dissertation, the S’-flanking regions of both baboon
1 1 P-HSD-1 and 11 p-HSD-2 genes were isolated and sequenced and subsequently shown 
to exhibit extensive nucleotide homology to their respective human genes. The baboon
11 P-HSD-1 gene has two transcriptional start sites 93 nucleotides apart and it appears 
that the upstream start site is the major one utilized in liver whereas the placenta appears 
to utilize the downstream start site. The baboon 11 P-HSD-2 gene also exhibited multiple 
transcriptional start sites in placenta and kidney, analogous to that in the human placenta, 
but not the human kidney (Agarwal et al., 199S). The baboon 11 P-HSD-1 promoter 
contains no TATA boxes, but two consensus CAAT boxes, which presumably regulate 
transcription initiation. The baboon 11 P-HSD-2 promoter contains multiple GC boxes 
that probably regulate transcription. Moreover, gene transfection analyses in JEG-3 cells 
indicated that the S’-flanking regions of both the baboon 11 P-HSD-1 and -2 genes are 
responsive and transcriptionally activated by 17P-estradiol in the presence of a co­
transfected ERa cDNA. These in vitro findings agree with our previous results (Pepe et 
al., 1996a) which demonstrated an ontogenetic increase in 1 lp-HSD-l and -2 mRNA and 
protein in baboon placental syncytiotrophoblasts.
Additionally, further support for the regulation of both baboon 11 P-HSD-1 and -2 
genes by estrogen was demonstrated utilizing sensitive and specific RT-PCR technology. 
The results presented here are the first to unequivocally demonstrate the in vivo 
transcriptional regulation of 11 P-HSD-1 and -2 genes in the baboon placenta by estrogen. 
CGS-20267, a potent and specific placental P4S0-aromatase inhibitor, when administered 
during the latter half o f pregnancy, reduced maternal estrogen levels from approximately
2 ng/ml to less than 0.1 ng/ml. This estradiol diminution resulted in a significant
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decrease in placental syncytiotrophoblast mRNA levels of both 11 P-HSD-1 and -2. This 
data is also consistent with recent observations in the nonpregnant rat uterus where 
estrogen potently up-regulated both 11 P-HSD-1 and -2 expression (Burton and Waddell, 
1999).
Because o f the importance of placental 11 P-HSD-1 and 11 P-HSD-2 in regulating 
cortisol transfer to the fetus and thus the function of the fetal hypothalamic-pituitary 
adrenal axis in the baboon (Pepe and Albrecht, 1995), studies of the regulation of both 11 
P-HSD-1 and 11 P-HSD-2 promoters in primary cultures of baboon placental trophoblasts 
obtained from animals at various stages of gestation with/without hormonal treatment in 
vivo should enhance our understanding of the mechanism(s) by which these genes are 
regulated in the placenta. Further studies employing quantitative RT-PCR analyses of 
estrogen-supplemented and control baboons during early gestation would lend further 
support for the in vivo regulation of 11 p-HSD-1 and -2  genes by estrogen. Additional 
studies utilizing gel-mobility shift assays (EMSA), DNase I foot-printing protection 
assays and promoter deletion transient transfection studies should be accomplished to 
determine which syncytiotrophoblast and/or JEG-3 nuclear proteins (ERa, ERP, Spl, 
AP-2, SF-1, SRC-1, SRC-2, CBP/p300, SMRT, NcoR, etc.) are binding and regulating 
specific 11 P-HSD-1 and 11 P-HSD-2 promoter regions. Also, in vitro transient 
transfection analyses of the interactions between co-transfected ERa and ERP and the 11 
P-HSD-1 /luciferase and 1 iP-HSD-2/luciferase promoter constructs would prove 
valuable. What effect does ERp have on the activation of 11 P-HSD-1/luciferase and 1 lp 
-HSD-2/luciferase promoter constructs by ERa? Hall and McDonnell (1999) determined 
that ERP functions as a transdominant inhibitor of ERa transcriptional activity and that
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ERP decreases the cellular sensitivity to estradiol. Utilizing EMSA technology, it can be 
learned which area of the 11 P-HSD-1 /luciferase and 11 P-HSD-2/luciferase S’-flanking 
regions bind ERa and/or ERp. Is ERP expressed in baboon placental 
syncytiotrophoblasts? Interestingly, many endocrine tissues, including the testes and 
ovaries, coexpress both ER subtypes (Hall and McDonnell, 1999). Also, the levels of ER 
a  and/or ERP mRNA could be determined quantitatively (RT-PCR) in 
syncytiotrophoblasts at different gestational ages with/without estrogen treatment. Are 
ERa and/or ERP transcriptionally regulated by estrogen?
Another unanswered question concerns the role of cortisol and its receptors (GRa 
and GRP) on the regulation of baboon 11 P-HSD-1. In sheep, 11 P-HSD-1 mRNA 
expression is enhanced adult liver but reduced in fetal liver following glucocorticoid 
administration in vivo (Yang et al., 1994), whereas in the hippocampus, glucocorticoids 
and chronic-stress upregulate neural 11 P-HSD-1 (Low et al., 1994). Are GRa and/or GR 
P receptors expressed in baboon placental syncytiotrophoblasts? What are the local 
cortisol levels ontogenetically within the placenta? How do these levels compare to 
maternal and fetal serum cortisol levels?
Analogous studies would be to quantitatively determine (RT-PCR) the mRNA levels 
of 11 P-HSD-1 and -2  in fetal tissues from baboons treated in utero with/without estrogen 
supplementation /amelioration. Are ERa and/or ERP receptors and/or GRa and/or GRP 
receptors expressed in these tissues? Perhaps both ERa and/or ERP receptors are 
expressed in the liver and down-regulating 11 P-HSD-1 and -2  expression, whereas in 
syncytiotrophoblast, only the ERa receptor is present and contributing to 11 p-HSD-1 and 
-2 up-regulation.
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Finally, the adenovirus gene therapy studies demonstrate an exciting tool to 
essentially “knock-down” an expressed gene in order to understand that gene’s unique 
physiological role. Our preliminary work demonstrates the capability to repress gene 
expression in vitro. Whether this can be accomplished in vivo remains to be determined.
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